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INTERNATIONAL MEGA-TRENDS AND GROWTH PROSPECTS 
OF THE FINNISH BIOTECHNOLOGY INDUSTRY – Essays on 
New Economic Geography, Market Structure of the Pharmaceutical Indus-
try, Sources of Financing, Intellectual Capital and Industry Projections.1 
Helsinki: ETLA, Elinkeinoelämän Tutkimuslaitos, The Research Institute of 
the Finnish Economy, 2004, 172 p. (A, ISSN 0356-7435; No. 40). ISBN 951-
628-410-8.  
ABSTRACT: The aim of this dissertation is to predict the economic 
growth impacts of the Finnish biotechnology industry on the Finnish 
economy and analyze the international and industry-specific factors be-
hind these predictions. The New Economic Geography of the European 
regions suggests that spatial agglomeration of economic activities will be 
strengthened internationally if European integration deepens. Sparsely 
populated geographic peripheries, such as Finland, might have difficul-
ties in creating a critical mass of factors of production. For example, the 
Finnish pharmaceutical industry has enjoyed high regulatory protection 
and it has achieved similar price markups during the 70s-90s as its coun-
terpart in the US. After changes in regulatory systems and problems in 
drug development within large pharmaceutical companies strong pres-
sure for lower markups arose. This drives large pharmaceutical compa-
nies to outsource their R&D activities to small biotechnology companies. 
The large companies are also interested in taking over the most promi-
nent and maturing biotechnology companies. The takeovers offer one 
pathway of exit to the investors of start-up companies.  
According to the analysis of small and medium-sized Finnish biotech-
nology industry, it seems that most promising biotechnology companies 
have a well-balanced combination of intellectual capital. According to 
the analysis of intellectual capital, there are many promising branches in 
addition to drug development activities, such as applications related to 
biomaterials, diagnostics, food and feed, industrial enzymes, agriculture 
and forestry. Despite expectations of rapid growth, it will take decades 
rather than years for the biotechnology industry to catch up with the  
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three pillars of the Finnish industry: pulp and paper, metal products and 
engineering, and the electronics industries. To fulfill the expectations, 
there is a need for the creation of a critical mass of factors of production 
and comparative advantage by building collaboration and financing net-
works between the biotechnology industry and traditional industries, 
such as forest industry, electronics industry and pharmaceutical industry. 
Most of the current Finnish biotechnology companies are related to 
health care activities. The health care sector has reached a major cross-
roads owing to the aging of the population and advances made in medi-
cal science. On the one hand, the aging of the population and the medi-
cal possibilities to diagnose and treat more illnesses than before increase 
the cost pressures on health care. On the other hand, biotechnology ap-
plications are expected to spawn cost savings over the long run by, for 
example, making time-consuming diagnostic methods more efficient and 
facilitating targeted therapy. As a policy implication for companies, pub-
lic sector and academia, this dissertation concludes how the Finnish bio-
technology industry could offer solutions to the cost crisis in health care 
while at the same time spurring development of an internationally com-
petitive industrial cluster. 
Key Words: spatial agglomeration, price-cost margins, capital structure, 
intangible assets, input-output analysis.  
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Kiitän väitöskirjatutkimuksen rahoittajia: Tekesin ProACT- ja NeoBio-
tutkimusohjelmia sekä Yrjö Jahnssonin säätiötä. Kiitän nykyistä työnan-
tajaani Etlatieto Oy:tä ja ETLAa, joka on tarjonnut puitteet viedä tämä 
projekti onnistuneesti läpi. Kiitokset myös Suomen kulttuurirahastolle, 
joka on tukenut esseessä 1 esitettävää tutkimusta, ja Teknillisen korkea-
koulun Lahden keskukselle, joka on tukenut taloudellisesti esseessä 4 
esitettävää tutkimusta. Yrjö Jahnssonin säätiön rahoitus ulottuu väitöskir-
jan lisäksi siihen, että voin lähettää tutkimuksia arvioitavaksi kansainväli-
siin tiedejulkaisuihin esseiden aihealueista.  
Ohjaajani professori Ilkka Kauranen Teknillisestä korkeakoulusta on 
kannustanut minua läpi koko projektin. Erityiset kiitokset haluan osoittaa 
Ilkalle hänen suvaitsevaisuudestaan erilaisten tutkimusmenetelmien ja eri 
tutkimusalojen kirjallisuuden käytössä. Ilkka ei pyrkinyt väkisin suuntaa-
maan tutkimustyötä vain niille alueille, jotka ovat hänen omaa keskeistä 
osaamisaluettaan, vaan hyväksyi monen ohjaajan ja asiantuntijan käytön 
eri alojen esseitä laadittaessa. Ilkka kommentoi ja ohjasi kaikkien esseiden 
valmistumista, mutta erityisen lämpimästi muistelen esseen 4 valmistami-
sessa läpikäytyjä vaiheita ja sen kuluessa intensiivistä ja mutkatonta yh-
teistyötä.  
Kiitän myös väitöskirjan muita ohjaajia. Ismo Linnosmaa Kuopion yli-
opistosta (tätä kirjoitettaessa Ismo on tutkimusvierailulla Bostonin yli-
opistossa) ohjasi esseessä 2 esiteltävää tutkimusta. Ismo perehdytti  minut 
esseen 2 aihealueeseen ja otti minut mukaan ennen esseen 2 kirjoittamis-
ta yhteisjulkaisuun itsensä ja Taru Hallisen (Kuopion yliopisto) kanssa. 
Martti Kulvik Helsingin yliopistollisesta keskussairaalasta ohjasi esseen 5 
valmistumista ja antoi tärkeitä kommentteja koko väitöskirjan yhteen- 
vedon ja politiikkasuositusten kirjoittamiseen. Väitöskirjan yhteenvedon  
ja johtopäätösten kannalta koen tärkeinä myös esimieheni Pekka Ylä-
Anttilan (ETLA, Etlatieto Oy) kanssa käymäni keskustelut Suomen 
innovaatiojärjestelmästä ja siitä, miten bioteollisuuden kasvunäkymiä voi-
daan heijastaa koko teolliseen kenttään.  
Väitöskirjan esitarkastajina toimivat professori Paavo Okkoa Turun 
kauppakorkeakoulun kansantaloustieteen laitokselta ja professori Karl-
Erik Sveibyä Hankenin Företagsledning och organisation -laitokselta. 
Kiitän kumpaakin esitarkastajaa heidän asiantuntevista kommenteistaan 
  
ja yhteistyöstä. Kiitän myös vastaväittäjääni professori Morton Kamienia 
(Northwestern University) yhteistyöstä ja joustavuudesta väitöstilaisuu-
den ajankohdan järjestämisessä.   
Tämän näköistä väitöskirjaa ei olisi olemassa, ellei Vesa Harmaakorpi 
olisi vuonna 1998 palkannut minua tutkijaksi Teknillisessä korkeakoulus-
sa juuri perustettuun Aluetalousinstituuttiin. En olisi muutoin siirtynyt 
koulumaailmasta taloustutkimuksen pariin. Olin vuonna 1996 tehnyt pro 
gradu -työni ns. uudesta talousmaantieteestä Helsingin yliopiston kansan-
taloustieteen laitoksella. Graduni aihe oli onnekseni juuri sitä, mitä Vesa 
oli kaavaillut yhdeksi tutkimusaiheeksi Aluetalousinstituutissa. Samasta 
aiheesta syntyi vuonna 2000 professori Pertti Haaparannan (Helsingin 
kauppakorkeakoulu) ja professori Ilkka Kaurasen ohjauksessa lisensiaa-
tintyö Teknilliseen korkeakouluun. Olen kiitollinen Vesalle myös siitä, 
että sain suorittaa tohtoriopintoja Helsingin kauppakorkeakoulussa lä-
hinnä kansantaloustieteen, laskentatoimen sekä organisaatioiden ja joh-
tamisen laitoksilla. Opinnoista huomattava osa sisällytettiin lisensiaatin 
tutkintooni.  
Pekka Ylä-Anttila palkkasi minut ETLAan elokuussa 2000. Aloitin työt 
ennusteryhmässä ja vastasin ulkomaankaupan sekä metalliteollisuuden ja 
kemianteollisuuden ennusteista. Ennusteryhmässä työskentely ohjasi minua 
voimakkaasti kohti konkreettisia reaalitalouden tapahtumia ja näkymiä. 
Olen kiitollinen tuolloisille esimiehilleni, ensin Markku Kotilaiselle ja 
myöhemmin Pasi Sorjoselle siitä, että sain kehitellä indikaattoreita ja me-
netelmiä vapain käsin, ”kunhan vain hoidan hommani ajallaan”. Olen 
kiitollinen siitä, että ennustetoimen johtaja Olavi Rantala tuki opintojani 
ja että sain osallistua alue-ennuste-projektiin.  
Kiitän kolleegojani ennusteryhmässä, Anthony de Carvalhoa, Hannu 
Kasevaa, Juha Kinnusta, Reijo Mankista ja Paavo Sunia siitä, että he jak-
soivat kärsivällisesti ohjata tuonaikaista työtäni neuvomalla monissa me-
netelmällisissä ja tilastoaineistoja koskevissa kysymyksissä. Työskentely 
ennusteryhmässä oli vaativaa enkä kyennyt tuohon aikaan edistämään 
väitöskirjan valmistumista haluamallani tavalla. Toisaalta ilman tätä vii-
vettä väitöskirjan aihe olisi ollut toisenlainen. Lisäksi on todettava, että 
ilman työskentelyä ennusteryhmässä en olisi kyennyt tai uskaltanut tehdä 
väitöskirjaani konkreettisia Suomen bioteollisuutta koskevia ennusteita.  
Kiitän ETLAn toimitusjohtajaa Pentti Vartiaa siitä tavasta, jolla hän on 
osaltaan rohkaissut minua työssäni eteenpäin. Rohkaisevin ja samalla 
hämmästyttävin kokemus sai alkuna kesällä 2001, kun professori Pentti 
Vartia kertoi saaneensa pyynnön kirjoittaa High Technology Finland  
-julkaisuun. ”Kulmahuone” ohjasi tehtävän minulle ja kohta kirjoitukseni 
  
komeili julkaisussa heti seuraavaksi pääministeri Paavo Lipposen esipu-
heen jälkeen. Koin jonkinasteista ansiotonta arvonnousua, mutta tällä 
tavalla professori Pentti Vartia rohkaisi nuorta tutkijaa ottamaan paikkan-
sa julkisuudessa. Julkisuus on osa taloustutkijan työtä.  
Valmistelimme siirtymistäni ETLAn ennusteryhmästä Etlatietoon yri-
tys- ja toimialatutkimuksen pariin vuoden 2001 aikana yhdessä Pekka 
Ylä-Anttilan ja Petri Rouvisen kanssa. Petri ja Pekka näkivät tuohon ai-
kaan, että bioteollisuus on tutkimisen arvoinen toimiala. Olin osallistunut 
aiemmin Petrin vetämään projektiin, jossa tarkasteltiin Suomen kemian-
teollisuuden kansainvälistä kilpailukykyä. Tuossa yhteydessä tuli esiin bio-
teknisten sovellusten mahdollinen merkitys arvonlisäyksen aikaansaajana. 
Tein Petrin kanssa useita Suomen bioteollisuutta koskevia tutkimushake-
muksia. Petrin eräänä ajatuksena oli liittää bioteollisuuden kehitys porte-
rilaiseen klusteritarkasteluun. Väitöskirjan jälkeisessä tutkimuksessa on 
tarkoitus analysoida Suomen bioteknisen tutkimuksen osaamisperustojen 
ja markkinapotentiaalin välistä yhteyttä myös porterilaisesta näkökulmasta.  
Vuoden 2002 alusta siirryin ETLAn omistamaan Etlatieto Oy:hyn ja 
samalla Pekka Ylä-Anttilan johtamaan yritys- ja toimialatutkimusryhmään. 
Ennusteryhmässä olin pohtinut jonkin verran Nokian vaikutuksia Suo-
men kansantalouteen ja oli luontevaa aloittaa tutkimus Nokian roolista 
Suomen innovaatiojärjestelmässä yhdessä Jyrki Ali-Yrkön kanssa. Jyrki ja 
Pekka jakoivat avoimesti tietojaan ja käsityksiään Suomen innovaatiojär-
jestelmästä. Tällä on ollut myöhemmin tärkeä sija bioteollisuuden tutki-
muksessa, onhan innovaatiojärjestelmä tiedeperustaisen bioteollisuuden 
keskeinen voimavara.  
Tein yhteistyötä VTT:stä ETLAan siirtyneen Terttu Luukkosen kanssa 
bioteollisuutta koskevien rahoitushakemusten loppuun viemisessä. Etla-
tieto sai rahoitusta tutkimushankkeeseen ”Bioteollisuus osana kansallista 
innovaatiojärjestelmää” kauppa- ja teollisuusministeriön ja Tekesin Pro-
ACT-tutkimusohjelmasta ja myöhemmin NeoBio-tutkimusohjelmasta. 
Aloin suunnitella Tertun kanssa biotekniikkayrityksille suunnattua kyse-
lyä. Kiitän Terttua yhteistyöstä.  
Kyselyaineisto on tämän väitöskirjan keskeinen aineistolähde esseissä 
3, 4 ja 5. Saimme korvaamatonta apua Etlatiedosta Ari Hyytiseltä ja Mika 
Pajariselta. He olivat valmistelleet koko yrityssektorin rahoitusta koske-
van kyselyn hieman aiemmin. Ilman heidän kontribuutiotaan kysely olisi 
jäänyt vaillinaiseksi. Kiitokset muillekin ETLAssa kyselyn sisältöä kom-
mentoineille henkilöille. Ulkopuolisista mainittakoon Eija Ahola Tekesis-
tä, Leena Hömmö maa- ja metsätalousministeriöstä, Sakari Karjalainen 
opetusministeriöstä, Hannele Kuusi Suomen bioteollisuus ry:stä, Paula 
  
Nyberg kauppa- ja teollisuusministeriöstä ja Ari Leppälahti Tilastokes-
kuksesta. Kiitokset myös monille muille kommentoijille.  
Hannele Kuusi Suomen bioteollisuus ry:stä (nykyisin PiceaTech Oy:ssä) 
tarjosi käyttöömme bioteollisuuden yritysrekisterin yhteystietoineen. Tä-
mä oli erittäin tärkeätä, koska tutkimuksen alkuvaiheessa meillä olisi ollut 
ylitsepääsemättömiä ongelmia biotekniikkayritysten määrittelyssä ja koska 
Tekes edellytti, että tuotamme tilastotietoa Suomen akatemian asettamal-
le kansainväliselle evaluointiryhmälle. Evaluointiryhmä arvioi Suomen 
biotekniikkasektorin nykytilaa. Myöhemmässä vaiheessa toimimme edel-
leen yhteistyössä myös Suomen bioteollisuus ry:n Carmela Kantor-
Aaltosen (nykyisin Helsingin yliopistossa) ja Saara Hassisen kanssa. Kii-
tän myös Riikka Heikinheimoa ja Kimmo Pitkästä Tekesissä saamastani 
biotekniikan määrittelyä koskevasta yksityisluennosta.  
Väitöskirjani essee 1 käsittelee samaa aihetta kuin lisensiaatintyöni 
mutta laajennetulla paneeliaineistolla. Esseen 1 aihealuetta on rahoittanut 
erityisesti Suomen kulttuurirahasto. Kiitän professori Ilkka Kaurasta ja 
professori Hannele Walleniusta Teknillisestä korkeakoulusta esseetä 1 kos-
kevista kommenteista. Samalla kiitän heinäkuussa 2002 pidetyn “EcoMod 
Conference on Policy Modeling” -konferenssin osallistujia esseen aiemman 
version kommentoinnista.  
Essee 2 perustuu pitkälti Ismo Linnosmaan (Bostonin yliopisto / 
Kuopion yliopisto) kehittelemään tutkimusasetelmaan, jossa sain olla 
mukana vuonna 2002. Artikkeli julkaistaan yhdessä Ismon ja Taru Halli-
sen kanssa The European Journal of Health Economics -lehdessä kulu-
van vuoden aikana. Sovimme Ismon kanssa, että kehittelen analyysiä 
hänen ohjauksessaan. Uusi malli sisältää myös tutkimus- ja kehitystoi-
minnan panokset. Olen viettänyt useita pitkiä päiviä Ismon kanssa joko 
ETLAn tiloissa tai Kuopion yliopistolla. Yhteistyö on ollut hauskaa ja 
samalla uusia ideoita pursuavaa. Olen saanut Kuopion matkoillani yöpyä 
Ismon kodissa, mistä myös kiitos Ismon vaimolle Suville. Kiitän myös 
elokuussa 2003 Bergenissä järjestetyn NHESG-konferenssin osallistujia 
kommenteista. Erityisen kiitoksen ansaitsee Sverre Kittelsen (Frisch Centre 
for Economic Research, Oslo). Sverre paneutui kommentaattorina es-
seen 2 aihepiiriin ja antoi tarkasti perusteltuja kommentteja ja useita sivu-
ja muistiinpanoja.  
Esseen 3 syntymisestä voin pitkälti kiittää Anna Maria Nuutilaa VTT 
Biotekniikasta. Hän pyysi minua keväällä 2003 kirjoittamaan lääkealan 
biotekniikkayritysten rahoitusrakenteista farmaseuttisen aikakauskirja Do-
siksen erikoisnumeroon. Olin aiemmin tehnyt keskustelupaperin  pienten 
ja keskisuurten biotekniikkayritysten rahoitusrakenteista yhdessä Antti 
  
Tahvanaisen kanssa. Tästä oli hyvä jatkaa lääkealan tarkastelua. Kiitokset 
selkeistä kommenteista Dosis-lehden toimitusneuvostolle ja erityisesti pää-
toimittajalle, professori Jouni Hirvoselle Helsingin yliopistosta. Haluan 
kiittää erityisesti työtovereitani Christopher Palmbergia ja Antti Tahva-
naista paperia koskevista kommenteista.  
Minulla oli ilo jakaa työhuoneeni reilun parin vuoden ajan Tomi Hus-
sin kanssa. Tomi valmisteli väitöskirjaa tietämyksen johtamisesta ja osaa-
mispääomasta Hankenille. Ilman Tomin kanssa käymiäni keskusteluja en 
todennäköisesti olisi koskaan ryhtynyt käyttämään tietämyksen johtami-
sen kirjallisuudessa esitettyjä viitekehyksiä osaamispääoman mittaamises-
sa. Kiitän Tomia työtoveruudesta ja kyvystä jakaa arjen sekä juhlan ilot ja 
surut. Esitin esseen 4 aiemmat versiot vuosien 2002 ja 2003 aikana kah-
dessa konferenssissa, jotka kummatkin Chalmersin teknillinen yliopisto 
järjesti Göteborgissa. Kiitokset osallistujille kommenteista. Kiitokset eri-
tyisesti professori Maureen McKelveylle (Chalmersin teknillinen yliopis-
to) myötäkulkevasta asenteesta. Professori Ilkka Kaurasen ohjaustyö ja 
kommentointi korostui esseessä 4. Kiitokset tehokkaasti sujuneesta yh-
teistyöstä. Tutkimus on jätetty julkaistavaksi R&D Management -lehteen, 
jonka kommentaattoreilta olen saanut esseetä selkeyttäviä huomioita. 
Kiitän professori Pekka Korhosta (Helsingin kauppakorkeakoulu) fakto-
ri- ja regressioanalyysiin liittyneistä kommenteistaan.  
Esseen 5 kirjoittamista aloittaessani sain arvokkaita kommentteja use-
aan otteeseen Olavi Rantalalta ETLAsta sekä tutkimusasetelmaan että 
tilastoaineistoon liittyen. Reijo Mankinen pelasti minut muutaman ker-
ran suosta, johon ajoin itseni panos-tuotos-taulujen ja matriisilaskennan 
keskellä. Kiitokset myös marraskuussa 2002 järjestetyn Triple Helix  
-konferenssin osallistujille sekä elokuussa 2003 järjestetyn Biotech Society  
-konferenssin osallistujille kommenteista. Essee 5 jätettiin julkaistavaksi 
The International Journal of Biotechnology -lehteen. Erikoisnumeron 
toimittajat Henrik Bruun ja Richard Langlais ansaitsevat kiitoksen koko 
esseetä selkeyttävistä kommenteista. Loppuvaiheessa tutkimustyötä ohja-
si biotekniikan kehitystyön substanssia ymmärtävä Martti Kulvik Helsin-
gin yliopistollisesta keskussairaalasta.  
Kiitän Pekka Ylä-Anttilaa siitä, että hän näki koulutuksen tärkeyden, 
kun ryhdyimme Etlatiedossa tutkimaan bioteollisuutta. Sain käydä työn-
antajani kustannuksella Helsingin kauppakorkeakoulun MBA-ohjelmassa 
järjestetyn Biotechnology Management -suuntautumisvaihtoehdon, joka 
olennaisesti syvensi käsityksiäni biotekniikka-alasta ja sen tarjoamista talou-
dellisista mahdollisuuksista. Kiitän Biotechnology management -koulutuk-
sen vastuuhenkilöitä, kouluttajia ja toisia opiskelijoita erittäin asiantunte-
vasta yhteistyöstä. Esimerkiksi hyödynsin esseessä 5 professori Constance 
  
Lütolf-Carrollin vetämällä ”Valuation of Biotechnology Firms” -kurssilla 
harjoiteltua Monte Carlo -simulaatiota. Sain tutkimustyötäni koskevia 
rohkaisevia kommentteja myös ohjelman muilta kouluttajilta, professori 
Michael Geringeriltä (California Polytechnic University), professori 
Daniel Rodriguezilta (Emory University) ja Eden Yiniltä (Cambridge 
University).  
ETLAn tarjoamiin fasiliteetteihin on kuulunut myös henkilöiden osaa-
miseen sitoutunut inhimillinen pääoma. Tuula Ratapalo on taittanut väitös-
kirjani ja Laila Riekkinen hoitanut sen painamiseen liittyvät valmistelut. 
Kimmo Aaltonen on yhdenmukaistanut väitöskirjan kuvien graafisen 
ulkoasun. Petteri Larjos pelasti aikanaan kotikoneellani olleet kirjoitukset, 
kun kone muuten kieltäytyi yhteistyöstä. Tämän jälkeen Petteri hankki 
minulle kannettavan tietokoneen, jolla työ on sujunut ETLAn ulkopuo-
lellakin. Arja Räihä on pitänyt minut leivän syrjässä kiinni huolehtimalla, 
että saan oikean ja riittävän määrän lounasseteleitä ja matkaennakkoja. 
Pirjo Saariokari on huolehtinut yhteistyökumppaneitteni kestityksestä ja 
henkisestä virkeydestäni. Hannele Immonen on pitänyt hyvää huolta 
siitä, etten tee töitä täysin epämääräisiin aikoihin. Kiitokset myös kaikille 
muille Etlalaisille.  
Sain englanninkielisiin ilmaisuihin ja kielenhuoltoon merkittävää apua 
John Rogersilta ja Roderick Dixonilta. Aiemmassa vaiheessa myös Juha 
Hermans ja Theodore Ashforth tarkastivat tutkimusteni kieliasua. Kii-
tokset kuuluvat myös työtoverilleni Antti Tahvanaiselle kielen selkiyttä-
misestä. Kiitän Tuula Nokkasta varauksettomasta yhteistyöstä väitöspro-
sessin ja väitöstilaisuuden valmistelussa.  
Kiitän perhettäni minua kohtaan osoittamastaan kärsivällisyydestä. Kii-
tos isälleni Juhanille ja äidilleni Marjatalle siitä, että päästitte minusta irti, 
kun muutin kotoa pois 18-vuotiaana ja kasvoin mieheksi kodin ulkopuo-
lella. 100-prosenttisen varmaa on, että ilman vanhempiani tätä väitöskir-
jaa ei olisi syntynyt. Osoitan kiitokset veljelleni Rafulle ja hänen vaimol-
leen Saaralle aina kannustavasta ja rohkaisevasta asenteesta. Kiitän sisar-
tani Paulaa ja hänen miestään Theodorea keskusteluista, joissa olemme 
ulottaneet monopolistisen kilpailun arjen tasolle. Kiitän veljeäni Juhaa 
mukanaolosta tutkimuksen muokkaamisessa. Kiitokset veljelleni Samille 
ja hänen vaimolleen Virvalle proaktiivisesta asenteesta: minua on titulee-
rattu tohtoriksi jo vuosia ennen väitöstilaisuutta.  
Kiitän appeani Markkua ja anoppiani Eilaa siitä, että sain ryöstää teiltä 
16-vuotiaan tyttösen itselleni vaimoksi. Samasta syystä osoitan kiitokset 
myös appeni vanhemmille Pentille ja Irjalle sekä anopin äidille Airalle. 
Olen varma, että ilman tytärtänne ja vaimoani Outia tätä väitöskirjaa ei 
  
olisi. Outi on ohjannut minua pysymään paikoillani vaikeina hetkinä ja 
jatkamaan väitöskirjatyötäni silloinkin, kun ruoho on ollut vihreämpää 
aidan toisella puolella ja muut työtehtävät ovat näyttäneet mielenkiintoi-
semmilta.  
Olen ollut viime vuosina paljon pois kotoa fyysisesti ja välillä henkises-
ti. Kiitän perheenjäseniäni siitä, että olette pitäneet aktiivisesti minuun 
yhteyttä. Vanhimman lapsemme Johannan ratsastusonnettomuus pysäh-
dytti koko perheen viime syksynä. Pitkä sairasloma kääntyi kuitenkin 
parhain päin, kun Johannan tulevaisuuden suunnitelmat alkoivat selkiy-
tyä. Toivotan, Johanna, sinulle onnea ensi kevään ylioppilaskirjoituksiin 
ja sen jälkeisiin koitoksiin. Nyt kun olen valmistumassa tohtoriksi, niin 
vapautan Joonaksen taakasta suorittaa jotain minun puolestani. Rohkai-
sen sinua toimimaan valitsemasi päämäärän suuntaan rohkeasti ohimene-
vistä tuulista välittämättä. Kuuntele näissä asioissa äitiäsi. Hän tietää, mis-
tä puhuu. Haluan kiittää Juliaa rohkaisevista viesteistä, joiden avulla olen 
jaksanut eteenpäin pimeinä syksyjen ja talvien hetkinä. Yksi pikkutyttönä 
paperilapulle kirjoittamistasi viesteistä on edelleen lompakossani. Toivon, 
että säilytät iloisen ja kiitollisen asenteesi koko elämäsi ajan. Samelia kii-
tän siitä, että olen saanut kulkea rinnallasi, ja siitä, että uskallat olla oma 
itsesi ja tehdä perusteltuja ja yleisestä poikkeavia ratkaisuja, vaikka tätä 
eivät aina kaikki (aikuiset) ymmärtäisikään. Tarkoitan tällä esimerkiksi 
sitä, että voit piirtää kuvaamataidossa erilaisen kuvan kuin muut ja sinulla 
on tähän vielä perustelu. Yleisesti ottaen uuden tai erilaisen luominen ei 
tuo mukanaan välitöntä kunniaa totunnaisuuteen sidotussa maailmassa, 
mutta pitkällä aikavälillä se lienee tärkeä edellytys saavuttaa keskimääräis-
tä selvästi korkeampi taso.  
Kiitän Herra Jeesus Nasarealaista hänen esittämästään totuuden määri-
telmästä. Hän on vaikuttanut tutkimustyöhöni siten, että aiemmin lähes 
absoluuttisina totuuksina pitämäni teoriat tai niitä tuottavat tutkimustavat 
ovat minulle nykyisin vain työvälineitä, joiden avulla voin tarkastella 
mahdollisia syy-seuraus-suhteita eri näkökulmista. Tämä on innostanut 
minua käyttämään erilaisia menetelmiä ja näkökulmia myös väitöskirjas-
sani. Olen halunnut kuvata Suomen bioteollisuuden kehittymiseen liitty-
viä ilmiöitä monesta suunnasta ja monella eri tavalla. Laaja-alaisuuden 
vaarana on aina pinnallisuus, mutta toivon päässeeni ainakin joiltain osin 
pintaa syvemmälle.  
Helsingissä 15.6.2004 
 
Raine Hermans 
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INTERNATIONAL MEGA-TRENDS AND 
GROWTH PROSPECTS OF THE FINNISH 
BIOTECHNOLOGY INDUSTRY:  
An Introductory and Concluding Essay2 
Abstract 
The aim of this dissertation is to predict the economic growth impacts of 
the Finnish biotechnology industry on the Finnish economy and analyze 
the international and industry-specific factors behind these predictions. 
The New Economic Geography of the European regions suggests that 
spatial agglomeration of economic activities will be strengthened interna-
tionally if European integration deepens. Sparsely populated geographic 
peripheries, such as Finland, might have difficulties in creating a critical 
mass of factors of production. For example, the Finnish pharmaceutical 
industry has enjoyed high regulatory protection and it has achieved simi-
lar price markups during the 70s-90s as its counterpart in the US. After 
changes in regulatory systems and problems in drug development within 
large pharmaceutical companies strong pressure for lower markups 
arose. This drives large pharmaceutical companies to outsource their 
R&D activities to small biotechnology companies. The large companies 
are also interested in taking over the most prominent and maturing bio-
technology companies. The takeovers offer one pathway of exit to the 
investors of start-up companies.  
According to the analysis of small and medium-sized Finnish biotech-
nology industry, it seems that most promising biotechnology companies 
have a well-balanced combination of intellectual capital. According to 
the analysis of intellectual capital, there are many promising branches in 
addition to drug development activities, such as applications related to 
biomaterials, diagnostics, food and feed, industrial enzymes, agriculture 
and forestry. Despite expectations of rapid growth, it will take decades 
rather than years for the biotechnology industry to catch up with the 
three pillars of the Finnish industry: pulp and paper, metal products and  
 
                                                 
2  I want to thank Pekka Ylä-Anttila and Martti Kulvik for their supervision.  
  
2 
engineering, and the electronics industries. To fulfill the expectations, 
there is a need for the creation of a critical mass of factors of production 
and comparative advantage by building collaboration and financing net-
works between the biotechnology industry and traditional industries, 
such as forest industry, electronics industry and pharmaceutical industry. 
Most of the current Finnish biotechnology companies are related to 
health care activities. The health care sector has reached a major cross-
roads owing to the aging of the population and advances made in medi-
cal science. On the one hand, the aging of the population and the medi-
cal possibilities to diagnose and treat more illnesses than before increase 
the cost pressures on health care. On the other hand, biotechnology ap-
plications are expected to spawn cost savings over the long run by, for 
example, making time-consuming diagnostic methods more efficient and 
facilitating targeted therapy. As a policy implication for companies, pub-
lic sector and academia, this dissertation concludes how the Finnish bio-
technology industry could offer solutions to the cost crisis in health care 
while at the same time spurring development of an internationally com-
petitive industrial cluster.  
Key Words: spatial agglomeration, price-cost margins, capital structure, 
intangible assets, input-output analysis.  
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1.1 Introduction 
1.1.1  Background and Objectives 
The topic of the present doctoral dissertation is the economic growth 
prospects of the Finnish biotechnology industry. The dissertation is 
based on five partly overlapping studies on the topic (Essay 1, Hermans, 
2003b; Essay 2, Hermans – Linnosmaa, 2003; Essay 3, Hermans, 2003a, 
2004; Essay 4, Hermans – Kauranen, 2003 and Essay 5, Hermans – 
Kulvik, 2004a). Each research study is included in the dissertation as a 
separate essay. Essays 1 and 2 deal with economic mega-trends behind 
the Finnish biotechnology industry and the rest of the essays analyze the 
present and anticipated states of the Finnish biotechnology industry.  
The objective of the introductory essay of the doctoral dissertation is 
to present an overview of and conclusions on the five essays. The intro-
ductory essay analyzes Finland’s biotechnology industry from the view-
points of international and regional integration (Essay 1), the market 
structure of the pharmaceutical industry (Essay 2), capital and ownership 
structures of bio-pharmaceutical companies (Essay 3), as well as compa-
nies’ intangible assets and growth expectations (Essay 4) and discusses 
the results of a forecasting model based on the companies’ growth ex-
pectations and the probability of their success (Essay 5).  
At the beginning of the introductory essay an overview of the innova-
tion policy of Finland from the perspective of the biotechnology indus-
try is given. The biotechnology industry plays a special role in Finnish 
growth and innovation policy. This special role has shaped the questions 
addressed in these five studies and the way in which the research was 
carried out. 
Because biotechnology has played a significant role in Finnish innova-
tion policy, certain conclusions are drawn regarding each of the five 
studies both from the viewpoint of firms’ strategies as well as business 
and innovation policy. The last essay discusses the potential of the bio-
technology industry to grow into one of Finland’s main manufacturing 
industries or growth clusters, comparing it to the forest, machinery and 
electronic industries.3  
 
 
                                                 
3  See also Hermans and Ylä-Anttila (2004), which deals with the same topic.  
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1.1.2  Definitions 
The biotechnology industry does not exist as an individual branch in any 
official statistical classification. A single definition has preliminarily been 
agreed upon at an OECD ad hoc meeting held in 2002.4 According to 
the definition, biotechnology is: “The application of science and technology to 
living organisms, as well as parts, products and models thereof, to alter living or non-
living materials for the production of knowledge, goods and services.” In addition, a 
list-based definition specifies biotechnology processes in more detail.5 
Companies can develop biotechnology processes or they can apply bio-
technology processes in their production. The former can be called bio-
technology research companies and the latter biotechnology using firms. 
An individual company can be classified as belonging simultaneously to 
both categories. In this case the company can be called as an integrated 
firm.6 
The present dissertation employs with the biotechnology related data 
drawn from the ETLA survey.7 The ETLA survey was conducted in the 
beginning of the year 2002 and it covers 84 companies.8 There were ap-
proximately 120 biotechnology companies in Finland in the end of the 
year 2001. Thus, the coverage of the data seems sufficient. The problem 
of how to define biotechnology companies was solved by choosing the 
firms in the database of the Finnish Bioindustries Federation to repre-
sent the population of Finnish biotechnology companies.  
 
                                                 
4  The third OECD ad hoc meeting on biotechnology statistics was held in Espoo, 
Finland 13-15 May 2002. 
5  The following five categories were agreed on at the OECD ad hoc meeting. The list is 
indicative (not exhaustive): 
a) DNA (the coding): genomics, pharmaco-genetics, gene probes, DNA sequencing/ 
synthesis/amplification, genetic engineering. 
b) Proteins and molecules (the functional blocks): protein/peptide, sequencing/ 
synthesis, lipid/protein engineering, proteomics, hormones, and growth factors, 
cell receptors/signalling/pheromonics. 
c) Cell/tissue culture, tissue engineering, hybridization, cellular fusion, vaccine/ 
immune stimulants, embryo manipulation. 
d) Process biotechnologies: bioreactors, fermentation, bioprocessing, bioleaching, 
bio-pulping, bio-bleaching, biodesulphurization, bioremediation and biofiltration. 
e) Sub-cellular organisms: gene therapy, viral vectors. 
6  See Nilsson (2001). 
7  ETLA stands for The Research Institute of the Finnish Economy. 
8  The first descriptive analysis of ETLA biotechnology survey was presented by Her-
mans and Luukkonen (2002). 
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Figure 1.  Activities of the biotechnology companies in ETLA survey 
by branches. 
The Finnish Bioindustries Federation classified its member companies 
into 7 categories. In the ETLA survey an individual company could clas-
sify itself simultaneously in several categories. Figure 1 depicts in which 
categories the biotechnology companies consider themselves to be. Most 
of the companies are involved in the businesses of pharmaceuticals and 
diagnostics. 
1.2 Current Situation 
The following discussion on the current situation of the Finnish innova-
tion system is partially based on Hermans and Ylä-Anttila (2004). The 
structural change that occurred in the Finnish economy in the 1990s was 
relatively swift from an international perspective as well as relative to 
Finland’s own economic history. The transformation toward a compe-
tence-driven economy has continued for several decades already, but it 
accelerated considerably in the 1990s and strengthened the structural 
change. Technology policy played an important role even though most 
of the development was company driven (Ylä-Anttila – Lemola, 2003). 
Economic integration and the opening of the economy to international 
competition spawned a competence-driven phase of growth. The inno-
vation intensive sectors benefited more than other sectors from the new 
markets. Productivity and capital efficiency increased considerably. 
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The roots of the Finland’s current innovation policy date back to the 
1970s and 1980s, when the decisions to increase science and technologi-
cal investment were made.9 Then and partly already in the 1960s the ba-
sic pillars of research policy were built and the first programs for applied 
research were started. The goal was to lift the technological level of Fin-
nish industries and to reduce the dependence on raw material driven 
production and exports. The one-sided structure of exports was regarded 
as a problem – the intermittent problems with deep imbalances in the 
economy were due largely to strong cyclical fluctuations in the export 
industry.  
Still at the end of the 1970s Finland’s research and development 
(R&D) expenditures relative to gross domestic product (GDP) was one 
of the lowest in the industrialized countries. The 1980s was a decade for 
systematic and goal-oriented technology policy. One of the key vehicles 
for implementing this policy was the National Technology Agency of 
Finland, Tekes, established in 1983. Regional science parks and techno-
logical centers were established to support the dissemination of research 
findings and utilization of regionally generated information. The R&D 
expenditures grew in real terms at a rate of about 10 percent per annum, 
which was one of the fastest in the OECD countries.  
The main tools for implementing technology policy were technology 
programs, which fostered the implementation of a strategic innovation 
policy, thus making use of the small country’s scarce resources. Accord-
ing to this policy, heavy investments were made in information and 
communication technology (ICT) in several technology programs that 
were initiated already before the founding of Tekes. The huge success of 
Nokia and the ICT cluster that emerged around it was a sign of the suc-
cessful policy choice, even though the policy naturally accounted for only 
part of the success (Rouvinen – Ylä-Anttila, 2003).  
The 1990s can be called a decade of the national innovation system in 
terms of innovation or science and technology policy. Innovation activi-
ties started to be seen more and more as a key product of dialogue and 
interaction between different actors – companies, research institutes, 
financiers of innovative activities and other policy makers.   
Changes in technology and business policy and innovation policy in-
evitably have an impact also on the biotechnology sector. The impacts 
are clearly apparent in at least two respects.  
                                                 
9  For more on the background and development of science and technology policy, 
see Lemola (2002), Georghiou et al. (2003) and Ylä-Anttila – Lemola (2003). 
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Figure 2.  Location of the Finnish biotechnology companies in 2003. 
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First, since it was possible to use policy to foster the success of the 
ICT sector, it was deemed possible to do the same thing in the biotech-
nology sector. The R&D investments of the companies in the ICT sector 
– mainly Nokia – rose sharply in the 1990s and the early 2000s (Ali-
Yrkkö and Hermans, 2004). As regards research activities Finland has 
specialized more in the ICT sector than any other country in the world. 
Public investment was especially important in the 1980s and 1990s dur-
ing the recession. By the end of the decade research activity become 
more company-oriented, even though the ICT sector’s share of public 
research funds is still substantial. Public investment in the ICT sector 
had spawned a considerable increase in private investment: the ICT sec-
tor seems to be an example of a successful strategy of innovation policy, 
so it could be worthwhile to search for another sector with new poten-
tial, biotechnology. 
Second, the founding of regional competence centers has had a posi-
tive impact on the biotechnology sector and on investment in companies 
in this sector. Most of the companies in this sector are located in five of 
the science and technology parks located around Finland (see Figure 2). 
From the standpoint of the biotechnology and bioresearch, the situation 
is problematic: it is difficult to find a sufficient critical mass. Further-
more, Kafatos et al. (2002) pointed out that there is little cooperation 
between the regional biotechnology centers in Finland.  
The differences between the biotechnology and ICT sectors from the 
standpoint of the functioning of the innovation system and technology 
policy are significant, as Luukkonen and Palmberg (2004) demonstrate. 
Biotechnology is not closely affiliated with existing sectors that are cur-
rently strong in Finland – the sector has no strong manufacturers or 
growth engines. The Finnish biotechnology sector has concentrated – as 
in several other countries – on biopharmaceuticals. The significance of 
the pharmaceutical sector in Finland’s industrial structure has neverthe-
less been relatively small compared to many other countries. There is 
relatively little biotechnology research and manufacturing activity related 
to the large traditional processing industries, such as the forest and 
chemical industry. 
The research and manufacturing activity related to biomedicine – or 
biotechnology in general – has been chosen as a focal point of business 
and technology policy in almost all developed countries. Competition 
in the sector is thus keen and demands high investments. The risks 
related to the public financing of innovation policy and biotechnology 
are great. 
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Table 1.  Biotechnology industry in Finnish enterprise sector. 
 
Million 
euros   
Biotechnology industry’s 
share (%) of enterprise 
sector 
 
Bio- 
technology 
industry 
SMEs  
Total bio- 
technology 
industry*  
(incl. multi-
sector firms)
Total  
enterprise
sector SMEs 
Total bio- 
technology 
industry* 
(incl. multi- 
sector firms) 
Number of  
companies 110 130 225,000 0.05 % 0.06 % 
Sales revenues 200 1,400 272,000 0.1 % 0.5 % 
Value added 90 500 88,000 0.1 % 0.6 % 
Employees 2,000 14,000 1,319,000 0.2 % 1.1 % 
Exports 120 600 54,000 0.2 % 1.1 % 
R&D  
expenditures 162 300 3,300 4.9 % 9.1 % 
Table is based on data for 2001 (ETLA, Statistics Finland) 
*  Sales revenues and exports of multi-sector companies are estimated for biotechnology 
production and employment and for employment as a whole.  
Sales revenues, value added, exports and R&D expenditures are based on figures provided 
by enterprises regarding extent of biotechnology activities. 
 
Finland’s biotechnology sector is currently quite small. In 2001 the 
value added by the entire biotechnology sector was about EUR 500 mil-
lion (table 1). This figure includes an estimate for biotechnology-related 
production of large multi-sector enterprises. The total value added of 
small and medium-sized biotechnology enterprises was less than EUR 
100 million in 2001.  
The situation of the biotechnology industry is illustrated by the fact that 
the R&D expenditures of the small and medium-sized enterprises (SMEs) 
are considerably higher (approximately 40%) than their value added. The 
research investments have for the time being generated very little produc-
tion. The research investments of SMEs are funded primarily by the gov-
ernment. Since the public financing of the biotechnology sector’s research 
has been about EUR 400 million since the beginning of the 1990s (Fig-
ure 3), the average financing per SME has been EUR 3-4 million. This sum 
includes both direct funding to the SMEs and also funding to univer-
sities and research institutions that companies can utilize indirectly. 
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Figure 3.  Biotechnology-related funding from Tekes, The National 
Technology Agency of Finland, the years 1990-2003. 
Even though public financing has not been comparatively high, relative 
to the size of the economy and the number of active enterprises it has 
been of significant magnitude.   
1.3  Growth Prospects of Biotechnology Sector 
1.3.1  Economic Integration and Regional Competitive  
Advantages  
The biotechnology industry cannot be treated as a sector of its own iso-
lated from the mega-trends affecting international economic develop-
ments. Essay 1 investigates the effects of economic integration on the 
regional location of production in line with the body of the international 
trade literature known as the new economic geography theory.10  
 
                                                 
10  The earlier version of Essay 1 was printed as ETLA’s Discussion Paper Series no. 
883 (Hermans, 2003b). A preliminary version of the essay was presented in Eco-
Mod Conference on Policy Modeling, held 4-6 July 2002 in Brussels. 
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The main idea of this study is to compare the differences between 
countries’ internal regional structures, on the one hand, and international 
regional structures, on the other hand. Economic integration can be as-
sumed to be deeper within countries than internationally. For decades 
there has been free trade within countries and ordinarily clear cultural 
unity between different regions within the same country. This situation 
can be considered an extreme economic integration. At the same time, 
there are certain trade barriers between countries including tariffs or 
quotas as well as cultural differences and geographic location. Economic 
integration in recent years has nevertheless deepened in Europe and 
globally.  
One of the main findings of Essay 1 is that economic activity is in-
clined to become concentrated on regions where the innovation intensity 
is higher than in other regions. On the other hand, this kind of conclu-
sion could not be made in the international context. However, if the 
integration between separate economies occurs in the same nature as it 
has occurred in the internal economic context, then by investigating the 
countries’ internal regional structures we can predict and evaluate the 
trends in the international economy. 
Based on the findings of Essay 1, it can be predicted that at the inter-
national level economic activities will become concentrated in regions 
where there is a high intensity of investment in innovative activity. This 
scenario brings challenges also for Finland, which is located geographi-
cally on the periphery of Europe. 
The new economic geography framework enables us to make policy 
recommendations of a general nature. Fostering a high intensity of in-
novative activity, for instance, is a key way of attracting direct invest-
ment and keeping jobs in the region. In order to deepen the policy rec-
ommendations it is fruitful to look at the theoretical framework of Ri-
cardo as well as Heckscher, Ohlin and Samuelson (HOS), which are 
based on comparative advantage. According to the HOS framework, 
free trade leads to regional specialization of production in goods re-
quiring resources (knowledge, capital, natural resources) that are rela-
tively abundant in the region. Also Nelson (1990) emphasizes the sig-
nificance of comparative advantages generated by natural resources and 
intellectual capital facilitating the functioning of the national innovation 
system. Taking advantage of the principle of comparative advantage at 
the international level is deemed to increase the welfare of all the coun-
tries participating in free trade. 
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1.3.2  Market Structure of the Pharmaceutical Industry  
in Finland and the US 
The pharmaceutical industry is one of the main sectors that has been 
able to take advantage of biotechnology in its product development. It is 
thus important to evaluate the market structure of the pharmaceutical 
industry in order to be able to conceptualize the ”playing field” where 
also most of the Finnish biotechnology companies operate.  
Essay 2 compares the price cost margins of the pharmaceutical indus-
try prevailing in Finland and the United States in 1975-1999.11 The study 
is based on the same theoretical framework as Linnosmaa, Hermans and 
Hallinen (2004). The effects of research and development costs have 
been added to the model.  
The development of drugs is heavily regulated by the public sector in 
both Finland and the United States via the procedures for getting new 
drugs approved. The pharmaceutical market in Finland has been marked 
by extensive price regulation while price setting in the US has been free 
(Rinta 2001). Most of the pharmaceutical industry’s products in both 
countries have ended up meeting domestic demand during the period 
under investigation. It could be imagined that the domination of markets 
by domestic manufacturers and differences in price controls would mean 
that the price-cost margins of the Finnish pharmaceutical industry would 
remain at a lower level than in the US. In other words we can assume 
that Finnish companies have less price setting power than US compa-
nies.  
A main finding of Essay 2 was that no difference between Finland and 
the United States in the average price-cost margins of the pharmaceutical 
industry could be found during the period under investigation. This re-
sult is surprising given the fundamental difference in price controls in the 
respective two countries.  
On the one hand, this phenomenon may stem from the dual nature of 
the pharmaceutical markets in both countries. Drugs protected by pat-
ents or brand name products can be priced at a higher level in the United 
States in line with monopolistic principles. In Finland, on the other  
 
                                                 
11  The earlier version of Essay 2 was printed in ETLA’s Discussion Paper Series, no. 
883 (Hermans and Linnosmaa, 2003). Preliminary versions of the essay were pre-
sented in the 24th Nordic Health Economists' Study Group Meeting, 15-16 August 
2003, Bergen, Norway, and in the 4th World Congress, International Health Eco-
nomics Association, 15-18 June 2003, San Francisco, USA. 
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hand, patent-protected products have been subject to price controls. In 
the United States after patent protection expires there are huge markets 
for generic drugs and competition is fierce, which pushes down the level 
of prices.  
In Finland, competition with respect to generic products has not been 
as keen owing to the relatively small market potential and the tendency 
of domestic manufacturers to turn their products into brand names. The 
above-described differences between the market structures of these two 
countries and the segmentation of markets between patent-protected and 
generic products may lead to the same average overall price-cost margins 
in the pharmaceutical industry.   
It is also possible that the Finnish price control system has not worked 
in the way desired, but rather the pharmaceutical companies have been 
able to negotiate a relatively high price level for their drugs. Deeper 
analysis of the market structure and regulatory schemes is necessary so 
that we can shed light on the reasons behind the similarities in the mar-
ket power of the pharmaceutical industry. 
The historical development of the drug industry, its competitive situa-
tion and price setting behavior are of great significance for the biotech-
nology industry. Owing to the considerable costs and risks associated 
with drug development, large pharmaceutical manufacturers have begun 
to outsource the initial stages of its research and development activities, 
for example to external biotechnology companies.  
1.3.3  Capital Structure of the Finnish Bio-Pharmaceutical  
Industry 
The length of time needed for product development is very long in the 
pharmaceutical industry. The time from the initial product innovation 
to launch of the final product on the market can take as long as 10-15 
years.  The product life cycle is considerably longer than in most other 
manufacturing sectors. For example, innovations in the software indus-
try are on the store shelves within two years on average. Drug devel-
opment thus entails considerable risks for the financiers of the R&D 
work. The profit expectations regarding drugs that are able to break 
through successfully onto the global market are also high. Nevertheless 
only a small fraction of the development projects become commercially 
successful.   
Drug development is heavily regulated in the industrialized countries. 
The drugs have to go through pre-clinical tests on animals and clinical 
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tests on people, a process that ordinarily takes several years. The tests are 
designed to assess the suitability of the drug molecules for humans as 
well as the desired effects on a certain sickness or alleviation of symp-
toms. Depending on the type of medication, the number of people to be 
tested may climb into the hundreds or even thousands. Especially the 
third stage of clinical tests costs vast sums of money. 
The international marketing of pharmaceuticals is very expensive and 
even large-scale marketing efforts cannot guarantee a product break-
through. Many new drugs are marketed directly to the physicians who 
write the prescriptions. On the other hand, the advertising of prescrip-
tion medication is to a growing extent also directed toward the final 
consumers. 
As a consequence of the uncertain and expensive product develop-
ment and marketing process, the development and investment company 
3i estimates that turning one blockbuster drug into a commercial success 
costs on an average about USD 500-800 million. In Finland, SMEs as a 
whole in the bio-pharmaceutical sector have received financing of about 
EUR 225 million for their activities. We can therefore easily conclude 
that Finnish companies will not try to export drugs to the global markets 
by themselves, but rather they will do it in cooperation with larger part-
ners such as international pharmaceutical manufacturers. 
As the innovative activity of large international pharmaceutical com-
panies is unable to produce enough new commercially successful prod-
ucts, large pharmaceutical companies have decided to outsource their 
R&D activities and risks to small biotechnology companies. Large phar-
maceutical companies can help bring the most promising innovations of 
small biotechnology companies to the market. In practice, the large 
companies can buy licenses, all of the rights or a majority or minority 
stake in the companies that undertook the development work. 
According to Essay 3, the transfer of prolonged promising projects to 
another pharmaceutical company reflects upon the ownership structure 
of Finnish bio-pharmaceutical companies.12 The older companies generat-
ing sales revenues have a different ownership structure than the younger 
ones. The owners of the older companies are mostly other companies. 
The ownership of the younger companies, on the other hand, is rather 
                                                 
12  The earlier version of Essay 3 was printed in ETLA’s Discussion Paper Series, no. 
888 (Hermans, 2004). A Finnish version of the essay was published in Dosis, Phar-
maceutical Journal, vol. 19, no. 3 (Hermans, 2003a). 
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evenly distributed among the persons actively engaged in the company, 
Sitra13 and private capital venture firms. 
1.3.4  Intangible Assets and Growth Expectations of  
Biotechnology Companies 
The present value of a company is based on the expectations of its future 
returns. The historical accounting data for the biotechnology industry 
does not enable us to form expectations based on previous revenue and 
profitability figures. When making investments, external investors should 
have indicators at hand that help them project future earnings in light of 
the company’s current situation. Without these kinds of measures, the 
earning expectations with respect to the potential investment target may 
be distorted. 
According to the literature related to knowledge management, intangi-
ble assets and intellectual capital inherently reflect a company’s potential 
to create value and future earning expectations. Essay 4 investigates 
whether the growth expectations of Finnish small and medium-sized 
biotechnology companies are attributable to their intangible assets.14 The 
objective of Essay 4 is to empirically verify impacts of intellectual capital 
on the anticipated future sales of companies.  
In the study the value of a company’s intangible assets is quantified 
and defined by modeling the intellectual capital and value creation of 
companies from the viewpoint of knowledge management. The model is 
able to explain about 70% of the biotechnology companies’ anticipated 
sales in 2006. Technically, the model’s ability to explain 70% of the vari-
ance of the anticipated future sales controls for the risk of randomness 
of these anticipations disclosed by the biotechnology companies. This 
means that a large portion of the companies’ growth expectations is 
based on the value stemming from intangible assets. This approach also 
                                                 
13  The Finnish National Fund for Research and Development (Sitra) is a public foun-
dation under the supervision of the Finnish Parliament. 
14  The earlier version of Essay 4 was printed in ETLA’s Discussion Paper Series, no. 
856 (Hermans and Kauranen, 2003). It was submitted to R&D Management and it 
is still under review process. Preliminary versions of the essay were presented in 
“Innovations and Entrepreneurship in Biotech/ Pharmaceuticals and IT/ Tele-
com”, School of Technology Management & Economics, Chalmers University of 
Technology, May 19-20, 2003, Gothenburg, Sweden and in the Workshop ”The 
Economics and Business of Bio-Sciences & Biotechnologies: What can be learnt 
from the Nordic countries and the UK?" September 25-27, 2002, Gothenburg, 
Sweden. 
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offers a means for making economic projections based on the compa-
nies’ growth expectations.  
It seems that a well-balanced combination of human capital, struc-
tural capital, and relational capital implies value creation potential and 
high- anticipated future sales. This notion calls for a well-prepared 
strategy even for the early stages of the company in order to attract 
capital inflows. Despite of the fact that many companies which are in-
volved in drug development have high growth anticipations, there are 
many other promising, albeit occasionally under-resourced, branches 
within the biotechnology industry. These include applications related to 
biomaterials, diagnostics, food and feed, industrial enzymes, agriculture 
and forestry.   
1.3.5  Impact of Biotechnology Industry Growth on Finnish 
Economy in Near Future  
Essay 5 compiles an economic growth forecast where the probability 
distribution is formed from the companies’ sales growth forecast and 
their current sales revenues.15 The model also incorporates the bank-
ruptcy risk. The modeling technique is based on the sectoral input-
output method utilizing the purchase and sales volumes announced by 
companies in the respective sectors.  
According to the forecast model based on the data from the year 
2001 the biotechnology cluster is able to produce EUR 850-1200 mil-
lion worth of value added with a probability of 90 % in the year 2006. 
In the year 2001 the entire biotechnology sector’s value added was 
about EUR 500 million, meaning that annual growth of the entire clus-
ter would be approx. 10-18 percent. Despite this, the value added will 
remain relatively low because the biotechnology companies use a high 
amount of funds for purchasing services and goods from outside the 
firm. According to the forecasting model, by 2006 the biotechnology 
cluster’s contribution to annual GDP growth will be about 0.05-0.09 
percentage points. 
                                                 
15  The earlier version of Essay 5 was printed in ETLA’s Discussion Paper Series, no. 
894 (Hermans and Kulvik, 2004a). It was then submitted to The International Jour-
nal of Biotechnology and it is still under review process. Preliminary versions of the 
essay were presented in the conference of BioTech Society, 29-30 September 2003, 
Espoo, Finland, and in the 4th Triple Helix Conference, Track 10: Technology 
Foresight in the Triple Helix, 6-9 November 2002, Copenhagen, Denmark. 
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Figure 4.  Production by sector 1970-2002, in year 2000 prices (Her-
mans and Kulvik 2004b). 
Industrial history shows us that if a region or a country has no previ-
ous industrial traditions in a certain sector successful businesses and new 
growth emerge slowly or only seldom. Finland has pinned high hopes on 
biotechnology as a source of new research-intensive growth. Almost all 
industrialized countries have the same goal, and many of them already 
have long traditions in this sector. The biotechnology sector has a short 
history in Finland. The biotechnology sector’s volume of production 
measured by value added is about EUR 500 million. In order to put the 
growth possibilities of the biotechnology sector in perspective, we can 
ask when Finland’s currently strong sectors – the forest, machinery and 
electronics industries – were in the same situation (Figure 4).  
In the year 2000 prices, the value of forest industry production was 
half a billion euros in the early 1950s. The electronics industry reached 
that level in the mid-1970s. If the biotechnology sector achieved the 
same growth as that of the electronics industry fueled by Nokia, it would 
be reach the position of the “fourth pillar” of industry in about 30 years. 
If the life cycle of the biotechnology industry as an independent sector is 
like that of the forest industry, it would take 50 years. If a long run 
growth rate of production of the biotechnology sector is sustained at  
the same level as in the forecast period 2001-2006, it would take 15-30 
years to reach the same production level as electronics or pulp and paper 
industry have today.  
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The health care sector’s domestic service production is at relatively 
high level compared even with highly export-oriented industries (Figure 
4). The massive health care sector has reached a major crossroads owing 
to the aging of the population and advances made in medical science. On 
the one hand, the aging of the population and the medical possibilities to 
diagnose and treat more illnesses than before increase the cost pressures 
on health care. On the other hand, biotechnology applications are ex-
pected to spawn cost savings over the long run by, for example, making 
time-consuming diagnostic methods more efficient and facilitating tar-
geted therapy. It is investigated below some policy implications how the 
Finnish biotechnology industry could offer solutions to the cost crisis in 
health care while at the same time spurring development of an interna-
tionally competitive industrial cluster.  
1.4  Conclusions 
1.4.1  Policy Implications 
A small country cannot do everything itself. From the standpoint of in-
novation intensity, the safeguarding of sufficient critical mass is of pro-
found importance if the emergence of a biotechnology industry is 
deemed worthy in Finland. In order to foster the success of biopharma-
ceutical companies, a business concept ranging “from services to devel-
opment of own drugs” must be developed, which will spawn profitable 
business activities also in the pharmaceutical sector. The protection of 
intangible rights and exploitation of business expertise right from the 
onset of the research projects will help biotechnology companies receive 
financing and launch successful business activities. The growth of the 
biotechnology companies can be facilitated by directing resources to 
niches where Finland has comparative advantages and where the com-
mercial applications have substantial market potential in the future. 
The following list comprehends 5 implications broadly derived from 
the essays of the thesis. 
Essay 1. Market structure and regional concentration: In order to 
reach a critical mass, small companies seek to concentrate their activi-
ties in the vicinity of other companies in the same sector. In the future 
it is expected that the activities of companies will become more con-
centrated on innovation-intensive regions also across international 
borders. 
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Implication 1: Sufficient innovation intensiveness and critical mass must be safe-
guarded and defined in the individual biotechnology competence segments in the fu-
ture if Finland wants to have an economy based on knowledge, not e.g. wage cost 
advantages.   
 
Essay 2. The price-cost structure in the pharmaceutical industry 
seems to be the same in a small economy with price controls as in a 
large economy without price controls. In order to bolster profitability 
the pharmaceutical industry, companies outsource their research and 
development because of the considerable risk associated with these ac-
tivities. 
Implication 2: In the near future it is possible to operate profitably as a small en-
trepreneur in certain niches in the pharmaceutical sector. Some large Finnish 
pharmaceutical company could strengthen its position in global markets by col-
laborating with small and technologically advanced Finnish biotechnology compa-
nies. The kind of collaboration could offer synergy in the combination of most 
modern technology of small biotechnology companies and resources and logistics of 
a large pharmaceutical company.  
 
Essay 3. The investigation of financial sources and business 
strategy of biopharmaceutical companies confirmed that the main 
sources of financing for young companies are the persons working at 
the company, private venture capitalists and the public sector. The 
growth expectations of young companies are pointed far into the fu-
ture. The older biopharmaceutical companies owned by other firms 
have already been able to generate revenues, which is indicative of the 
pharmaceutical industry’s new strategy of outsourcing R&D activities. 
Implication 3: The equity financing of biopharmaceutical companies in the start-
up phase is based on the premise that the investors think they can exit at a later 
stage. In the current situation in the international financial markets the most 
common way to exit is via an acquisition or other type of restructuring. The com-
pany is an attractive target for acquisition and its value will simultaneously grow 
when the company has begun to produce considerable amounts of revenues or its 
product development has proceeded far enough. This calls for dynamic corporate 
strategies, in which positive cash flows can be generated even at the start-up phase 
of the company in order to finance the later development phases of the company’s 
products. 
 
Essay 4. The analysis of intangible assets and growth potential 
of Finnish small and medium-sized biotechnology companies 
concludes that when a company’s intellectual capital (human capital, 
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structural capital and relational capital) are balanced and soundly 
managed, the company’s present value is relatively high. Then poten-
tial investors or buyers of the company are able to make a strategi-
cally justified estimate of the company’s future earnings expectations 
and the present value. Financing paves the way for the company to 
turn its innovations into commercial products.  
Implication 4: The management of biotechnology companies’ intangible assets and 
competencies is an important measure of future earnings expectations and therefore 
the company’s present value. Thus the integration of business expertise right from 
the start as a part of the technological development occurring in the network of 
biopharmaceutical companies helps determine whether the company’s business 
strategy is based on development of the market potential of products, not just tech-
nological competencies. 
Essay 5. The growth forecast for the biotechnology industry 
presents the SMEs in the biotechnology industry as a sector of its 
own. Growth impacts of the biotechnology industry extend to many 
sectors, foremost the chemical industry, which includes also the 
pharmaceutical sector.  
Implication 5: The biotechnology industry as a distinct sector will not become one 
of the main pillars of the Finnish economy for at least a decade, even if the growth 
is swift. It is likely that the Finnish economy’s new engine of growth will emerge 
from a combination of already existing new and old sectors. In this case, biotech-
nology may play a significant role of its own. To fulfill the anticipations, there is a 
need for the creation of a critical mass of factors of production and comparative 
advantage by building collaboration and financing networks between the biotech-
nology industry and traditional industries, such as the forest industry, electronics 
industry and pharmaceutical industry. 
 
Health care cost crisis and growth potential of biotechnology in-
dustry  
As seen above biotechnology is often linked with drug development and 
various types of health care applications such as diagnostics and bioma-
terials (Figure 1). Almost 60 percent of the small and medium-sized bio-
technology companies indicate that they operate in the pharmaceutical 
industry or have ties with clients in the pharmaceutical industry. Fields 
linked indirectly with health care include functional foodstuffs, enzymes 
and assorted research services. However, the Finnish pharmaceutical 
industry and other health care-related industry is nevertheless relatively 
small on a global scale.  
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Inaccurate diagnoses or a lack of appropriate treatment leads to a 
wasteful use of personnel resources and medication. In other words, if 
the illness is not known or it cannot be treated, the patient has to un-
dergo time-consuming procedures and the treatment may have to be 
changed numerous times. The patient may have to be institutionalized 
due to inefficient treatment. If more efficient ways can be found to make 
diagnoses and treat patients that would otherwise need long-term care, 
relatively expensive methods can generate cost savings by shortening the 
duration of treatment times (see case study; Hermans and Kulvik 2004b). 
 
Case study: Use of biotechnology and related fields in treating 
strokes: more efficient treatment and decrease in total cost of treat-
ment (Kaste, 2004) 
A stroke is the most common type of disruption of blood circulation to 
the brain. Its treatment takes many days of acute treatment, which has led 
to an increase in treatment costs. In 1999 about 6 percent of total health 
care expenses were related to treatment of strokes. The acute treatment of 
patients suffering from brain circulation disorders takes an average of 
about 2.5 years, which in Helsinki costs about 100,000 euros (Kaste, 
Fogelholm and Rissanen 1998; Finne-Soveri 2003). Fogelholm, Rissanen ja 
Nenonen (2002) estimate that the aging of the population means that the 
need for acute treatment will double by the year 2030.    
The neurological polyclinic of the Helsinki University Central Hospital 
(HYKS) has started to treat stroke patients with so-called thrombolysis, 
where a doctor tries to remove a blood clot by dissolving it. Thrombolysis 
uses alteplasis medication, which is recombinant DNA, produced with the 
help of hamsters’ ovarian cells. Despite the favorable results obtained by 
the thrombolysis, it has two drawbacks. First, the medication is relatively 
expensive: one dose costs over 1000 euros. Second, the thrombolysis must 
be started quickly, about 3-4 hours, after a stroke.  
In 2002 about 8 percent of the stroke patients coming to the HYKS 
neurological clinic received the solvent treatment with good results. About 
60 percent of the patients receiving thrombolysis recovered. The total cost 
savings with respect to the recovered patients was about 84,000 euros per 
patient, which represents over 80 percent of the non-recovering patients’ 
total costs (Lindsberg, Roine ja Kaste 2000; Finne-Soveri 2003). ”The timely 
and efficient treatment of stroke victims is the cheapest alternative for society in economic 
terms, but for the patient it is like winning the lottery.” (Kaste, 2004.) 
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Targeted therapy is based on a deep understanding of the interaction 
of organs even on a genetic level, so that treatment of illnesses can be 
given on a patient group-specific basis or even on a patient-specific basis. 
Targeted therapy requires development of diagnostic methods and 
equipment together with targeted medicines or dosages. In order for 
targeted therapy to become economically feasible, the actors from differ-
ent fields will have to engage in intensive cooperation and offer compre-
hensive services and product concepts to customer groups and interest 
groups.  
Instead of individual drugs, the comprehensive service and product 
concept caters to different patient groups by offering customized diag-
nostic methods, variations of medication, other new treatment methods 
as well as related equipment and software.  
In addition to the training of end users, the financiers of health care 
can be offered calculation models of the cost savings vis-à-vis ordinary 
procedures without targeted therapy. The comprehensive product con-
cept based on these kinds of product mixes and related services offers a 
means for cooperation between biotechnology companies and global 
distributors with complementary expertise so that the benefits gained by 
the customer are maximized in terms of the effectiveness and cost effi-
ciency of the treatment. At the same time the knowledge base of small 
biotechnology companies will become more diversified as cooperation 
with firms in closely related sectors spawns new operative procedures 
and innovations.   
In Finland there are several types of diseases significant from a public 
health care perspective, the treatment of which have considerable mac-
roeconomic effects. The macroeconomic effects can entail other costs 
than those stemming directly from health care. For example, worker 
absenteeism and premature pensions affect the productivity of various 
industries.   
Illnesses significant from a public health care perspective have steered 
the allocation of domestic research resources, which has spawned inter-
nationally significant areas of expertise in medical science and related 
fields. The research knowledge and demand for its commercial applica-
tions arising from these kinds of public health care needs enable the do-
mestic market to be used as a commercial test market. Finnish end users 
of health care products represent the top experts in their fields, which 
promotes the product development of biotechnology companies and 
development of service concepts as well as prepares companies products 
and services to compete on international markets.   
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1.4.2  Topics for Further Research 
Further research is needed to evaluate which potential niches the bio-
technology sector should seek to fill when developing products with 
commercial potential. When seeking to identify these niches, it is impor-
tant to keep in mind that the competence base must be sufficiently large 
to generate the critical mass necessary for spawning products and ser-
vices with sufficiently large market potential. We can look at the precon-
ditions for turning research into commercial products from the stand-
point of the competence base underlying this critical mass: knowledge-
intensive entrepreneurship, financing possibilities and international mar-
ket potential 
1) by distinguishing the main incentives and barriers regarding en-
trepreneurship in a research segment with a deep competence 
base. In addition, by investigating the distribution of biotechnol-
ogy companies that have already emerged, we can seek to find 
niches that have a considerable competence base but also a 
“commercialization gap”. 
2) by analyzing the preferences of financiers investing in biotech-
nology companies, which is then compared with the distribution 
of the competence base of biotechnology research. 
3) by analyzing and comparing the international market potential to 
Finland’s competence base.  
This type of further research would be beneficial for planners of gen-
eral technology policies and actors in various sub-sectors of the bio-
technology industry. Technology policy experts can benefit from the 
research results when gauging use of alternative types of aid in light of 
the principle of comparative advantage based on international trade 
analysis. In Finland substantial amounts of state aid are directed to the 
biotechnology sector. The private and public investment activity is 
rather modest by international standards. Resources should thus be 
allocated prudently. 
Biotechnology research can be applied in many diverse areas. There 
is a danger that when making financing decisions the authorities are 
unable to “see the forest for the trees”. Therefore, start-ups that base 
their activities on isolated top-notch research fields may end up without 
financing. A reason can be the lack of a viable business plan even if the 
segment has considerable market potential. 
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Further research should offer such new information about the bio-
technology sector that would assist public and private financiers in better 
understanding the biotechnology sector and its companies. A proper 
understanding is necessary for making sound decision when scarce re-
sources are steered toward promising fields of application. 
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ESSAY 1.  
New Economic Geography of Market  
Potential – Innovation Intensity and  
Labor Structure in EU Regions16 
Abstract  
In the present study, we ask how economic integration affects the loca-
tion of economic activities and the spatial distribution of market poten-
tial in Europe. The theoretical framework is based on the new eco-
nomic geography approach in the trade analysis literature. Empirical 
analysis transforms data into a synthetic free trade area (SFTA) that is 
constructed by standardizing the values of each variable to a compara-
ble level in each country. Then SFTA is compared with the real trade 
area (RTA). The comparison offers insights into how “extreme” inte-
gration within countries (SFTA) has affected the location of economic 
activities and how this integration differs from the spatial structures 
among countries (RTA). 
The empirical results suggest that regional innovation intensity has 
affected the spatial market potential within countries but not among 
the same countries. This has important implications for the discussion 
about regional development during the economic integration process. 
The results imply that if international integration gets forms similar to 
those that “extreme” integration has had within countries, lower inter-
national trade barriers will lead to geographic concentration in the re-
gion with high innovation intensity. The conclusions of the results 
change in some respects when we use different data subgroups. Inno-
vation intensity does not seem to be a relevant driver in all the sub-
groups formed. However, the labor share of agriculture remains a pow-
                                                 
16  I thank professor Ilkka Kauranen, professor Hannele Wallenius, and participants 
of the EcoMod Conference on Policy Modeling, held 4-6 July 2002 in Brussels, 
for their comments on the preliminary versions of this study. I also appreciate the 
notes I obtained from professor Pertti Haaparanta when he acted as an examiner 
of my licentiate thesis. The financial support from the Yrjö Jahnsson Foundation, 
the Finnish Cultural Foundation, and Tekes is gratefully acknowledged.  
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erful predictor of geographical concentration in all the subsets and 
models.  
Key words: economic integration, location, monopolistic competition, 
sunk costs, trade.  
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1.1  Introduction 
The economic and political integration process has been recently deep-
ening globally. European countries in particular have integrated relatively 
rapidly and the plans for the expansion of the EU have been widely dis-
cussed. There has been much discussion on how the deepening integra-
tion affects the regional distribution of economic activities. Theoretical 
developments in trade analysis, in particular, have advanced rapidly in 
recent years. Krugman (1991a, 1991b) set the basis for the new eco-
nomic geography by applying the monopolistic competition framework á 
la Dixit and Stiglitz (1977). Krugman and Venables (1995) and Venables 
(1996) extended the framework to the use of intermediaries in manufac-
turing. Puga (1999) solved the model analytically. Fujita, Krugman, and 
Venables (1999) concluded the theoretical contributions of the time. 
Ottaviano (2001) endogenized capital inputs in the models. Martin and 
Rogers (1995), Baldwin et al. (2003) considered the role of regional pol-
icy in the framework. However, there are few empirical studies published 
in the field (e.g. Hanson, 1998; Davis and Weinstein, 1999; Redding and 
Venables, 2000; Midelfart-Knarvik et al., 2000).  
The present study aims to analyze how economic integration affects 
the location of economic activities and the spatial distribution of mar-
ket potential in Europe. The theoretical framework behind the empiri-
cal analysis in this paper employs an approach called new economic 
geography, which takes into consideration the interrelation between 
market structure and the spatial structure of economic activities. The 
independent variables for the analysis are chosen in accordance with 
the theory.  
The empirical section presents a regression analysis of the inner areas 
of 12 EU countries. The inner area of each country is assumed to have 
integrated extensively. In contrast, there have been relatively high trade 
barriers on the international level between these countries. An analytical 
tool, called the Synthetic Free Trade Area (SFTA) is constructed in order 
to compare the spatial structures both within the countries and between 
them. The SFTA is constructed first by standardizing all the variables 
within single countries. Second, all the data is pooled together to form a 
SFTA aggregate, which is, in turn, used in regression analysis.  
International economic structures are compared with the internal spa-
tial economic structures of traditional states. International trade is here 
assumed to have higher trade barriers and higher trade costs than intra-
state trade. Therefore, we can compare SFTA and the actual data of the 
Real Trade Area (RTA) in order to obtain more information about spa-
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tial agglomerations in highly integrated regions (within countries) and 
among less integrated regions (among countries).  
In other words, if the form of economic integration between countries 
is similar  to that of intra-state areas, then economic integration might 
have a similar impact on the international structure of spatial market 
potential as individual countries have had on intra-state trade. In order to 
make such an analysis possible, the actual area, including 187 regions, 
and the corresponding synthetic area of the same size are presented on 
the NUTS2 level. Changes of cross-sectional regression coefficients are 
investigated over time. The SFTA analysis is also benchmarked by using 
a more conventional panel data analysis. 
The remainder of the study is as follows. Chapter 2 presents the theo-
retical model that describes how the market structure affects the location 
of economic activities. Empirical methodology and variable construction 
appears in Chapter 3. Chapter 4 discusses the empirical results and the 
last section concludes the study.    
1.2 The Theoretical Model 
The theoretical model used in this study is based on the monopolistic 
competition model by Dixit and Stiglitz (1977). The spatial framework 
relies mainly on Krugman (1991a, 1991b).  
1.2.1  Consumption Structure 
Let us assume that there are two production sectors in two economies.  
Sector A produces identical goods under perfect competition and con-
stant returns to scale (CRS). This sector is referred to as a local agricul-
tural sector. Sector M produces differentiated goods under monopolistic 
competition and increasing returns to scale (IRS). It is often referred to 
as a manufacturing sector. 17 The theoretical presentation focuses here on 
the latter sector.  
Consumer preferences can be presented as a Cobb-Douglas function 
between the two sectors.  
(1)  10 ,)1( <<= − πππ AMCCU . 
                                                 
17  For example, Krugman, 1991a; Krugman, 1991b; Krugman and Venables, 1995. 
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The consumption aggregate CM of  sector M is the share π (percent) of 
the total consumption and the consumption of product CA of sector A is 
then the share 1-π (percent). Manufactures are consumed as the constant 
elasticity to substitution (CES) aggregate function implies: 
(2)  NicC
iiM
,...,1  ,1 ,
11 =>⎥⎦
⎤⎢⎣
⎡= −
−∑ σσ
σ
σ
σ
. 
The term ci in equation above is a single manufacturing good. The 
number of goods (N) produced in the sector is large, although all the 
possible varieties are not produced. The elasticity of substitution is sim-
ply σ (sigma), according to the CES preferences of the consumer:  
(3)  
d( c c )
c c
d( p p )
p p
j kj k
j k
k j
k j
⋅ = ≠σ ,  . 
Consumer preferences are presented by a constant elasticity to scale 
(CES) function within industrial sector goods. The terms j and k denote 
differentiated product variations. This preference type implies the sym-
metrical but imperfect substitutability of the goods. The larger the value of 
sigma, the more substitutable the goods are with each other, and vice versa.  
1.2.2  Production Structure 
Increasing returns to scale are introduced in the model through fixed 
(sunk) costs. Sunk costs are denoted as a. Marginal costs are denoted as 
b. The production volume of a single manufacturing firm is measured by 
xMi. The production function is of the linear form: 
(4) MiMi xL βα += , 
where LMi is the labor used to produce xMi goods output. Sunk costs can 
be regarded as costs caused by research and development (R&D) activi-
ties or marketing and advertising activities which are related to consumer 
preferences. And vice versa, the consumer preferences are directly related 
to the scale economies of the production process. When new firms are 
allowed to enter the market, then no firm can capture abnormal profits 
in the long run. This implies the following link between the cost struc-
ture of a firm and the consumer preferences: 
  
32 
(5) wpi βσ
σ
1−=  
The term w denotes the wage level. The interpretation of s is related 
to elasticity of substitution and consumer preferences (see eq. 2 and 3). 
The price of a single product is a mark-up over marginal costs. The 
mark-up is related to the elasticity of substitution. Accordingly, the aver-
age unit costs of the production must also be covered when the produc-
tion process contains not only marginal costs, but also sunk costs. 
We can solve the quantity of goods produced by a manufacturer with 
the help of a price equation (eq. 5) and by using a zero-profit assump-
tion. The assumption is related to the long-run definition: market entry is 
free in the long run and, therefore, the profit margin drops. The produc-
tion quantity is then: 
(6) β
σα )1( −=ix  
The higher the sunk costs, the more a single firm produces. On the 
other hand, the consumer preferences limit the sunk cost effect.  
We can also count the number of firms in a market: 
(7) ασβα
M
i
M L
x
Ln =+=  
The smaller the number of firms, the higher the sunk costs. The mar-
ket structure is then affected considerably by sunk costs (for instance 
R&D activities) and also by consumer preferences. These simplifications 
play an important part when we determine how the market structure is 
related to the firms’ decisions about the location of their activities. 
1.2.3  Two-region Model  
The present study follows Krugman (1991a, 1991b) to construct the 
two-region model. The only essential modification made concerns the 
numeric simulation presentations. In addition, some corrections are 
made to partial derivations in the end of the analysis. This model de-
scribes a situation where manufacturing has agglomerated in the other 
region, whereas the agricultural workers are evenly distributed between 
both regions. The trade barriers, or trade costs, between the two regions 
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are presented by Samuelsonian iceberg costs. The simplest example of 
trade barriers is transport costs due to the distance between the regions. 
According to the iceberg costs part of the goods exported to another 
region “melts away” during the transportation.  
In the present study, the wage level of the agriculture sector is chosen 
to be unity. We also assume that the total production of both regions, 
and the amount of total labor, equals unity. There is π (percent) of work-
ers employed in the manufacturing activities. The term π is at the same 
time the proportional share of manufacturing labor out of the total labor 
and manufacturing production out of total production. Because region 1 
(labelled with the subscript one) is a core region, its gross regional prod-
uct, and income, (Y) is: 
(8) 
2
1
1
π+=Y . 
The regional income of the peripheral area, region 2, is presented in 
equation 9: 
(9) 
2
1
2
π−=Y . 
We form the ratio of regional incomes between regions 1 and 2: 
(10)  π
π
−
+=
1
1
2
1
Y
Y . 
When all the manufacturing goods are produced in region 1, the sales 
(V) of a single manufacturing firm in region 1 is:  
(11) 
n
V π=1 . 
The wage levels (w) can vary between the regions. 
(12) ππ τ )(
1)(
1
2
1
2 ==
P
P
w
w  
The competitive wage level must equal the price index (P) ratio be-
tween the regions weighted by the manufacturing labor share. This in 
turn depends on trade costs (τ) between the regions. The larger the 
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trade costs between the core and periphery, the higher the wage level 
offered in the periphery must be when labor is mobile between the 
regions as assumed. The imported manufacturing goods are more ex-
pensive in the periphery than in the core region due to the trade costs 
between the regions. This implies also a higher price level and demand 
for higher wages in order to achieve the same utility level in both re-
gions.  
The sales of a potential entrant manufacturer in the periphery are shown 
in equation 13. 
(13) [ ]2)1(
1
2
1
)1(
1
2
2 )()( Yw
wY
w
w
n
V −−−− += σσ ττ
π  
[ ])1(
1
2)1(
1
2 )(
2
1)(
2
1 −−−− −++= σσ τπτ
ππ
w
w
w
w
n
 . 
From equations 11 and 13 we get the manufacturer’s sales ratio be-
tween the regions: 
(14) [ ])1(1)1(
1
2 )1()1(
2
1 −−−− −++= σσσπ τπτπτ
V
V  . 
The sales ratio exceeds the wage ratio:  
(15) πτ
1
1
2
1
2 =>
w
w
V
V . 
The outcome can be derived from the zero-profit assumption. The 
sunk costs must be covered by operating incomes and the sales must 
exceed the wage ratio.  
1.2.4  Theoretical Results 
A keystone of the theoretical analysis is based on equation 16. We get the 
market potential of a region by multiplying both sides of equation 14 by 
the result of the wage ratio in equation 15.  
(16) [ ])1(1 )1()1(
2
1 −−− −++= σσπσ τπτπτυ  . 
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Equation 16 presents the market potential index. When the market 
potential index is lower than 1, it is not profitable to set up a firm in the 
peripheral region. When the value is greater than 1, it is profitable to 
start manufacturing also in the periphery. The market potential index 
emphasizes three drivers, which affect the firms’ choices about where to 
locate their production activities according the model. These three driv-
ers are 1) trade costs, 2) the labor share of manufacturing, and 3) the 
increasing returns to scale in manufacturing. Note that the increasing 
returns to scale are related to the sunk costs as well as consumer prefer-
ences in this model.  
We take partial derivatives from equation 16 in order to analyze how 
the central parameters affect the location decisions of firms, and, there-
fore, the spatial agglomeration of economic activities. 
First, we check how the market potential index is affected when the 
labor share of manufacturing alters, other things being equal:  
(17) [ ])1(1
2
1)(ln −−− −+= σσσπ ττττυσ∂π
∂υ . 
The result of equation 17 is simulated also numerically in Figure 1.  
 
Figure 1.  Determining the location of production activities by changes 
in labor share of manufacturing. 
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The labor share of the sector experiencing scale economies (here: 
manufacturing) has a straightforward impact on the spatial agglomera-
tion. If the labor share is relatively low, it is profitable to start production 
also in the periphery. And if the labor share is relatively high, staying in 
the core region is the profitable choice. Sunk costs implying increasing 
returns to scale in manufacturing affect, in a parallel manner, the profit-
able location choices. Enhancing scale economies lowers the dispersion 
boundary of spatial agglomeration.  
In equation 18 we analyze how interregional trade costs affect the lo-
cation decisions of the firms:  
(18) [ ]τ τπτπσττπσυ∂τ∂υ
σσπσ
2
)1()1()1( )1(1 −−− −−+−+=  
Figure 2 presents a numeric solution for the partial derivative. The 
change in trade costs (or trade barriers) affects the profitability of the 
location of the manufacturing firm. When the trade costs diminish, the 
spatial agglomeration becomes the profitable way to organize the busi-
ness. However, if the scale economies are relatively low (e.g. for small 
R&D activities), the geographical concentration occurs only when the 
trade costs are very low.  
 
Figure 2.  Determining the location of production activities by changes 
in trade barriers [costs].  
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Lastly, we control for the changes in the scale economies of the 
model. The effect has been captured in the two previous figures:  
(19) [ ])1(1 )1()1(
2
1)ln( −−− −−++= σσπσ τπτπτπυτ∂σ
∂υ  
))()(ln( ∂τ
∂υ
σ
ττ= . 
The partial derivative of equation 19 states that high scale economies 
imply high spatial agglomeration. The trade costs work in the same direc-
tion as presented above in Figure 2. 
The theoretical results contribute to the empirical investigation of the 
economic reasoning behind the location of economic activities. The re-
sults of the model can be generalized from equations 16-19 and pre-
sented as a function of the labor share of agriculture, increasing returns 
to scale and trade costs:  
(20) ⎟⎟⎠
⎞
⎜⎜⎝
⎛= +−+− )( costs trade,costssunk e,agricultur of share laborpotentialMarket a . 
The market potential index, n in equation 16, is denoted as market po-
tential below and in equation 20. There are three main independent vari-
ables derived from the model. First, the market potential is affected by 
labor share of agriculture, 1-p, which is a reciprocal variable of the labor 
share of manufacturing, p, presented in the model above. Second, in the 
model, high sunk costs imply increasing returns to scale in production 
and corresponding changes in consumer preferences, s/(s-1). The rela-
tion between increasing returns to scale and sunk costs ensues from the 
condition for the optimal price setting in equation 5. Accordingly, the 
firms set a sufficient mark-up over marginal costs in order to cover also 
sunk costs. Third, there are trade costs, t, which affect to the market 
potential.  
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1.3  Empirical Analysis 
1.3.1  Background 
The present study examines the regional distribution of the market poten-
tial, or “density” of economic activities, the market structure and the labor 
structure of an economy in accordance with the model by Krugman 
(1991a). The effect of trade barriers is taken into account in a novel way. 
We compare the spatial structure of the intra-country trade costs with the 
international spatial structure of the trade costs, which are conventionally 
assumed to be greater internationally than within the countries. A close 
example of statistical regression analysis is Hanson’s (1998) analysis of the 
distribution of regional demand shocks in the United States. Hanson esti-
mates the effect of the distance between the regions on the demand for 
labor and on changes in the wage level in different regions. 
The regional market potential18 is specified on the NUTS2 level of 
European regions.19 The data is described with the help of statistical and 
geographical information.20 In the present study, an object of interest is 
whether there appear to be geographic agglomeration advantages on the 
level of NUTS2 regions and how the existence of such regional agglom-
eration advantages can be explained.  
According to Hanson (1998) the question concerning the reasons for 
the formation of spatial agglomeration was theoretically undefined ear-
lier, but Krugman (1991b) derived the causal relation of the market 
structure and spatial agglomerations theoretically. Hanson here takes 
advantage of the concept of market potential. The market potential of a 
                                                 
18  Literature of Economic geography (initially Harris, 1954; Hanson, 1998, 9) presents 
market potential as follows: 
,)(∑
∈
=
Kk
jkkj dfYMP
 in which MPj depicts the market 
potential of region j, Yk the production level of region k and djk the distance between the 
regions j and k. Function f( ) is a monotonically decreasing function, which presents 
how geographic distance affects the transport or trade costs. Here we simplify the defini-
tion of market potential to the form GDP / km2 and transport / trade costs are ana-
lysed by Real Trade Area and Synthetic Free Trade Area analysis. 
19  NUTS is an abbreviation for the nomenclature of Territorial Units for Statistics. 
According to the NUTS classification, Eurostat has sought to form a division of 
member countries for the collection of coherent statistical data from the regions of 
the EU. Cultural differences have also been taken into account, due to which the 
differences between the sizes of some regions are notable. (European Commission 
1994, 172).   
20  For example, Bivand (1998) specifies the methods of spatial-economic research. 
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region is determined by its size and relative location. With the help of the 
market potential estimates obtained from the regional data of the United 
States, Hanson simulates how strongly a demand shock that has oc-
curred in one region affects the wage levels of other regions. Hanson 
uses numerical geographical information and computer-assisted maps to 
demonstrate the results. 
The mobility of the labor force was emphasized in the theoretical 
model presented earlier. Hanson’s hypothesis is that a high wage level 
explains the density of economic activities, that is, the market potential. 
Hermans (2000) uses innovation intensity as an instrument variable to 
explain the income level. The result of the 2SLS cross-section model is 
that the wage level significantly affects both the international and the 
intranational distribution of economic activities. In the present study, 
innovation intensity is used directly as a theory-based depiction of in-
creasing returns to scale in production. 
1.3.2  Assumptions 
In the statistical analysis we assume that the trade between the inner re-
gions of a country has been free with relatively low barriers for decades. 
The concept of a synthetic free trade area is constructed so that we could 
analyze spatial structures within countries. The real situation, where pro-
portionately high trade barriers between the countries have appeared, is 
compared with the synthetic free trade area. Although the trade barriers 
between the countries have recently become lower, for example, between 
European countries, it can still be thought that there have been more 
trade barriers between countries than within a separate country. One 
reason is that the trade barriers were caused by the exchange of currency 
and cultural and linguistic differences. Naturally, there are still trade bar-
riers within the countries but, by and large, it is reasonable to suppose 
that within the countries trade barriers have historically been relatively 
lower than between the countries.21 
 
                                                 
21  For example Davis and Weinstein (1999) conclude in their empirical research that 
the advantages of spatial agglomeration are significant between the regions within 
the country but not internationally. They maintain this is the case because within the 
countries the transport costs and other trade barriers are lower than on the interna-
tional level and that the mobility of factors of production between the inner regions 
of the countries is greater than internationally.  
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The central assumptions of the analysis concerning the synthetic free 
trade area can be divided into two main parts: the nature of trade within 
the countries and between them. When both inputs and final products 
are looked at, the assumption concerning free trade within the countries 
and international trade barriers can be characterized with the help of the  
following example. In the supply of inputs, in this case the labor force, it 
is evident that in Finland the supply and mobility of the labor force can 
be relatively flexible, for example, between eastern and southern Finland 
in comparison with, for example, the situation between Estonia and 
southern Finland. There have been regulations that restrict the labor 
mobility between the countries. Although internationalization is nowa-
days rapid, evidently in past decades the international markets can never-
theless be said to have been open to free trade in Europe concerning 
both inputs and final products if compared to markets within countries. 
On the basis of this assumption an effort is made to demonstrate how 
economic activity has been organized spatially within the countries in 
“extreme integration” over a long period in comparison with way eco-
nomic activities have been agglomerated internationally. International 
development has been affected by trade barriers that are greater than 
under “extreme integration”. 
Economic integration into the international economy has strength-
ened and widened remarkably, for example, concerning Austria, Finland, 
and Sweden in the 1990s. These countries joined the EU in 1995. Due to 
the stage-by-stage nature of integration, available time series are short-
term and with their help the possible long-term effects of integration 
cannot be found. However, by forming a synthetic free trade area, the 
spatial structure within the countries can be aggregated and compared 
with the real trade area. 
Another central assumption concerns the significance of different 
sectors (agriculture, industries, and services) in an economy as an in-
dependent variable. The different sectors are operationalized as an 
estimation of the share of agricultural labor out of the total employed 
labor. On the international level, the labor share of agriculture largely 
describes the stage of the economic development (e.g. Camm et al. 
1986). On the other hand, within the countries the share of agricul-
tural labor out of the total employed labor is probably frequently 
bound to the surface area of the land, since the soil is used as an input 
in agriculture.  
The second independent variable is the increasing returns to scale 
(IRS) in production processes. High sunk costs imply high increasing 
returns to scale in the model, ceteris paribus. We assume that a signifi-
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cant part of sunk costs are related to R&D activities. Consequently, 
IRS is denoted as innovation intensity measured by the region’s pat-
ent applications per GDP. The theoretical model suggests that the 
greater the IRS, the greater is also the spatial agglomeration of market 
potential. The third theoretically relevant variable, trade costs (or 
trade barriers), is investigated by comparing the results of RTA and 
SFTA analysis.  
1.3.3  Data 
The data employed in this study comes from Eurostat’s New Chronos 
Regio database. The database covers a great deal of different regional 
information. Unfortunately, the Regio database includes a serious prob-
lem of time series deficiencies. The selected data comprises NUTS2 re-
gions in 12 countries. The whole set of observations covers the years 
1996-1999.  
The 12 countries in the study include 187 regions in the following 
countries: Austria, Belgium, Finland, France, Germany, Greece, Italy, the 
Netherlands, Portugal, Spain, Sweden, and the United Kingdom. The  
countries are selected according to the data available in the period cover-
ing 1996-1999. The subgroup of 8 countries is used in analyzing the 
longer period 1989-1999 containing 128 regions. The 4-country subgroup 
of Austria, Finland, Sweden, and the United Kingdom contains 59 regions 
and covers the years 1996-1999.  
Figure 3 depicts the distribution of economic activities among Euro-
pean regions in 1999. The activities are measured by GDP per km2. The 
distribution is not equal over the regions, but the densest agglomeration 
is located within the area reaching from Northern Italy to South-East 
England. The areas located on the geographic peripheries are mainly 
economically less active than those located near the geographic gravity 
centers of the EU.  
The overseas regions of France have been omitted from the data 
due to the lack of time series. Furthermore, these regions do not seem 
to have significant relevance for the economic integration process 
within Europe. The regions located in the former East Germany have 
been omitted from the analysis partially also due to the lack of time 
series. In addition, the East German regions have been developed 
under a non-market-oriented environment during recent decades. 
Hence, the development of economic structures varies from the rest 
of the data.  
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Figure 3.  Geographic distribution of market potential (GDP per km2 
in Millions of Euros) in European NUTS222 regions.  
 
 
 
                                                 
22  Eurostat utilizes the NUTS classification in producing and combining European 
statistics. The abbreviation stands for Nomenclature of Territorial Units for Statistics. 
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1.3.4  Variable Construction 
In the theory described above the spatial agglomeration of market poten-
tial is regarded as a convenient dependent variable for empirical analysis. 
We measure spatial agglomeration of market potential as annual Gross 
Domestic Product (GDP)23 per region’s surface area in square kilome-
ters. The independent variables in the models are the labor share of agri-
culture (LSA) and increasing returns to scale (IRS). The trade costs, or 
trade barriers, are investigated in comparing the two sets of models. Due 
to the different scales of regions, we construct a Metropolitan dummy 
variable. It is zero for the regions that are classified alike at both NUTS1 
and NUTS2 levels. Each variable is logarithmized before other trans-
formations. 
Labor structure (LSA) is formed as the share of agricultural labor out 
of the total labor employed in the region. The labor share of manufactur-
ing in the model is converted reciprocally into the labor share of agricul- 
ture. The theoretical model above contains only two sectors, manufac-
turing and agriculture. However, some service activities have also tended 
to agglomerate spatially. Thus, we measure the labor share of agriculture 
(1-p in the model) instead of the manufacturing share. It is arguable that 
agriculture is a proper measure for the empirical analysis because agricul-
ture uses land intensively as an input in its production.  
Increasing returns to scale in production activities are linked with the 
firms’ cost structure in the model. There is an absence of sunk cost fig-
ures available in our data. In the present study, the number of patent 
applications is regarded as the outcome of R&D activities and sunk 
costs. Accordingly, the increasing returns to scale in the model are meas-
ured by innovation intensity, that is, patent application per capita.  
The trade costs in the previous model are investigated empirically 
in comparison with two models. We form the Real Trade Area (RTA) 
and Synthetic Free Trade Area (SFTA) in order to analyze the effects 
of the different levels of trade costs, or trade barriers. All the annual 
values are standardized by reducing the annual mean of the same vari-
able in the entire data. Then each outcome is divided by the respec-
tive standard errors. In this manner we form the RTA, which de-
scribes actual data but is strictly comparable with the following SFTA 
transformation.  
                                                 
23  GDP is purchasing power parity stabilized in each country. 
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The Synthetic Free Trade Area (SFTA) is constructed by standardizing 
each variable separately in each country according to Hermans (2000). 
The standardization is then done by reducing the country-specific means 
and dividing them by country-specific standard errors. Then we pool the 
data and analyze one entity (SFTA). SFTA describes a synthetic area, in 
which the spatial structures have been developed under “extreme” eco-
nomic integration, in intra-country conditions.   
Table 1.  Definition of variables. 
Theoretical  
model 
Basic variable for 
empirical analysis 
Real trade area 
(RTA) 
Synthetic free 
trade area (SFTA) 
Agglomeration of 
market potential 
index (dependent 
variable) 
Regional market 
potential GDP  
per km2 (log) 
GDP / km2 of a 
region subtracted 
by its average of 
entire data and 
then divided by 
standard deviation 
of entire data 
GDP / km2 of a 
region subtracted 
by its average in a 
country and then 
divided by standard 
deviation in a  
country 
Labor share of 
non-agriculture  
Labor share of agri-
culture 
Labor share of agri-
culture of a region 
subtracted by its 
average of entire 
data and then 
divided by stan-
dard deviation of 
entire data 
Labor share of agri-
culture of a region 
subtracted by its 
average in a country 
and then divided by 
standard deviation 
in a country 
Increasing returns 
to scale 
Innovation inten-
sity measured as 
patent applications 
per population  
Patent applications 
per population of a 
region subtracted 
by its average of 
entire data and 
then divided by 
standard deviation 
of entire data 
Patent applications per 
population of a region 
subtracted by its 
average in a country 
and then divided by 
standard deviation 
in a country 
Trade barriers Benchmarking the 
results of RTA 
and SFTA models 
  
 
Table 1 concludes the construction methods and definitions of vari-
ables included in the empirical analysis below.  
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1.4  Empirical Results 
The statistical analysis is divided into two parts. First, the data is analyzed 
by a regression model based on the evolution of the cross-sectional re-
gressors of RTA and SFTA. Secondly, the conventional panel data analy-
sis is used as a benchmark for the first phase results.  
1.4.1  Results of Synthetic Free Trade Area (SFTA) Analysis  
We employ OLS as a basic regression method. Each year’s parameters 
are estimated separately as cross sections. The RTA describes drivers 
affecting the spatial agglomeration of economic activities among the 
countries and the SFTA within the countries. Table 2 presents the results 
of the 12-country model.  
The results of the 12-country model emphasize the difference be-
tween the agglomeration forces in the RTA and SFTA. Spatial ag-
glomeration in the RTA is affected solely by the labor share of agri-
culture. This implies that the high international distribution of eco-
nomic activities cannot be explained by the IRS effect, or innovation 
intensity. According to the theory, this might be due to high interna-
tional trade barriers. 
Instead, the SFTA model seems to imply that IRS affects relatively 
strongly the agglomeration of market potential (table 3). In 1996-1999, the 
IRS effect is significant. Because there are some changes in the level of 
significance, this may imply a collinearity problem. However, the SFTA 
model implies that the IRS effect, or innovation intensity, is parallel with 
the spatial distribution of market potential over the entire period investi-
gated here.  
 
 
  
Table 2.  Regression analysis (OLS) of 12 countries24 1996-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 12 countries 
 Real Trade Area  
Year Descriptives Constant Labor structure effect, LSA 
(labor share of agriculture) 
Increasing returns  
to scale effect, IRS  
(patents per capita) 
Metropolitan area  
(NUTS1) 
1996 
 
R2 = 0.658 
F=106.512*** 
N = 170 
 
-.037 
(.044) 
-.704*** 
(.057) 
0.004 
(0.050) 
1.043*** 
(0.260) 
1997 
 
R2 = 0.617 
F=89.245*** 
N = 170 
 
-.040 
(.047) 
-.696*** 
(.062) 
-.005 
(.053) 
.871** 
(.285) 
1998 
 
R2 = .649 
F=107.869*** 
N = 179 
 
-.045 
(.045) 
-.723*** 
(.057) 
-.010 
(.051) 
1.045*** 
(.274) 
1999 
 
R2 = .607 
F=76.081*** 
N = 152  
 
-.035 
(.054) 
-.718*** 
(.070) 
.035 
(.056) 
1.025*** 
(.287) 
Standard errors are in parentheses.  
The asterisk labels (*) stand for:   * 5 percent risk level,  ** 1 percent risk level,  *** 0.1 percent risk level.   
                                                 
24  The 12 countries include the same countries as the 8-country analysis, but Austria, Finland, and Sweden are also included. The countries are 
selected according to the data available in the period covering 1996-1999. 
  
Table 3.  Regression analysis (OLS) of 12 countries25 1996-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 12 countries 
 Synthetic Free Trade Area  
Year Descriptives Constant Labor structure effect, LSA 
(labor share of agriculture) 
Increasing returns  
to scale effect, IRS  
(patents per capita) 
Metropolitan area 
(NUTS1) 
1996 
 
R2 = .708 
F=134.160*** 
N = 170 
 
-.032 
(.040) 
-.700*** 
(.046) 
.094* 
(.043) 
.932*** 
(.233) 
1997 
 
R2 = .687  
F=121.592*** 
N = 170 
 
-.017 
(.041) 
-.689*** 
(.047) 
.091* 
(.044) 
.833*** 
(.245) 
1998 
 
R2 = 0.714  
F=145.314*** 
N = 179 
 
-.054 
(.040) 
-.693*** 
(0.045) 
0.154*** 
(0.042) 
1.095*** 
(0.235) 
1999 
 
R2 = .703  
F=116.687*** 
N = 152 
 
-.043 
(.045) 
-.700*** 
(.052) 
.124** 
(.046) 
.930*** 
(.239) 
Standard errors are in parentheses. The asterisk labels (*) stand for:   * 5 percent risk level,  ** 1 percent risk level,  *** 0.1 percent risk level. 
  
                                                 
25  The 12 countries include the same countries as the 8-country analysis, but Austria, Finland, Sweden and the UK are also added. The countries 
are selected according to the data available in the period covering 1995-1999. 
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When we compare the annual values of regression coefficients be-
tween the RTA and SFTA, it seems evident that economic integration 
has evolving under lower trade barriers within countries (SFTA) than 
between them (RTA). The labor share of agriculture explains the vari-
ance of spatial agglomeration in all the cases at the 0.1 percent risk level. 
The IRS effect deviates from zero at least at the 5 percent risk level in all 
the years in the SFTA but not even once in the RTA. Accordingly, this 
implies different spatial structures among the countries and within them. 
If international economic integration acquires similar forms to those of 
intra-national “extreme” economic integration26, the innovation intensity 
can be expected to be a driving force in the relocation of economic ac-
tivities. However, it is noticeable that the selected country sets have some 
effects on the qualitative implications. 
Tables A1 and A2 in the Appendix present the results of the 8-country 
analysis during 1989-1999. The model is adjusted by removing the four 
countries with the shortest time series. Thus, the data ranges from 1989 to 
1999. The labor share is still a significant predictor of spatial market po-
tential. As in the 12-country model, the IRS effect, innovation intensity, is 
not a significant predictor of spatial agglomerations in the RTA. In con-
trast with the 12-country model, the IRS effect does not significantly ex-
pound spatial distribution of market potential in the SFTA even at the 5 
percent risk level, excluding 1998. Therefore, the difference described 
above in the spatial structures within the countries and internationally is 
no longer as significant as it is with tighter risk level requirements. Accord-
ing to the theory, the smaller difference between the RTA and SFTA 
could be explained by the fact that the integration among the countries is  
already quite advanced. On the other hand, it seems to be a difficult ques-
tion: how to select the most plausible set of countries for the analysis. We 
can try to use as long as possible time series with a limited number of 
countries, or the highest number of countries with a limited time series. In 
other words, there is a trade-off between the maximum number of years 
and the number of countries chosen for the analysis.  
Finally, the set of four countries, Austria, Finland, Sweden, and the 
United Kingdom, omitted in the 8-country analysis, are also analyzed 
separately (see Tables A3 and A4 in the Appendix). The results provide 
parallel support to the first model with 12 countries. Though the labor 
                                                 
26  Intra-national development in Europe can be mostly emphasized by free trade, 
relatively low transport costs, and low cultural barriers during the past decades. 
Such an economic environment describes the “extreme” integration which has 
formed the economic structures within countries such as they are. 
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share of agriculture is still the significant force of the distribution of 
market potential. The IRS effect is also significant in every year in the 
SFTA, but not in the RTA. This implies that trade barriers are lower in 
intra-national trade than internationally. It may tell something about spe-
cific features of Finland and Sweden, which have large sparsely popu-
lated regions. These countries have high innovation intensity but a rela-
tively low level of market potential in general. However, market potential 
has agglomerated in some regions within these countries.  
Figures 4 and 5 present the information on cross-sectional regression 
coefficients. The evolution in the RTA seems to be similar in every sub-
set of the data (Figure 4). The labor share of agriculture significantly lim-
its the spatial agglomeration of economic activities and simultaneously 
the IRS effect does not expound the spatial market potential. As men-
tioned above, none of the RTA models offered confirmation for the 
significance of the IRS effect (innovation intensity).  
 
Figure 4.  Real Trade Area (RTA). Innovation intensity and the labor 
share of agriculture explaining the regional agglomera-
tion of economic activities among the countries.  
Figure 5 presents the evolution of the SFTA regression parameters. 
The labor share of agriculture does affect the distribution of economic 
activities in a consistent way in different data sets (the lower part of the 
figure). Apart from the RTA scheme, the IRS effect seems to affect spa-
tial market potential more consistently in the 4- and 12-country models 
than the entire 8-country model.  
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Figure 5.  Synthetic Free Trade Area (SFTA). Innovation intensity 
and the labor share of agriculture explaining the regional 
agglomeration of economic activities within the countries. 
1.4.2  Results of Panel Data Analysis 
We also benchmark the results of the RTA and SFTA analyses by using the 
more conventional panel data analysis.27 Panel data is analyzed in two ways. 
First, the data is investigated using fixed effect models in within-countries 
and between-countries frameworks. Secondly, we introduce dummies 
for each country and each year in the entire panel data. The results are 
presented in Table 4.  
In the fixed effect (within-countries) model, both the labor share of 
agriculture and IRS effect are significant drivers affecting the market 
potential. Furthermore, the IRS effect is not a significant driver of spatial 
agglomerations in the between-countries model. The dummy model im-
plies that both of the basic regressors are significant and that market 
potential levels are systematically higher in most of the countries than in 
Sweden, which is selected to be the base. Sweden and Finland score the 
lowest average market potential. At the same time, there are no signifi-
cant agglomeration variations over the years in the model. 
                                                 
27  Panel data contains the data of the 8 countries covering the period of 1989-1999.  
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Table 4.  Results from regression analysis of the panel data.  
Dependent variable: Agglomeration of market potential (GDP per km2) 
Variable Fixed 
effect  
Between 
countries28 
OLS with 
dummies 
Constant   -1.940*** (.078) -4.528   (2.273)   -4.152*** (.127) 
Metropolitan area (NUTS1)     1.269*** (.090)    1.268*** (.090)   
Labor structure effect, LSA 
(labor share of agriculture) 
    -.981*** (.020) -1.443*  (.563)   -.980*** (.020) 
Increasing returns to scale effect, 
IRS (patent appl. per GDP) 
  .031* (.013) -.296  (.239) .030* (.013) 
Belgium      2.202*** (.101) 
Germany      2.279*** (.094) 
Greece      2.530*** (.121) 
Spain      1.971*** (.105) 
France      1.782*** (.097) 
Italy      2.649*** (.010) 
The Netherlands      2.920*** (.010) 
Austria      2.020*** (.118) 
Portugal      2.347*** (.133) 
Finland   .259 (.155) 
The United Kingdom      1.833*** (.099) 
Year 1999   0.056 (0.067) 
Year 1998   0.056 (0.064) 
Year 1997   0.086 (0.064) 
Year 1996   0.051 (0.064) 
Year 1995   0.028 (0.066) 
Year 1994   0.074 (0.068) 
Year 1993   0.040 (0.068) 
Year 1992   0.068 (0.068) 
Year 1991   0.070 (0.069) 
Year 1990   0.077 (0.070) 
Number of observations 1509 1509 1509 
F 1419.06 3.83 325.83 
R2 (overall) 0.6755 0.5616 0.8405 
Standard errors are in parentheses. The asterisk labels (*) stand for:  * 5 percent risk level,  
** 1 percent risk level,  *** 0.1 percent risk level.   
* 5 percent risk level, ** 1 percent risk level, *** 0.1 percent risk level. 
                                                 
28  When the model also contains the metropolitan area dummy variable, as a regressor, 
the regression coefficients of the constant, metropolitan area, labor structure effect, 
and sunk cost effect are (standard errors in parentheses): -4.015 (2.279), -8.731 (7.625),  
-1.166 (0.604), and -.311 (.235), respectively. None of them deviates significantly from 
zero at the 5 percent risk level.  
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The results are consistent with the RTA and SFTA comparison at the 
5 percent risk level. The IRS effect seems to be parallel with the spatial 
market potential within the countries but not between them. And as 
mentioned above, if international integration is as deep as the intra-
country has been, we can expect that the IRS effect will become an im-
portant driver of the relocation of economic activities. 
1.5 Conclusions 
In the present study, the research question was: How does economic 
integration affect the location of economic activities? First, we con-
structed a theoretical model of the new economic geography from the 
international trade literature. Secondly, we tested the theoretical model 
empirically using data covering 187 NUTS2 level regions in 12 European 
countries. The data was divided into three subsets according to the in-
formation availability over time. Data on 8 of the countries covered the 
years 1989-1999 while data on the other 4 countries was available for the 
years 1996-1999. All the countries were also pooled together in 1996-
1999. 
The theoretical model raised three main drivers affecting the geo-
graphical concentration of market potential. The dependent variable, 
market potential, was measured as GDP per km2. The first driver, the 
labor structure effect was measured by the labor share in non-agricultural 
working activities in the theoretical model. In the empirical analysis, it 
was converted into its opposite, the labor share of agriculture. The sec-
ond driver, increasing returns to scale in production, theoretically related 
to sunk costs, was measured as innovation intensity (patent applications 
per capita in a region). The third driver, trade costs or trade barriers were 
investigated by a comparison between Real Trade Area (RTA) and Syn-
thetic Free Trade Area (SFTA). The RTA and SFTA framework was 
constructed so as to get strictly comparable coefficients over time. A 
dummy variable, metropolitan area, controlled for the dichotomous ef-
fect of five regions defined simultaneously as NUTS1 and NUTS2 re-
gions. Lastly, the results, obtained from the SFTA and RTA analyses, 
were also benchmarked by conventional panel data analysis.  
The economic integration was assumed to be very deep within coun-
tries. In other words, trade barriers were assumed to be low between the 
regions within the same country. This was expected to imply different 
spatial structures in RTA and SFTA contexts.  
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An important result of the comparison between SFTA and actual data 
was that market potential has agglomerated in different ways within the 
countries on the one hand and internationally on the other: the market 
structure had strongly affected the location of economic activities within 
the countries, but not positively internationally among the countries dur-
ing the period 1996-1999 in the entire data of 12 countries.  
The results of both the RTA-SFTA analysis and the panel data analysis 
seem to have some consistent aspects. As expected, the labor share of 
agriculture was the strongest driver affecting the geographical concentra-
tion of market potential in both the RTA and SFTA models. However, the 
IRS effect seemed to be related to spatial agglomerations of market poten-
tial only in the within-country context. An exception to this was the 8-
country set in which the IRS effect was significant only at the end of the 
time series. This is to say, generally speaking that business activities have 
not been located internationally according to the level of the IRS effect or 
innovation potential of regions. This implies that economic integration has 
not been as deep internationally as it has been within the countries.  
The model was adjusted by removing the four countries with the 
shortest time series. Thus, the data ranged from 1989 to 1999. Then the 
statistical model employed involved the problem of varying results de-
pending on the group of countries investigated. The increasing returns to 
scale (IRS) effect (sunk cost effect / innovation intensity) no longer pre-
dicted the agglomeration of economic activities as significantly as in the 
12-country case either in SFTA or in RTA. However, the four countries 
removed were also analyzed separately. Then the IRS effect was signifi-
cant in any period in SFTA in the four-country model. Finally, we used 
the entire time series (1989-1999) panel data and benchmark the above 
results by a conventional panel data analysis. The benchmark supported 
the results obtained from the entire 12-country and 4-country models. 
The IRS effect steered the location of economic activities within the 
countries, but not between them.   
In the present study, we scrutinized the regional structures emerging 
within and among the countries. Although the regional time series avail-
able were relatively short, the assumption of “extreme” integration within 
countries guided us in understanding the long-run development. The cur-
rent spatial structures have been developed over many decades. Hence, the 
short time series capture only the outcome of the long-run development. 
The small variation of the coefficients over time supports the statement: 
Regional effects of economic integration did not seem to change during 
the period investigated. The only exception was the 8-country subset in 
which we observed this phenomenon only at the end of the time series. 
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Innovation intensity seems to be an important target for further re-
search. Industrial sectors and their market structures could be analyzed 
in a regional context. The industry-specific empirical framework could 
offer new insights for the discussion on regional development especially 
in the industries with high innovation intensity. 
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Appendix 1.  Regression analysis of 8 countries. 
Table A1.  Regression analysis (OLS) of 8 countries 1989-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 
8 countries  
 Real Trade Area  
Year Descriptives Constant Labor structure
effect, LSA 
(labor share  
of agriculture) 
Increasing returns 
to scale effect, IRS
(patents per 
capita) 
Metro- 
politan 
area 
(NUTS1) 
1989 R2 = .751 
F=109.436*** 
N = 113 
 
.014 
(.042) 
-.758*** 
(.059) 
.029 
(.039) 
.351 
(.364) 
1990 R2 = .771 
F=112.525*** 
N = 104 
 
.115** 
(.043) 
-.727*** 
(.057) 
.039 
(.041) 
.857** 
(.280) 
1991 R2 = .760 
F=114.758*** 
N = 113 
 
.011 
(.042) 
-.721*** 
(.057) 
.016 
(.042) 
.850** 
(.287) 
1992 R2 = .761 
F=120.766*** 
N = 118 
 
.001 
(.042) 
-.670*** 
(.055) 
.078 
(.042) 
1.055*** 
(.285) 
1993 R2 = .762 
F=123.043*** 
N = 119  
 
-.017 
(.039) 
-.675*** 
(.052) 
.052 
(.038) 
.939*** 
(.269) 
1994 R2 = .761 
F=122.992*** 
N = 120 
 
.003 
(.038) 
-.681*** 
(.053) 
0.017 
(.039) 
.095*** 
(.268) 
1995 R2 = .750 
F=115.735*** 
N = 120 
 
-.004 
(.041) 
-.686*** 
(.057) 
.043 
(.043) 
.850** 
(.295) 
1996 
 
R2 = .766 
F=131.899*** 
N = 125 
 
.098* 
(.040) 
-.741*** 
(.058) 
.027 
(.042) 
1.225*** 
(.272) 
1997 
 
R2 = .731 
F=108.061*** 
N = 123 
 
.111* 
(.043) 
-.743*** 
(.064) 
.017 
(.045) 
1.075*** 
(.298) 
1998 
 
R2 = .719 
F=100.577*** 
N = 122 
 
.127** 
(.043) 
-.745*** 
(.065) 
.012 
(.045) 
1.261*** 
(.347) 
1999 
 
R2 = .746 
F=87.267*** 
N = 93  
 
.234*** 
(.047) 
-.846*** 
(.078) 
.016 
(.044) 
.670* 
(.303) 
Standard errors are in parentheses. The asterisk labels (*) stand for: * 5 percent risk level,  ** 1 
percent risk level,  *** 0.1 percent risk level. 
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Table A2.  Regression analysis (OLS) of 8 countries 1989-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 
8 countries 
 Synthetic Free Trade Area  
Year Descriptives Constant Labor structure
effect, LSA 
(labor share  
of agriculture) 
Increasing returns  
to scale effect, IRS 
(patents per 
capita) 
Metro- 
politan 
area 
(NUTS1) 
1989 R2 = .765 
F=118.264*** 
N = 113 
 
.016 
(.047) 
-.859*** 
(.054) 
.009 
(.053) 
.535 
(.383) 
1990 R2 = .771 
F=112.392*** 
N = 104 
 
.007 
(.049) 
-.826*** 
(.054) 
.058 
(.053) 
.952** 
(.310) 
1991 R2 = .746 
F=106.607*** 
N = 113 
 
-.001 
(.049) 
-.789*** 
(.055) 
.061 
(.055) 
.936** 
(.330) 
1992 R2 = .740 
F=107.899*** 
N = 118 
 
-.013 
(.048) 
-.775*** 
(.053) 
.097 
(.053) 
1.051** 
(.325) 
1993 R2 = .747 
F=112.888*** 
N = 119  
 
-.005 
(.047) 
-.767*** 
(.052) 
.092 
(.051) 
1.023** 
(.321) 
1994 R2 = .743 
F=111.901*** 
N = 120 
 
.004 
(.046) 
-.764*** 
(.052) 
.069 
(.051) 
.096** 
(.318) 
1995 R2 = .721 
F=100.008*** 
N = 120 
 
-.018 
(.050) 
-.762*** 
(.056) 
.074 
(.054) 
1.065** 
(.339) 
1996 
 
R2 = .724 
F=106.017*** 
N = 125 
 
-.029 
(.047) 
-.759*** 
(.053) 
.060 
(.051) 
1.214*** 
(.325) 
1997 
 
R2 = .729 
F=106.747*** 
N = 123 
 
-.015 
(.047) 
-.766*** 
(.053) 
.062 
(.052) 
1.066** 
(.332) 
1998 
 
R2 = .695 
F=89.444*** 
N = 122 
 
-.033 
(.049) 
-.714*** 
(.054) 
.143** 
(.053) 
1.320** 
(.053) 
1999 
 
R2 = .662 
F=58.181*** 
N = 93  
 
-.031 
(.061) 
-.713*** 
(.069) 
.079 
(.063) 
.970* 
(.382) 
Standard errors are in parentheses. The asterisk labels (*) stand for: * 5 percent risk level,  ** 1 
percent risk level,  *** 0.1 percent risk level.   
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Appendix 2.  Regression analysis of 4 countries. 
Table A3.  Regression analysis (OLS) of 4 countries 1996-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 
4 countries 
 Real Trade Area  
Year Descriptives Constant Labor structure 
effect, LSA  
(labor share 
of agriculture) 
Increasing returns
to scale effect, IRS
(patents per 
population) 
Metro-
politan 
area 
(NUTS1) 
1996 
 
R2 = 0.654 
F=25.791*** 
N = 45 
 
-.354* 
(.137) 
-.825*** 
(.117) 
-.405 
(.308) 
.723 
(.482) 
1997 
 
R2 = 0.637 
F=25.177*** 
N = 47 
 
-.416** 
(.131) 
-.841*** 
(.121) 
-.302 
(.268) 
.449 
(.510) 
1998 
 
R2 = .732 
F=48.224*** 
N = 57 
 
-.470*** 
(.103) 
-.909*** 
(.098) 
-.142 
(.224) 
.815* 
(.393) 
1999 
 
R2 = .690 
F=40.870*** 
N = 59  
 
-.502*** 
(.103) 
-.864*** 
(.104) 
-.138 
(.219) 
1.022* 
(.411) 
Standard errors are in parentheses. The asterisk labels (*) stand for: * 5 percent risk level, ** 1 
percent risk level, *** 0.1 percent risk level.   
 
Table A4.  Regression analysis (OLS) of 4 countries 1996-1999. 
Dependent variable: Agglomeration of market potential (GDP per km2), 
4 countries 
 Synthetic Free Trade Area  
Year Descriptives Constant Labor structure 
effect, LSA 
(labor share of
agriculture) 
Increasing returns
to scale effect, IRS
(patents per 
population) 
Metro-
politan 
area 
(NUTS1) 
1996 
 
R2 = .738 
F=38.551*** 
N = 45 
 
-.075 
(.068) 
-.481*** 
(.083) 
.211** 
(.072) 
1.007** 
(.312) 
1997 
 
R2 = .649  
F=26.494*** 
N = 47 
 
-.060 
(.075) 
-.405*** 
(.093) 
.203* 
(.079) 
1.060** 
(.357) 
1998 
 
R2 = 0.767  
F=58.053*** 
N = 57 
 
-.110 
(.067) 
-.621*** 
(.082) 
.185* 
(.070) 
1.146*** 
(0.301) 
1999 
 
R2 = .778  
F=64.304*** 
N = 59 
 
-.066 
(.080) 
-.652*** 
(.080) 
.208** 
(.068) 
.967** 
(.296) 
Standard errors are in parentheses. The asterisk labels (*) stand for: * 5 percent risk level, ** 1 
percent risk level, *** 0.1 percent risk level.   

  
61 
ESSAY 2.  
Price Markups and R&D Inputs:  
The Pharmaceutical Industry  
in Finland and the USA29  
Abstract  
The aim of this paper is to compare the price-cost margins in the phar-
maceutical industry in Finland and USA. We employ data on the Finnish 
and the US pharmaceutical industry. The estimation is theoretically based 
on a modification of the conventional growth models and its extensions 
under imperfectly competitive markets. The results show that the esti-
mated price-cost margin is 0.60-0.67 in Finland and 0.51-0.67 in the US 
with demand-driven instruments and lagged R&D expenditure-related 
instruments. When R&D stock is estimated and included as one produc-
tion input in the model, the price-cost margin drops to 0.43-0.55 in 
Finland and 0.40-0.58 in the US. Therefore, differences in regulatory 
environments have not altered the price-cost margins in the pharmaceu-
tical industry within these countries. This is due either to the inefficient 
regulation system in Finland or it is due to the differences between mar-
ket structures and the competitive environment.   
Keywords: competition, market structure, price-cost margin, pharma-
ceuticals, price regulation.  
 
                                                 
29  I thank Ismo Linnosmaa for his supervision of writing this essay.  I also thank espe-
cially Sverre Kittelsen for his important insights in the model setting. I appreciate 
the comments, concerning the preliminary versions of this paper, given by the par-
ticipants of The 24th Nordic Health Economists' Study Group Meeting, 15 - 16 
August 2003, Bergen, Norway. The financial support from TEKES (the National 
Technology Agency of Finland) and Yrjö Jahnsson foundation is gratefully ac-
knowledged. 
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2.1  Introduction 
There is a great need for international price comparisons of pharmaceu-
ticals particularly those being utilized in regulatory planning activities. 
The price comparison studies provide direct information on international 
price levels of pharmaceuticals. Such information is conventionally com-
bined with information on the costs of pharmaceutical production and 
research and development (R&D) and then utilized in decision-making 
and regulatory planning.  
Instead of comparing international prices directly, this article focuses 
on analyzing price-cost margins. There are some interesting price com-
parison studies (Danzon and Chao, 2000; Berndt et al., 1995). They show 
that international price comparison studies may provide biased results if 
they are based on unrepresentative samples and unweighted indices of 
pharmaceuticals. Furthermore, there also seems to be a lack of indispen-
sable information on factors affecting price levels. The price comparison 
studies describe the situation, but do not explain why price levels differ. 
Factors behind the price differences can be derived from the cost struc-
tures of firms, degree of competition, regulatory practices, or domestic 
income levels. In order to take into account these factors, this article 
measures the price-cost margins.  
The aim of this article is to provide information on factors influencing 
price levels in pharmaceutical markets. To do this, the price-cost margin 
of the pharmaceutical industry is estimated in two countries, Finland and 
the USA. These  differ from each other, for instance, in regulatory and 
competitive settings, and the size of the pharmaceutical industry.  
This paper is divided into three main sections. The following section 
provides some background information on pharmaceutical markets in 
Finland and the US. The theoretical model is set up in section 3 for the 
empirical analysis. Then section 4 presents the data, and the results of the 
estimation are given. Section 5 discusses the results compared to other 
studies and in the perspectives of regulation and R&D activities in the 
pharmaceutical industry. Section 6 concludes the paper. 
2.2  Regulation and Market Structure 
The pharmaceutical market in Finland has experienced strict price regu-
lation (see e.g. Rinta 2001). Before 1995, the approval of a pharmaceuti-
cal product for the public reimbursement system was linked with the 
institutionally-set price. Since 1995, drug prices have been deregulated in 
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principle. However, if a company applies to have the drug accepted as part 
of the Finnish reimbursement system, the pharmaceuticals pricing board 
sets the price at twice the amount that  will be refunded. In contrast, 
there has been no price regulation in the US market.  
The size of the US market is 200 times larger than that in Finland. On 
the one hand, the large size of the markets could theoretically imply some 
closeness to the features of perfect competition. On the other, because 
there are many patent protected products with some monopoly power, 
one would expect that many US companies, without direct price regulation, 
would charge more than their counterparts in a more regulated setting. 
One would expect that differences in the regulatory measures and size 
of the markets would cause a difference to the price-cost margin in the 
two countries taking into account economies of scale in production. If 
the industry could achieve increasing returns to scale in its production 
processes, the average costs of production would decrease with higher 
volumes of production. However, marginal costs do not necessarily de-
crease together with the decrease in average costs if, for instance, the 
cost function is linear. However, if marginal costs also decrease along 
with production volume, then we could expect higher price-cost margins 
in the US than in Finland, and vice versa, if there are increasing marginal 
costs. There could also exist a certain point or points in production vol-
umes at which the marginal costs begin to decrease or increase in a given 
time. This can be, for instance, due to additional costs of  hiring new 
employees from other sectors. 
The method in our study is based on Solow’s (1957) seminal work. 
The estimation procedure consists of Solow’s method for measuring 
technical change called Solow’s residual. The model ignores the question 
of increasing returns to scale by assuming constant returns to scale in 
production. Hall (1988) and Domowitz, Hubbard and Petersen (1988) 
developed the model and analyzed Solow’s residual in both perfect and 
imperfect competition frameworks. They showed that Solow’s residual is 
independent of the growth rate of the output-capital ratio if perfect 
competition prevails. However, if the market is imperfectly competitive, 
there is a correlation between the two variables and the growth of the 
total factor productivity is pro-cyclical.  
The estimation of price-cost margin can be based on the Solow’s 
residual setting. The method was applied by Linnosmaa, Hermans, and 
Hallinen (2004). They estimated the price-cost margin of the Finnish 
pharmaceutical industry. The estimation employed time series data and 
provided a fixed price cost margin over time. The present paper  extends 
that application and utilizes R&D expenditures and estimated R&D 
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stock in order to take R&D stock into account as a productive input in 
the pharmaceutical industry. This modification is justified given the high 
R&D intensity of the pharmaceutical industry.  
Finnish pharmaceutical markets have been highly regulated compared 
to US markets. On the other hand, the production capacity of the US 
pharmaceutical industry is over 200 times higher than the capacity in 
Finland. We restricted the sample to two countries because there was no 
further international data available which was plausible for measuring 
price-cost margins. We can also compare our results with other studies 
on the US markets (e.g. Scherer and Ross, 1990). It is also important to 
test the applicability of the method in two different countries with dif-
ferent data sources to see if the method could be utilized further in wide-
scale international studies.   
2.3  The Model 
The model is from Domowitz, Hubbard, and Petersen (1988) and Lin-
nosmaa, Hermans, and Hallinen (2004). The production function is the 
form: 
( )1  ( ) ( ) ( ) ( ) ( )( )tKtStLftAtQ ,,=  
where Q signifies production, A is a measure for the technical change 
not captured by other factors of production, L, S and K denote labor, 
research and development, and capital inputs, respectively. The term t 
stands for time, implying that all the variables are measured at a certain  
time. To simplify the notation, however, the time variable is dropped 
from the following analysis. 
Solow (1957) derived a measure for technological process, sometimes 
called Solow’s residual. Applying the same assumptions and principles to 
the above production function, Solow’s residual can be shown to be:  
( )2  AAKKLLbKKSSbKKQQ LS
&&&&&&& =⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−− ~~
, 
where the dotted variables stand for derivatives with respect to time. 
We denote the input shares simply as: 
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( )3
 cQ
SP
b SS =~
 
and 
cQ
LPb LL =~
, 
in which Sb
~ measures the share of R&D costs of the value of output, and 
Lb
~ stands for the share of the total labor wages of the value of output. 
The industry is assumed to be perfectly competitive and hence the out-
put is valued at marginal cost c.  
Under imperfect competition a firm’s output is not valued at marginal 
cost, but the price exceeds marginal cost. Under imperfect competition, 
the shares of labor and R&D can be rewritten as: 
( )4
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and LLL bc
p
pQ
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c
pb ==~
. 
The terms Sb  and Lb  stand for the ratio of  R&D expenditure to value 
added of production and the ratio of labor wages to value added of pro-
duction, respectively. Substitution of the shares in equation 4 in Solow’s 
residual in equation 2 provides: 
( )5  AAKKLLbcpKKSSbcpKKQQ LS
&&&&&&& =⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−−
. 
We define the Lerner index for monopoly power as follows:  
( )6
 p
c
p
cp =−−= λλ 1 and 
.
 
Term λ stands for the Lerner index, that is the price-cost margin, and 
1- λ depicts the price-cost ratio. The generalized residual can be further 
rewritten as30  
( )7  ( ) ( ) AAKKLLbKKSSbKKQQ LS
&&&&&&& =⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−−⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−−− −− 11 11 λλ
. 
                                                 
30  This also equals Hall’s (1988) specification, which is the basis of his empirical esti-
mation procedure. 
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Multiplying both sides of equation 7 by ( )λ−1  and rearranging it, we 
get:  
 
( )8
 
( ) ⎟⎟⎠
⎞
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. 
If λ is zero, firms have no market power and Solow’s residual (the left-
hand side of equation 3) is technical change. If firms can price their 
products over marginal costs, Solow’s residual depends on the changes 
in production and it fluctuates pro-cyclically (the right-hand side of equa-
tion 8).   
2.4  Data 
The data on the US pharmaceutical industry was collected from the 
OECD Health data and OECD STAN database. R&D figures for both 
countries were taken from the OECD ANBERD database. The data set 
for Finland was aggregated from the firm-level data in Statistics Finland. 
It contains all Finnish pharmaceutical firms, which have more than 20 
workers. The firm-size restriction was made in order to avoid the prob-
lem of inconsistent data in the capital stock variable. The capital stock 
figures for the smallest places of business were deemed to be unreliable 
over time. Figures on pharmaceutical expenditures were obtained from 
OECD Health Data. 
The US data set covers the time from 1970 to 1997 and the Finnish 
data from1975-1999. The R&D information covers 1973-1997. The 
data set contains information on nominal and real output, nominal 
and real value added, working hours, the number of workers, labor 
costs, R&D investment, and capital stock. The capital stock series was 
constructed from data on capital stock per labor hours. Table 1 below 
presents the descriptive statistics of the growth rates of the original 
variables used in this study. Output, value added, wages, and capital 
stock variables are measured in Finnish Markkas (FIM) and in US 
dollars (USD).   
Table 1 presents the real growth rates of value added, labor, capital, 
R&D expenditures, estimated R&D stock, GDP, and nominal pharma-
ceutical expenditure.  
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Table 1.  Descriptive statistics. 
Percentage annual rates of growth in volumes (1995 prices) 
 
Geometric
mean 
Std.  
deviation Minimum Maximum 
Value added 
Finland 6.2 % 19.6 % -14.9 % 82.9 % 
USA 4.6 % 5.2 % -4.7 % 18.4 % 
Labor 
Finland (working hours) 1.9 % 5.4 % -6.9 % 10.4 % 
USA 2.7 % 3.0 % -3.4 % 8.6 % 
Capital stock 
Finland 7.6 % 15.1 % -21.1 % 41.6 % 
USA 3.1 % 6.8 % -11.4 % 14.6 % 
R&D expenditure    
Finland 6.9 % 7.9 % -12.7 % 24.9 % 
USA 7.4 % 5.8 % -6.2 % 19.4 % 
Estimated R&D stock    
Finland 7.4 % 2.7 % 3.2 % 13.8 % 
USA 7.5 % 1.3 % 4.6 % 9.7 % 
Domestic pharmaceutical expenditure (in current prices) 
Finland 11.0 % 4.1 % 5.3 % 21.8 % 
USA 9.7 % 2.0 % 5.8 % 13.6 % 
GDP 
Finland 2.2 % 3.1 % -6.3 % 6.8 % 
USA 3.1 % 2.3 % -2.1 % 7.3 % 
 
Volume indices for output and value added were constructed in Statis-
tics Finland and are presented in 1995 prices for the Finnish data. Ex-
cluding the instrument variables, we received ready-made data in both 
value and volume terms. As instruments we used the nominal expendi-
ture on pharmaceuticals and gross domestic income. Data for the first 
instrument were obtained from the Social Insurance Institution of Finland 
while all the other data came from Statistics Finland. The volume indices 
for R&D data were constructed utilizing the GDP price indices. In the 
US data, the volume of production was estimated utilizing pharmaceuti-
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cal prices that were used as a production price deflator. The capital stock 
volume was formed employing the price index for investments in the US 
chemical industry.  
The first two instruments employed in models 1 and 2 – the growth 
rate of the nominal expenditure on pharmaceutical products and the 
growth rate of real GDP – can be held as indicators which are demand-
driven and do not affect the total factor productivity. Instead, a third 
instrument, the growth rate of real R&D expenditures with a lag of one 
year, is more problematic. If most of the R&D activities concentrate on 
improving the production processes of pharmaceutical firms, they boost 
the productivity. In this case, the instrument is not valid due to the 
causal relation with the dependent variable. But, if the R&D activities 
were mainly channeled to long-term drug development, they would not 
be mirrored closely in the short-term fluctuations in productivity. Keep-
ing this in mind, we add the growth rate of real R&D expenditure to one 
of our models as an instrument.   
2.5  Variable Construction 
The variables are constructed straightforwardly in light of the theory. 
First, variables are converted from nominal to real terms. Then the an-
nual changes are measured and contrasted with the growth rate of the 
capital stock (equation 8). The new and most critical part in the variable 
construction is the formulation of the R&D stock as part of the price-
cost margin estimation procedure.  
The R&D stock is applied in this study, instead of employing R&D 
expenditures, because our theoretical model employs the growth of 
stocks. The development in the growth of stocks is smoother over time 
than the growth of expenditure. The concept of knowledge stock is 
comparable to the capital stock presented in the original model. Second, 
R&D efforts seem to affect the knowledge stocks with lags. The stock is 
changing after a lag compared with R&D expenses.  
About half the R&D expenditure is wages (Guellec and Ioannidis 1997). 
Part of the R&D costs is intermediate input and capital investment. Ac-
cordingly, half of the R&D expenditure is deducted from the total cost of 
labor compensation to avoid counting it twice. Part of the R&D-related 
investment in equipment is possibly also documented in the capital stock, 
which may lead to counting the same data twice. Unfortunately, the data 
on intermediate input and share of R&D-related capital stock were not 
available. If R&D stock and capital stock are counted twice, the Lerner 
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index in the empirical model could even be negative. When these inputs 
are not reduced from the estimated figures, this has two possible impacts. 
It can distort the growth rates of R&D stock and the share of R&D stock 
of the total value added. The first mentioned effect is restricted if the in-
put changes symmetrically with the growth of the entire stock. However, 
the share of R&D stock can be overestimated, which in turn causes the 
Lerner index to be underestimated. However, when the data of both 
countries are treated similarly, the comparison is expected and uniformly 
reflects the reality. It is also illustrative to compare the results of both 
models, with and without the R&D stock effect.  
The R&D stock is created as follows. First, the R&D stock is calculated 
by conventional accounting standards. The R&D stock is formed by mul-
tiplying the R&D expenditure of the first period, 1973, by a factor of five. 
Five years is a conventional and cautious estimate for the range of the 
economic influence of the expenditure on R&D activities in conventional 
accounting standards. This is, the research and development activities this 
year are expected to affect the earning prospects of the industry during the 
next five years on average.  
The ratio between R&D investments and R&D stock is approximately 
1 / 5. In other words, the actual R&D expenditure is assumed to be the 
best estimator for the cumulative R&D stock. In order to fill this condi-
tion, we fix the annual depreciation rates of R&D stocks in both countries. 
The fixed depreciation rate of real R&D stock for Finland is estimated at 
14.5% and the US at 14.0%. The GDP deflator has been employed as a 
proxy for R&D prices. Hence, the real R&D stock grows as much as the 
real annual R&D expenditure and is depreciated by the fixed rate above. 
This corresponds to a 7.4% real rate of growth for the R&D stock in 
Finland and 7.5% in the US. In this setting, we can utilize the cumulative 
nature of knowledge, which is applied and formed in R&D activities.  
2.6  Empirical Model 
The empirical estimation is based on equation 8. We estimate a linear re-
gression model:  
( )9  ttt uqr ++= 21 αα . 
The left-hand side equals Solow’s residual rt  and the independent vari-
able corresponds to the output-capital ratio in the right-hand side of the 
equation 8. The independent variable is endogenous because the output-
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capital ratio appears on both sides of equation 8. We use the 2SLS esti-
mation technique to estimate the above model.  
2.7  Results 
We first estimate the model (equation 9) without the R&D stock variable 
and then later add this variable to the model. We utilize the nominal 
growth of pharmaceutical expenditure and the real growth of the GDP 
as instruments in two regression models estimated using 2SLS tech-
niques. Table 2 presents the estimation results of model 9 for both in-
strument variables. The estimates of the pooled regression model are 
also shown.  
The results propose that Solow’s residual (left-hand side of equations 
11 and 12) is strongly pro-cyclical both in the US and Finnish pharma-
ceutical industries. The correlation between Solow’s residual without 
R&D stock and the growth rate of the output-capital ratio is 0.978 (p < 
.01) in Finland and 0.919 in the US. The correlation between value 
added and factor productivity is 0.962 (p < .01) in Finland and 0.880 (p 
< .01) in the US. All of the correlation estimates deviate significantly 
from zero. This implies the simultaneous determination of Solow's 
residual and the output-capital ratio. In other words, changes in both 
variables are pro-cyclical. 
Table 2 presents the estimates of the Lerner index when Solow’s re-
sidual does not include  the growth of the R&D stock. Estimates for the 
price-cost margin in the Finnish pharmaceutical industry range between 
0.597-0.668 and in the US between 0.512-0.671. According to the t-tests, 
any pair of Lerner indices, obtained by different instruments, do not 
differ from each other between Finland and the US (p < .05).  
The results obtained from the Finnish pharmaceutical industry are 
equivalent to those of Linnosmaa, Hermans, and Hallinen (2004). The 
estimates for the Lerner indices in the US pharmaceutical industry are 
close to those obtained by Scherer and Ross (1990). 
Table 3 presents the results of the model, which contains the R&D 
stock in Solow’s residual. The change in the R&D stock-capital ratio is 
now weighted by R&D expenditure per value added (R&D share) ac-
cording to equation 8. Half the R&D share estimates are labor wages, 
which are, in turn, deducted from the total wages. The price-cost mar-
gins vary between 0.43-0.55 in Finland and 0.40-0.58 in the US. Accord-
ing to the t-tests, the Lerner indices do not differ significantly (p < .05) 
between Finland and the US. Despite some contradictions between the 
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results of the models, the results of the R&D stock-corrected models 
clearly show that the mark-ups are lower than the estimates from models 
which do not take into account R&D effects. However, t-tests show that 
the Lerner index decreases significantly only in Finland when we use 
pharmaceutical expenditure as an instrument and the R&D stock effect 
is taken into account (Appendix 2). The values of the Lerner indices are 
lower in all cases when the R&D stock is considered, but the differences 
are not significant (p < .05).  
Table 2.  Results of Solow’s residual 2SLS model with labor and 
capital inputs. 
Dependent:  
Solow’s residual 
R2 
(adjusted R2) 
Constant (a1) Lerner index (a2) 
Instrument: growth of GDP / capital 
Finland  .8564 (.8499) .0193   (.0162) .5970*** (.1437) 
USA .8010 (.7927) .0077   (.0060) .5120*** (.0847) 
Pooled data 
Fixed effects .8405 
(within groups) 
.0127   (.0085) .5766*** (.0926) 
Instrument: growth of pharmaceutical expenditure / capital  
Finland  .9001 (.8956) .0200   (.0135) .6683*** (.0985) 
USA  .8060 (.7979) .0076   (.0059) .5207*** (.0868) 
Pooled data 
Fixed effects .8792 
(within groups) 
.0126* (.0074) .6382*** (.0697) 
Instrument: growth of lagged R&D expenditures / capital 
Finland .8663 (.8602) .0194   (.0157) .6114**   (.1588) 
USA .8523 (.8449) .0094* (.0047) .6709*** (.1044) 
Pooled data 
Fixed effects .8710  
(within groups) 
.0145* (.0082) .6212*** (.1058) 
Method: 2SLS and on pooled data 2SLS fixed effect model 
Standard errors are in parentheses. The asterisk labels (*) stand for the level of the 
statistical risk to reject the null hypothesis incorrectly: the regression coefficient is zero.  
*   10 percent risk level,  **   1 percent risk level,  ***  0.1 percent risk level. 
The results of model 1 state that the estimated Lerner indices differ 
significantly from zero and they are 0.44 in Finland and 0.40 in the US. 
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This implies the approximated price-cost ratios to be 1.79 and 1.66, 
respectively. Instead, the constant term does not deviate significantly 
from zero. The constant term partially describes the effect of technical 
change without the estimation of the growth of R&D stock (see equa-
tion 11). When we add the growth of the R&D stock to the model, we 
can expect that the R&D effects capture much of the effect of techni-
cal change. Due to the inclusion of the R&D stock in the model, it 
seems logical that the constant term does not differ significantly from 
zero.  
Table 3.  Results of Solow’s residual model with labor, capital, and 
R&D inputs. 
Dependent:  
Solow’s residual (rt)  
R2 
(adjusted R2) 
Constant  
(α1) 
Lerner index 
(α2) 
Model 1: growth of GDP / capital as an instrument 
Finland  .7125 (.6988) .0073   (.0234) .4424*     (.2097) 
USA .6815 (.6671) -.0029  (.0063) .3963**   (.1133) 
Pooled data 
Fixed effects .6032  
(within groups) 
.0007   (.0136) .3878*     (.1530) 
Model 2: growth of pharmaceutical expenditure / capital as an instrument 
Finland  .8138 (.8049) .0093   (.0187) .5549**   (.1361) 
USA  .7130 (.7000) -.0029  (.0060) .4355*** (.1014) 
Pooled data 
Fixed effects .7067  
(within groups) 
.0015   (.0117) .5091*** (.1108) 
Model 3: growth of lagged R&D expenditures / capital as an instrument 
Finland .6979 (.6836) .0071   (.0240) .4287       (.2496) 
USA .8336 (.8253) .0005   (.0048) .5823*** (.1055) 
Pooled data 
Fixed effects .6213  
(within groups) 
.0027   (.0145) .3983*     (.1947) 
Method: 2SLS and on pooled data 2SLS (fixed effects)  
Standard errors are in parentheses. The asterisk labels (*) stand for the level of the 
statistical risk to reject the null hypothesis incorrectly: the regression coefficient is zero.  
*    10 percent risk level,  **    1 percent risk level,  ***  0.1 percent risk level. 
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Model 2 estimates the values of the Lerner indexes to be 0.55 in 
Finland and 0.44 in the US. Hence, the price-cost ratios are higher than 
in model 1 in both countries, 2.25 in Finland and 1.77 in the US. Models 
1 and 2 imply that price-costs margins are higher in Finland than in the 
US. However, model 3 alters the relative ranks of the countries. The 
Lerner index of the Finnish pharmaceutical industry is 0.43, which equals 
the value of the price-cost margin of 1.75. The Lerner index of the US 
pharmaceutical industry is 0.58 and the price-cost margin is correspond-
ingly 2.39.  
In one case (Table 3, model 3, Finland), the Lerner index does not de-
viate significantly from zero. The correction of heteroscedasticity by 
White’s robustness check altered the standard error and significance of 
the coefficient so that the Lerner’s index became significant in this 
model (p < .05).  
2.8  Interpretation of Main Findings 
Carlton and Perloff (1994) list results from studies estimating price-
cost margins in different industries. The highest price-cost margins 
appear in the regulated banking (0.88) and coconut oil industry (0.89). 
Our estimates on price-cost margin are below these two estimates. 
Scherer and Ross (1990) utilize accounting data and find that the US 
pharmaceutical industry has the sixth highest price-cost margin when 
industries are ranked according to the estimated price-cost margins. 
The authors estimate the price-cost margin to be 0.614. On the basis 
of informal discussions, Berndt et al. (1995) assess that price-cost 
margins for H2 antagonists would fall into the range 0.75-0.9.   
The price-cost margins of the pharmaceutical industry seem to be at a 
same level in Finland and the US. This is interesting  because there are 
some noticeable differences in the pharmaceutical market environments 
of these countries. For instance, price regulation is stronger in Finland 
than in the US.  
There can be two potential reasons for the similarity of price-cost 
margins in the pharmaceutical industry in Finland and the US.  If the 
markets are otherwise identical in Finland and the US, but price regu-
lation is applied in Finland, then the price regulation is not binding. 
In this case, Finnish authorities could either scrap the entire regula-
tory system or alternatively tighten price regulation. The first alterna-
tive could be optimal in the case of a costly regulatory system.  
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The other explanation for the result is that the markets are not other-
wise identical. Market structure, technological advancement, or govern-
mental interventions could be very different in the two countries. In this 
case, the price regulation may be binding. There are even other forms of 
regulation that have some effects on the market structure and prices. For 
instance, the differences in drug approval processes may imply a differ-
ence in markups. 
Before 1994, price setting was linked to the market authorization of 
the pharmaceutical product in Finland (Rinta, 2001). Price regulation 
used to be tied to the reimbursement system and it aimed at defining the 
reasonable wholesale and retail price of pharmaceuticals. If a company 
wanted to include its product in the reimbursement system, Finnish au-
thorities set a maximum price level for the product. In contrast, prices 
are set by the market in the US system.  
The US markets are divided into two parts. First, there are drugs that 
are patent protected and, second, there are generic drugs without patent 
protection or the patent  has expired. The large marketplace implies 
higher potential returns in the first case with high market power. The 
second case of generic competition implies that there might be almost 
perfect competition due to the large number of suppliers and consumers. 
In Finland, the market was relatively closed. The Finnish companies 
produced many compounds under license, as well as their own brands. 
There has also been a tradition of branding even non-prescribed generic 
domestically produced pharmaceuticals for Finnish markets. In other 
words, there exist some kind of market dichotomies in both countries.  
The nature of the markets can be a partial explanation for the similar 
price-cost margins. In other words, high mark-ups obtained from patent-
protected products can be offset by low margins within severe generic 
competition in the US. In Finland, regulated prices of prescribed prod-
ucts may imply relatively low mark-ups, which were offset by relatively 
high mark-ups of non-prescribed branded products in generic markets.  
2.9  Conclusion 
This study compared price-cost margins in the pharmaceutical industry 
in the US and Finland. The study applied a uniform estimation technique, 
based on Solow’s residual, for the countries in order to get comparable 
results in the markets in which price regulation systems are different. 
According to the results, price-cost margins do not differ between 
Finland and the US.  
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This study also attempts to take into account the effects of changes in 
R&D expenditure. This allows us to assess the impact of specific fea-
tures of R&D intensity in the pharmaceutical industry on its price-cost 
margin. The price-cost margin seems to decrease by over 10 percentage 
points in Finland when R&D stock is included in the model. However, 
the difference is statistically significant only in Finland, as pharmaceutical 
expenditure is employed as an instrument. In the US, the absolute effect 
was under 10 percentage points. The notion is in accordance with the 
theory. It also shows that conventionally estimated price-cost margins 
can be generally higher without implementing the impact of R&D ex-
penditure on the measures. This particularly holds true in R&D-intensive 
industries, such as the pharmaceutical industry.  
The results raise some questions about the efficiency of regulatory set-
tings and the differences between the market structure. If the market 
structure is the same in both countries, then (price) regulation is not 
binding in Finland, and either the regulation should be tightened or 
eliminated. If there are also differences in market structure and competi-
tive environment, as seems to be the case, the policy implication above is 
no longer so straightforward. For a more careful investigation of the 
market structure, for instance, the dichotomy in the domestic markets 
and the significance of foreign trade should be considered in further 
research.  
There are some open technical questions following the above analysis. 
The availability of the firm-level micro-data would enhance the number 
of methods that could be applied when evaluating price-cost margins. If 
panel data were available, the results of this study could be benchmarked 
by other methods. Another possible path could be an international com-
parison of the margins. This would be important in order to assess the 
impacts and efficiency of different regulatory systems. The panel data 
would also offer an opportunity to test the main assumptions of this 
study, for instance, the economies of scale. In further research, it would 
also be important to test the impacts of policy changes on the firms’ 
price-cost margins over time.  
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Appendix 1.  
Table 1.  Results of Solow’s residual OLS model with labor and 
capital inputs. 
Dependent:  
Solow’s residual 
R2  
(adjusted R2) 
Constant Lerner index 
Finland  .9562 (.9542) .0220* (.0089) .8818*** (.0402) 
USA .8453 (.8389) .0056   (.0052) .6640*** (.0580) 
Pooled data 
Fixed effects .9331 
(within groups) 
.0120   (.0053) .8492*** (.0321) 
Method: OLS and on pooled data OLS fixed effect model 
Standard errors are in parentheses. The asterisk labels (*) stand for the level of the 
statistical risk to reject the null hypothesis incorrectly: the regression coefficient is zero.  
*    10 percent risk level,  **    1 percent risk level,  ***  0.1 percent risk level. 
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Appendix 2. 
 
Figure A2.1.  Confidence intervals (95%) of Lerner indices without R&D 
stock effect from Table 2.   
 
Figure A2.2.  Confidence intervals (95%) of Lerner indices with R&D 
stock effect from Table 3.   
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ESSAY 3.  
Finance of Small Bio-Pharmaceutical  
Industry in Finland – Descriptive Analysis31 
Abstract 
This study investigates the capital and ownership structures of small and me-
dium-sized pharmaceutical-related biotechnology firms (bio-pharmaceutical 
companies) in Finland. These structures are also analyzed taking into 
account general characteristics and intangible assets of the business ac-
tivities in the industry. Relatively young companies are typically owned 
by persons that are active in the business, private venture capital compa-
nies, and government institutions. Older firms are mostly owned by 
other non-financial companies. The major capital loan supplier has been 
Tekes, the National Technology Agency of Finland. Equity financing 
from private venture capital companies and governmental sources has 
supported growth in research and development activities in the compa-
nies examined. However, the companies owned mostly by non-financial 
companies have been able to generate relatively high sales. These firms 
are also anticipated to have the highest sales potential over the next 5 
years. The results here are contrasted with explanations of the capital 
structure found in the literature. No single theory seems to explain the 
capital and ownership patterns within Finnish bio-pharmaceutical com-
panies. Instead, the literature suggests many explanations for the ob-
served ownership patterns. For example, different patterns can be related 
to the owners’ willingness to monitor the managers and support activities 
with high earning prospects. 
Key Words: Biotechnology, capital structure, finance, intangible assets, 
pharmaceutical industry.  
                                                 
31  This essay is partially based on the article published (in Finnish) in Dosis, scientific 
journal of Pharmacy vol. 19 no. 3. I appreciate the comments of Christopher Palm-
berg and Antti Tahvanainen, and also linguistic support obtained from John Rogers. 
The financial support from Tekes, National Technology Agency of Finland, and 
Yrjö Jahnsson Foundation is gratefully acknowledged.  
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3.1  Introduction 
In Finland a great deal of emphasis has been placed in recent years on 
biotechnology research in scientific circles as well as in biotechnology 
companies, the number of which has grown sharply. The biotechnology 
sector has been an interesting one recently owing to the high growth 
expectations and risks related to this field. This sector is anticipated to 
spark a new phase of technological development that will have a pro-
nounced impact on economic growth. ETLA carried out a survey of 
biotechnology companies in spring 2002. This study presents the main 
findings about capital structures and business characteristics of bio-
pharmaceutical companies. Overviews of the Finnish biotechnology in-
dustry have been made by e.g. Kuusi (2001), Schienstock and Tulkki 
(2001) as well as Hermans and Luukkonen (2002). The study at hand has 
been influenced by a study on the capital structure of Finnish small and 
medium-sized companies (Hyytinen and Pajarinen, 2002), a study depict-
ing capital structures in the biotechnology industry (Hermans and Tah-
vanainen, 2002) and a study on the SME sector in the US (Berger and 
Udell, 1998). Furthermore, Tahvanainen (2003) has analyzed the capital 
structures prevailing in the Finnish biotechnology industry. The study at 
hand focuses on the capital structure of biotechnology companies en-
gaged in pharmaceutical-related activities at the end of 2001 (see also 
Hermans, 2003). 
The study has two main aims. The first aim is to identify the sources 
of financing for Finnish bio-pharmaceutical companies. The second 
aim is to depict how various sources of financing are related to the in-
tangible assets and other characteristic features of these companies. In 
order to fulfill the first aim the sources of financing and capital struc-
ture are evaluated with respect to the companies’ age and size as well as 
their research intensity. In order to accomplish the second aim, princi-
pal component analysis is used to evaluate how sources and types of 
financing are related to the companies’ intangible assets. The study also 
sheds light on the capital structures from the perspective of the finan-
cial literature. 
The study is organized as follows. After the introduction, in Section 
2 we provide an overview of the bio-pharmaceutical sector. The char-
acteristics of the small and medium-sized companies in this sector are 
compared to those of the overall biotechnology industry and SMEs as a 
whole in the Finnish economy. Section 3 describes the capital struc-
tures of bio-pharmaceutical companies and the results of the survey are 
compared with those reported in the finance literature. Section 4 pre-
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sents the findings of the principal component analysis and presents the 
interconnections between capital structures and business characteris-
tics. Section 5 discusses the results of the study.   
3.2  Characteristics of Bio-Pharmaceutical Sector 
The data used in this study is derived from on a database compiled by 
ETLA covering financial and business-related information on 84 com-
panies operating in the biotechnology sector. An overview of the data 
is presented in Hermans and Luukkonen (2002). From the database we 
selected 42 small and medium-sized firms that indicated they are part 
of the pharmaceutical industry or that their clients or subcontractors 
are in the pharmaceutical industry. ETLA’s survey was carried out in 
early 2002 and its information is based primarily on the situation at the 
end of 2001. The information from financial statements has been 
cross-checked with the trade register of the National Board of Patents 
and Registration of Finland.  
The number of personnel in small and medium-sized32 bio-
pharmaceutical companies is relatively high compared to other Finnish 
SMEs as a whole, but their sales revenues are lower on average than 
those of companies in other industries. Almost 30 percent of the bio-
pharmaceutical companies employ over 20 persons while the corre-
sponding share for all SMEs is 15 percent. Despite the fairly high num-
ber of employees, the turnover of biotechnology companies is less than 
other companies. The turnover of about 45 percent of the bio-
pharmaceutical companies is less than EUR 200,000 while the corre-
sponding share for SMEs as a whole is about 15 percent. The sales of 
the bio-pharmaceutical sector are oriented more toward foreign mar-
kets than sales of other companies on average. 
The companies of the bio-pharmaceutical sector are comparatively 
young. Slightly more than a third of the biotechnology companies have 
been founded in 1997 or afterwards, while the corresponding share for 
SMEs as a whole is some 14%. 
 
                                                 
32  Below we use the term SMEs to denote small and medium-sized enterprises. A 
company is called small or medium-sized if two of the following three conditions 
are met: the company has a maximum of 250 employees, its turnover does not ex-
ceed EUR 40 million and its total assets are less than EUR 27 million. 
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Table 1.  Comparison of Finnish Bio-pharmaceutical SMEs and 
SMEs as a whole. 
  Bio-pharmaceutrical 
SMEs (%) 
Total  
SMEs (%)33 
Number of personnel <5 33 % 44 % 
 5-20 38 % 41 % 
 >20 29 % 15 % 
Turnover, million euro < 0.2  45 % 15 % 
 0.2-1.5 40 % 56 % 
 1.6-8.0 12 % 24 % 
 >8 2 % 5 % 
Exports / turnover 0 % 43 % 70 % 
 0-1 % 2 % 22 % 
 2-5 % 7 % 4 % 
 6-10 % 0 % 2 % 
 >10 % 45 % 3 % 
 Unknown 2 % 0 % 
Age of company, years 0-2 14 % 5 % 
 3-4 21 % 9 % 
 5-24 64 % 70 % 
 >24 0 % 16 % 
0 % 5 % 53 % 
0-1 % 2 % 23 % 
2-5 % 5 % 13 % 
R&D expenditures / total costs (Total 
SMEs = R&D expenditures / turn-
over) 
6-10 % 7 % 3 % 
 >10% 79 %  6 % 
 Unknown 2 % 0 % 
Yes  74 % 6 % Company has patents or  
patent applications  No 26 % 94 % 
<0 % 0 % 1 % 
0-1 % 2 % 31 % 
2-5 % 0 % 20 % 
6-10 % 10 % 23 % 
Company’s expected turnover 
growth over next 5 years  
(Total SMEs = next 3 years 
>10 % 86 % 21 % 
 Unknown 2 % 5 % 
Total observations in sample  42 754 
 
                                                 
33  Hyytinen and Pajarinen (2002) used sector-specific data on Finnish companies to 
uncover the real structure of Finnish SMEs. This study weighted the data according to 
the age of the companies (as Hermans and Tahvanainen 2002). The weights are ob-
tained as follows: 
)(
)(
tsample
ttotal
n
n
. The term n denotes the number of companies in the to-
tal population and the sample. Term t denotes the three groups (t=1,2,3) in order of 
age. Group 1, group 2 and group 3 consist of companies founded in 1997-2001, 1991-
1996, and earlier, respectively.  
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The nature of the bio-pharmaceutical sector as a seller of scientific 
research is seen especially when we look at companies’ outlays on re-
search and development (R&D) as a percentage of their total expenses. 
Almost eight out of ten of the biotechnology companies have R&D 
outlays amounting to more than 10 percent of their total expenses. 
Accordingly, three-fourths of the bio-pharmaceutical companies have 
patents or patents pending, while 94 % of all SMES have neither of 
these. Instead, over half of all Finnish SMEs have no R&D expendi-
tures at all. Thus the biotechnology industry is more R&D intensive 
than other sectors on average.  
Commercialization of products by bio-pharmaceutical companies is 
geared primarily toward the future, in contrast with other SMEs. Active 
research activity is ordinarily anticipated to generate expectations of fu-
ture revenues. Otherwise it would not be worthwhile for the company to 
carry out R&D activity at all. On the other hand, the emphasis on com-
mercialization geared toward the future will increase the business risks, 
which will in turn increase the yield requirements of investors. Given the 
revenue expectations of entrepreneurs and the yield requirements of 
investors, it is understandable that 86 percent of the bio-pharmaceutical 
companies expect turnover to rise over the next five years at an average 
annual rate exceeding 10 percent. Only about a fifth of all SMEs expect 
turnover to grow faster than 10 percent per annum. 
3.3  Capital Structure and Financial Sources 
In this section we investigate the financing received by bio-pharmaceutical 
companies broken down by type of capital. Because almost half of the 
companies made a loss in the fiscal period evaluated, the losses realized 
reduced the amount of equity in the balance sheet. Since we want to as-
sess how much has been invested in the companies in the form of equity 
and capital loans and other forms of debt, the realized profits or losses 
are not taken into consideration at all in our study. Thus the capital 
structure presented in Table 2 does not correspond to the figures obtain-
able directly from the balance sheets.  
Himmelberg and Petersen (1994) show using US data on older listed 
companies that the internal financing of companies is a significant form 
of financing for R&D activities. This study emphasizes the special nature 
of the bio-pharmaceutical sector as a young research-intensive field, and 
thus it investigates the financing coming from investors. Revenue financ-
ing is evaluated from the viewpoint of turnover not profitability.  
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Table 2.  Capital structure by age and size of bio-pharmaceutical 
companies. 
  Equity Capital loans Loans 
Total financing 
(million euro) 
Total 70.6 % 18.3 % 11.1 % 225.4 
0-4 years 77.1 % 10.5 % 12.4 % 134.9 
5-8 years 71.0 % 27.9 % 1.1 % 59.3 
9-24 years 41.4 % 33.6 % 25.0 % 31.2 
Small 49.9 % 36.5 % 13.7 % 20.6 
Large 72.6 % 16.5 % 10.9 % 204.8 
 
Equity and capital loans are prominent forms of financing in all bio-
pharmaceutical companies (Table 2). Equity and capital loans are both 
considered part of the total shareholders’ equity. A company pays a 
dividend to shareholders and interest on capital loans only if it has 
profits that it can pay out. Bio-pharmaceutical companies have rela-
tively low levels of indebtedness. Loans account for 11 percent of total 
financing on average. Loan financing, which is classified as a liability, is 
relatively higher in older companies, a fourth of whose capital comes 
from loans.34  The nominal value of the equity financing of older firms 
is less than that of their younger counterparts at the end of 2001. Part 
of this may be explained by inflation and part with smaller levels of 
investments.  
The total equity financing of SMEs operating in the pharmaceutical 
industry is estimated to be slightly less than EUR 160 million (Table 3). 
Most of the companies are owned by persons actively engaged in the 
business, private venture capital companies and government institutions 
providing venture capital, mainly Sitra.35 Especially in older companies 
the owners are likely to be non-financial companies. Other companies 
own over 60 percent of the shares of bio-pharmaceutical companies that 
are more than 8 years old. The ownership of both private venture capital 
companies and government institutions is significant among relatively 
young companies. The investments of venture capitalists appear to en-
able companies to hire additional employees. 
                                                 
34  For an overview of theories on companies’ capital structures see e.g. Myers (1984; 
2001). 
35  Sitra denotes the Finnish National Fund for Research and Development. 
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Table 3.  Equity financing by age and size of bio-pharmaceutical 
companies. 
  
Persons 
active  
in the 
business 
Other 
persons 
Private
venture
capital 
company
Other 
financial 
institu-
tion 
Other
company
Govern-
ment 
institu-
tion Other
Total 
share 
capital 
(million 
euro) 
Total 25.6 % 4.8 % 31.7 % 2.6 % 10.4 % 23.6 % 1.3 % 159.0 
0-4  
years 27.5 % 4.1 % 42.0 % 0.3 % 0.9 % 25.0 % 0.2 % 104.0 
5-8  
years 22.3 % 7.6 % 13.6 % 8.5 % 17.8 % 25.9 % 4.2 % 42.1 
9-24  
years 21.4 % 0.6 % 8.6 % 2.0 % 62.4 % 4.9 % 0.2 % 12.9 
Small 42.5 % 6.2 % 7.4 % 0.0 % 17.0 % 22.1 % 4.8 % 10.3 
Large 24.5 % 4.7 % 33.4 % 2.8 % 9.9 % 23.7 % 1.1 % 148.8 
 
The capital loans supplied to bio-pharmaceutical companies have come 
almost entirely from the public sector. The largest supplier of capital loans 
is Tekes.36 Tekes accounts for over 80 percent of the capital loans supplied 
to this sector. When Sitra is taken into consideration in the calculations, 
the public sector’s share of capital loans rises above 95 percent. The role 
of Sitra as a source of capital loans is especially pronounced in small com-
panies with less than 20 employees. 
The most prominent source of loans for bio-pharmaceutical companies 
is accounts payable from other companies and loans from Tekes. Ac-
counts payable are usually related to business expenses. In Finland pay-
ment times for purchases are shorter than in many other countries. The 
relatively high portion for accounts payable tells that loan financing is not 
a popular means of financing in this sector where business risks (and also 
the risk related to repayment of the loan) are considerable. It is also typical 
of the bio-pharmaceutical sector that the company’s revenue expectations 
and assets are based to a large extent on intangible assets and competen-
cies, so companies seldom have collateral they can pledge to back loans. 
For example, bank loans are only taken by older bio-pharmaceutical com-
panies, the operations of which have to a certain extent stabilized and that 
have accumulated tangible assets. Companies in business for over 8 years 
account for about 77 percent of the sector’s tangible assets, such as ma-
chinery and equipment. 
                                                 
36  Tekes is The National Technology Agency of Finland.  
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Table 4.  Capital loan financing by age and size of bio-pharmaceutical 
companies. 
  
Private  
venture 
capital 
company 
Foreign
venture
capital 
company Sitra Tekes Finnvera
Other 
govern-
ment 
institu- 
tion Other 
Total 
capital 
loans 
(million 
euro) 
Total 1.5 % 0.0 % 15.4 % 80.3 % 0.2 % 1.0 % 1.6 % 25.1 
0-4  
years 1.1 % 0.1 % 18.9 % 76.0 % 0.2 % 1.5 % 2.2 % 16.7 
5-8  
years 0.0 % 0.0 % 0.0 % 94.0 % 0.0 % 0.0 % 6.0 % 0.6 
9-24  
years 2.5 % 0.0 % 9.0 % 88.5 % 0.0 % 0.0 % 0.0 % 7.8 
Small 7.0 % 0.0 % 40.0 % 41.3 % 1.5 % 8.9 % 1.3 % 2.8 
Large 0.8 % 0.1 % 12.3 % 85.3 % 0.0 % 0.0 % 1.6 % 22.3 
 
The most prominent source of capital for bio-pharmaceutical com-
panies is equity financing. Companies obtained over 70 percent of 
their financing in this form. Almost all of the capital loans, i.e. subor-
dinated loans on equity terms, came from government institutions 
(Table 4). Loan financing was relatively modest and over a third of 
the loans were related to daily business operations. In contrast, over 
60 percent of the equity of older firms (founded 9-24 years ago) is 
held by non-financial companies (Table 3). According to Table 2, they 
have relatively more loan financing and over 10 percent of the loans 
are from banks (Table 5).  
The prominent share of loan financing within older companies cor-
responds with the principal-agent theory regarding the relationship 
between a company’s owners and management presented by Jensen 
(1986). By taking a loan the company’s owner (in this case another 
company) seeks to monitor the behavior of the management and con-
strains spending by the management. On the other hand, according to 
Jensen and Meckling (1976), the high proportion of share capital pro-
vided by persons actively engaged in the business can be explained by 
constraints on fringe benefits stemming from their high ownership 
stakes. Owing to the pivotal role of equity financing as a whole, we 
will look at the significance of the ownership structure in more detail 
in the next section. 
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Table 5.  Loan financing by age and size of bio-pharmaceutical 
companies. 
  Bank 
Other 
financial 
institu-
tion 
Other 
com-
pany 
Other 
debt Tekes 
Finn-
vera 
Other 
govern-
ment  
institu-
tion  Bond Other
Total 
loan 
financing 
(million 
euro) 
Total 2.6 % 2.7 % 0.5 % 35.8 % 23.3 % 2.1 % 8.1 % 0.8 % 24.1 % 41.2 
0-4  
years 0.0 % 2.9 % 0.0 % 21.1 % 25.9 % 1.3 % 2.1 % 0.0 % 46.7 % 14.2 
5-8  
years 0.0 % 0.0 % 0.2 % 51.8 % 29.0 % 1.1 % 13.2 % 0.0 % 4.8 % 16.6 
9-24  
years 10.3 % 6.6 % 1.6 % 30.3 % 10.8 % 4.6 % 8.5 % 3.3 % 24.1 % 10.5 
Small 9.8 % 6.1 % 0.6 % 14.3 % 14.6 % 11.4 % 18.0 % 0.0 % 25.2 % 7.5 
Large 1.0 % 1.9 % 0.5 % 40.5 % 25.2 % 0.0 % 5.9 % 1.0 % 23.9 % 33.7 
 
As a rule, few bio-pharmaceutical companies have very high levels of 
turnover yet. Most of the equity financing is focused on firms with turn-
over less than EUR 1.5 million (Table 6). Those companies that have 
succeeded in creating some sales are mostly owned by non-financial 
companies. These companies primarily export their products or services 
abroad. Other investor groups have made most of their investments in 
firms that do not yet have significant turnovers. 
R&D activities and ownership of intangible assets is of key impor-
tance from the viewpoint of the companies’ revenue expectations. 
R&D is of pivotal importance in the pharmaceutical sector owing to 
the long lags in product development. The time from an innovation 
spurring development of a drug to the launch of the final product on 
the market may take 10-15 years. This inevitably means that a start-up 
firm’s R&D activities and intangible assets are of pivotal importance 
when assessing the firm’s expected stream of revenues and conse-
quent present value. For example, Garner, Nam and Ottoo (2002) 
evaluate the connection between R&D intensity and the company’s 
market value by using growth options.     
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Table 6.  Equity financing by realized turnover, i.e. sales revenue, 
and export intensity of bio-pharmaceutical companies. 
  
Persons
active
in the
business
Other
persons
Private
venture
capital
company
Other 
financial
institution
Other
com-
pany 
Govern-
ment 
institution Other 
Total 
share 
financing 
(million 
euro) 
Turnover  
under 1.5  
million euro 26.3 % 5.1 % 33.6 % 2.6 % 5.9 % 25.0 % 1.4 % 147.6 
Turnover  
over 1.5  
million euro 16.8 % 0.6 % 7.4 % 2.3 % 67.4 % 5.5 % 0.1 % 11.5 
Exports /  
turnover  
under 10% 26.9 % 5.4 % 36.6 % 2.9 % 0.7 % 27.2 % 0.4 % 133.4 
Exports /  
turnover  
over 10% 18.8 % 1.5 % 6.3 % 1.0 % 60.9 % 5.2 % 6.2 % 25.6 
Table 7.  Equity financing of bio-pharmaceutical companies broken 
down by realized R&D intensity37 and possession of pat-
ents and patent applications. 
  
Persons 
involved in 
company’s 
business 
Other 
persons
Private 
venture 
capital 
company 
Other 
financial 
institution
Other 
com-
pany
Govern-
ment 
institution Other 
Total 
share 
financing 
(million 
euro) 
Low R&D  
intensity 4.5 % 0.2 % 0.0 % 0.0 % 93.8 % 1.5 % 0.0 % 7.5 
High R&D  
intensity 26.6 % 5.0 % 33.3 % 2.7 % 6.2 % 24.7 % 1.4 % 151.6 
No patents 25.2 % 7.8 % 0.0 % 0.0 % 46.8 % 12.8 % 7.4 % 3.4 
Patents 25.6 % 4.7 % 32.4 % 2.7 % 9.6 % 23.9 % 1.2 % 155.6 
 
Owing to the nature of the biotechnology industry, most of the com-
panies have a relatively high level of R&D activity (Table 7). On the one 
hand, investors have stressed the importance of R&D activity by com-
                                                 
37  A company’s R&D intensity is high when research and development costs are over 
10 percent of total costs. 
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panies as a way of boosting future revenue expectations (Table 7 high 
R&D intensity). On the other hand, the R&D intensity of the companies 
may be a signal to investors about future revenue expectations, which 
makes the company an interesting investment target.  
Biotechnology R&D activity spawns patent applications but, on the 
other hand, companies possessing intangible assets are attractive invest-
ment opportunities. For this reason it is not clear whether most of the 
patent applications and patent ownership are mainly a result of research 
financed by equity or whether the company has been an interesting in-
vestment candidate and obtained equity financing because it has had in-
tangible assets such as patents already when the company was founded. 
The investigation of cause-effect relationships between intangible assets 
and equity financing would require time series data. In this study we have 
at our disposal only cross section data from the end of 2001 so that we must 
satisfy ourselves with discussing the causality relationships only in general 
terms. However, Luukkonen (2003) states that holdings of patent applica-
tions and patents are a necessary condition for a biotechnology company 
to obtain equity financing from private venture capital companies.  
A company’s present value is based on the expectations of the future 
stream of revenues generated by its business activities. In Table 8 the 
ownership structure is broken down by the sales expectations indicated 
 
Table 8.  Equity financing of bio-pharmaceutical companies by expected 
turnover in 2006 and expected annual growth in turnover. 
  
Persons 
in busi-
ness 
Other 
persons
Private 
venture 
capital 
company
Other 
financial 
institu-
tion 
Other 
com-
pany 
Govern-
ment
institu-
tion Other
Total 
equity 
invest-
ments 
(million 
euro) 
Expected sales in 
five years below  
1.5 million euro 26.4 % 6.4 % 36.1 % 3.3 % 0.1 % 27.4 % 0.2 % 107.4 
Expected sales in 
five years above  
1.5 million euro  23.9 % 1.4 % 22.6 % 1.1 % 31.6 % 15.9 % 3.5 % 51.7 
Expected rate of 
growth less than 
25% per annum 24.1 % 4.5 % 38.6 % 0.3 % 8.7 % 23.5 % 0.3 % 90.3 
Expected rate of 
growth greater than 
25% per annum  27.6 % 5.2 % 22.8 % 5.6 % 12.5 % 23.8 % 2.6 % 68.7 
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by the company. First let us look at the company’s own sales expecta-
tions in five years. A critical threshold of 1.5 million is set for expected 
sales after five years. Persons actively engaged in the business own about 
a fourth of the companies with both low and high revenue expectations. 
Private venture capital firms own slightly over a one-third stake in the 
companies with revenues anticipated to remain below EUR 1.5 million 
over the next five years but they account for slightly over a fifth of the 
ownership in companies with higher revenue expectations over the same 
time horizon. The role of government sources of venture capital, espe-
cially Sitra, will grow in connection with companies whose turnover is 
not expected to surpass 1.5 billion by the year 2006. On the other hand, 
non-financial companies have invested almost exclusively in companies 
whose sales expectations are relatively high.    
In this section we have presented the capital structure of companies in 
the bio-pharmaceutical sector broken down by factors describing the 
nature of the business. In the next section we will seek to form a more 
systematic overview of the above-described capital and ownership struc-
tures using statistical means.  
3.4  Financial Sources and Business Models 
3.4.1  Variable Selection 
The book value of a company is often below its market value deter-
mined, for example, on the financial markets (see Hall 2001). Investors 
seek to make investment decisions based on expectations of future re-
turns. The future return expectations regarding a company can be as-
sessed on the basis of financial statements and intangible assets at the 
disposal of the company. The intangible assets of a company are seldom 
booked at full value on the official balance sheet. In a broad sense the 
whole intellectual capital of a company can be regarded as an intangible 
asset. (e.g. Edvinsson and Malone, 1997; Sveiby, 1997).  
A company’s intellectual capital can be divided into human capital, 
structural capital and relational capital (Edvinsson and Malone, 1997). 
Human capital comprises the knowledge of the personnel. Biotechnology 
is a science-based sector where knowledge management is given more 
emphasis than in many other sectors. The total number of personnel and 
number of employees with doctorate degrees depict the company’s inter-
nal critical mass. The business experience of the CEO in years measures 
the business knowledge of the management while the educational level of 
the CEO signifies formal or practical competence. 
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Structural capital includes the company’s internal organizational struc-
tures and organization of activities whereby it seeks to use human capital 
efficiently. In this connection, structural capital is measured by R&D 
costs, the number of patents and patent applications as well as the age of 
the company (in years). In addition we look at the intensity of research 
and patents: the number of patents and patent applications is calculated 
as a percentage of the number of personnel and R&D expenditures are 
calculated as a share of the company’s total costs.  
Relational capital is comprised of the company’s external relation-
ships. The most critical aspect of relational capital is the company’s 
possibilities to exploit the market potential of its products, i.e. client 
relations. Without customers the company is not viable, even if the 
activities of its highly educated personnel is otherwise well organized. 
Ahonen (2000) and Hussi (2001) list the following mechanisms of 
value creation. They divide intangible assets into generative intangible 
assets and commercially exploitable intangible assets. The value of 
commercially exploitable intangible assets can be measured also by the 
ability to generate a return. With this in mind, the sales volume of the 
company in 2001 is evaluated separately under the heading of business 
performance. On the other hand, generative intangible assets (such as 
intellectual capital) are not expected to generate a return until later in 
the future. For this reason we look at the company’s expected turnover 
in the year 2006. The ability to take advantage of international markets 
is measured by exports’ share of total turnover. 
The return expectations of bio-pharmaceutical companies may often 
be several years away. For this reason market potential can be assessed 
from the perspective of financing received. If financiers have accepted 
the company’s business strategy and offered the company financing, this 
signifies that the plan is strategically well founded and credible. Here we 
evaluate whether the company’s activities have been financed by Sitra or 
Tekes, how much financing the company has received for R&D from 
government institutions as well as how large a share of its total R&D 
expenditures is financed by government institutions. Furthermore, the 
significance of various financing sources is depicted under the heading of 
capital structures by the amount of financing raised via equity capital and 
capital loans. The capital structure of the company is also depicted by the 
debt-equity ratio. 
In young bio-pharmaceutical companies, there is growing emphasis 
on joint research with other experts in the field. The critical mass 
needed in R&D can be achieved also via joint research with other ex-
perts in the field. Almost all companies engage in collaboration with 
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some domestic research institutions or universities. In the statistical 
analysis we assess the prevalence of international collaboration by look-
ing at whether the company collaborates with foreign academic institu-
tions. The nature of collaboration is also depicted by whether the com-
pany engages in R&D collaboration with subcontractors or clients.  
The company’s external relational capital also includes possibilities to 
recruit skilled labor. This is measured by whether the company indicates 
that it has encountered difficulties in hiring employees. The company’s 
external relations are also assessed as to whether the company’s account-
ing is handled by one of the big five accounting firms. 
3.4.2  Methodology 
In the following statistical analysis we will address the features character-
istic of the ownership structure of the bio-pharmaceutical sector. The 
analysis will make use of principal component analysis. The strength of 
the principal component analysis methodology in this connection is that 
its use does not require a theoretical model upon which the analysis is 
based. On the other hand, principal component analysis allows us to 
condense the information contained in the statistical data by using the 
joint variance of the variables. Principal component analysis is based on 
the assessment of correlations between selected variables and the mutu-
ally independent principal components.38 The results of the principal 
component analysis are presented in the appendix.  
The use of principal component analysis is justified by the observation 
that the variables appearing in the model are mutually correlated. In re-
gression analysis the correlation of the independent variables leads to a 
problem of multicollinearity, which may distort the results. For example, 
Tahvanainen (2003) encounters this problem when using regression 
analysis to evaluate the debt-equity ratio of SMEs in the biotechnology 
sector. In contrast, in the principal component analysis the variables are 
grouped into different principal components and one variable can be 
correlated with more than one principal component. Principal compo-
nent transformations are indeed supposed to be carried out so that each 
variable is strongly correlated with only one principal component. Thus 
the variable regarded as the dependent variable can be kept in the princi-
pal component analysis as one of the variables. We can therefore evalu-
                                                 
38  E.g. Sharma (1996) provides a detailed technical presentation of principal compo-
nent analysis.  
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ate separately the principal component that was correlated with the debt-
equity ratio in Tahvanainen (2003). 
In the next section the principal components are distinguished accord-
ing to whether the correlation between the selected variable and the prin-
cipal component is over 0.3, which corresponds roughly to the correlation 
level that differs from zero taking into account the sample size and assum-
ing a normally distributed population. 
In the next section presenting the results of the statistical analysis we 
name five principal components, the eigenvalues of which are greater 
than two. The strict method is necessitated by the fact that owing to 
the relatively large number of variables there are ten components with 
eigenvalues greater than one. In order to summarize the information 
contained in the data, we apply stricter criteria in the selection of the 
principal components. The analysis makes use of the rotation of prin-
cipal components, based on the varimax method. The method seeks to 
produce a rotated final result where each variable is prominent in only 
one principal component. The rotated principal components analyzed 
explain slightly over half of the variance of the selected variables. 
3.4.3  Results  
The principal components are presented in six boxes in Figure 1. Princi-
pal component 2 is presented in two parts as components 2a and 2b, 
which are mirror images of each other. The interpretation of the com-
ponents is based on the finance literature, which we extend upon in the 
study. This allows us to link our approach to one of the relevant bodies 
of corporate finance literature.  
According to the pecking order theory, the quality of companies’ devel-
opment projects affects capital structures in two main ways. First, because 
the personnel working inside the company know more about the real re-
turn expectations than foreign owners, in high quality companies (high 
expected return projects) the ownership share of persons actively engaged 
in the business is high. This means that in the first stage only loan financ-
ing is raised outside the firm. Only when the loan financing runs out does 
the company raise external equity financing. On the other hand, external 
investors can gauge the quality of the company according to either the 
average quality prevailing in the sector or the company’s intellectual capi-
tal. Below we will analyze the principal components both with respect to 
the “average quality” of the sector as well as the connection between the 
company’s intellectual capital and capital structure. 
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Figure 1.  Principal components numbered according to rotated 
component matrix (appendix).  
The original pecking order theory expects that in high quality projects 
the first external financing comes from loans, not equity financing 
(Myers and Majluf, 1984; Myers, 1984). In the biotechnology sector high 
quality can mean e.g. R&D-intensive activities. Nevertheless as a com-
pany’s research intensity grows, so does the information asymmetry be-
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tween the company’s personnel and external investors. Thus, for exam-
ple, the risk premium on loan financing may become surprisingly large. 
Hyytinen and Pajarinen (2002) maintain that in this kind of situation a 
reversed pecking-order may be the best model for an R&D-intensive 
company in practice because an R&D-intensive SME has difficulties in 
getting loan financing. Thus financing in the form of loans precedes fi-
nancing via external equity and capital loans. 
The reversed pecking order seems to appear in some of the features of 
the “Big and Beautiful” principal components. This principal component 
also features a high volume of R&D activity, a high number of employ-
ees with doctorate degrees and ownership of considerable intangible 
assets. The “Big and Beautiful” companies are typically owned by private 
venture capital firms, government institutions and persons actively en-
gaged in the company. This principal component is strongly correlated 
with variables depicting company size. The companies characterizing this 
principal component have a lot of personnel and tangible assets. 
Baysinger, Kosnik and Turk (1991) find for US data on large enterprises 
that a high equity stake held by institutional investors increases the com-
panies’ expenditures on R&D activities. Thus the information included 
in the “Big and Beautiful” component is consistent with the above-
mentioned study regarding the phenomenon that greater ownership by 
private venture capital firms and government institutions goes hand in 
hand with companies’ R&D expenditures. 
In the second principal component called “Promising Subsidiaries”, a 
prominent role is played by equity financing from non-finance compa-
nies. For the companies of this principal component it is typical that they 
are already generating sales and that they expect their sales will be on a 
high level in five years. A considerable portion of the sales of these rela-
tively older companies is directed abroad and they engage in collabora-
tion with their clients. These efficient companies with growth expecta-
tions have a large international accounting company acting as their audi-
tor. According to this principal component, the involvement of another 
company helps in the commercialization of products. On the other hand, 
it may be that other companies seek ownership in companies that have 
already been able to commercialize their products and services. In addi-
tion, this type of company has a higher portion of loan financing than 
other companies. According to Harris and Raviv (1990) the high promi-
nence of loan financing and tangible assets reflects the real state of the 
company. On the one hand, a company that can service its debt conveys 
a message about its ability to perform to investors. On the other hand, if 
the company goes bankrupt it is easier to liquidate tangible assets than 
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intangible ones, which reduces the risk to lenders of getting their money 
back. 
“Doctors in Turku” is an “inverse component” with respect to the 
preceding principal component. This means that the component is the 
same, but they are mirror images of each other. As the name indicates, in 
this type of relatively young company many of the owners are doctors 
and the activities are often located in Turku. The biggest owners are pri-
vate venture capital companies, government institutions and persons 
actively engaged in the business. A prominent feature of their capital 
structure is the small share of loan financing. This group thus seems to 
be characterized by the reversed pecking order.    
The “Sound Business Plan” principal component includes companies 
with particular emphasis on R&D activities, a large portion of which has 
been financed by the public sector. These companies have a large num-
ber of employees with doctorate degrees. The company has protected its 
expertise with patents. Their sales are directed primarily abroad, and their 
marketing plans are based on foreign trade also in the future. The man-
aging directors of these companies have long business careers behind 
them. In other words, the companies’ business plans are based on pro-
longed experience in business: the personnel with a high level of educa-
tion carries out R&D work, the results of which are protected via patents 
and growth is sought from international markets. 
Cooperation between Tekes and Sitra in financing the activities of bio-
technology companies is seen in the “Tekes and Sitra Collaboration” 
principal component. The companies fitting the characteristics of this 
principal component have received capital loans from the public sector 
as the companies have an experienced managing director. On the one 
hand, the track record of the management means something in the fi-
nancing decisions of government institutions. On the other hand the 
collaboration between Tekes and Sitra is not characterized by a certain 
type of ownership structure or, for example, certain growth expectations 
of the company seeking financing, but rather these government institu-
tions have engaged in cooperation in very diverse projects. This indicates 
that collaboration between the institutions enhances their monitoring 
ability. It is efficient for many financiers to monitor simultaneously the 
quality of companies’ projects. 
In the component called ”Experts Sought for International Collabora-
tion” some companies have had problems in obtaining skilled labor. 
These companies have obtained a great deal of financing for R&D from 
the public sector. The companies are engaged in international research 
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projects with foreign research institutes. Even though they do not have a 
high turnover, they plan to commercialize their products or services and 
export them abroad within five years.  
3.5  Discussion and Conclusions 
This study analyses the capital structure of biotechnology companies that 
develop pharmaceutical products. The financing received from the com-
pany’s investors is usually equity financing and to a lesser extent capital 
loans, i.e. subordinated loans on equity terms. On the other hand, ordi-
nary loan financing is not a very popular form of financing in the bio-
pharmaceutical sector. 
The classic pecking order theory by Myers and Majluf (1984) does 
not appear to explain the forms of financing prevalent in the Finnish 
bio-pharmaceutical sector. The pecking order theory predicts that ex-
ternal equity financing is too expensive for R&D-intensive start-ups. 
According to this theory, external equity financing would be available 
on unfavorable terms. Thus entrepreneurs, i.e. the persons actively en-
gaged in the business, fund the project themselves. After this the company 
can take a risk-free or low-risk loan and only after this is equity financing 
sought from external investors. In the Finnish bio-pharmaceutical sector, 
external financiers such as private venture capital firms and govern-
ment institutions are participating as owners of the company in a rather 
early stage.  
Bhagat and Welch (1995), Hall (2002) as well as Hyytinen and Pa-
jarinen (2002) showed that SMEs are less dependent on loan financing 
the more R&D intensive their activities are. This decision gains only 
partial support in the descriptive principal component analysis, but this 
phenomenon can be observed in certain individual bio-pharmaceutical 
companies. Many older bio-pharmaceutical companies owned by other 
companies have relatively low R&D intensity and solidity ratios. Fur-
thermore, the reversed pecking order theory predicts high shares for 
external equity and capital loan financing and low shares of loan financ-
ing in young but relatively large R&D-intensive companies. 
Ang, Cole and Wuh Lin (2000) observed that the owners’ cost of moni-
toring the management of the company grows when the number of for-
eign investors increases and the ownership share of the management de-
creases. The management knows more about the situation of the company 
than outside investors. This empirical observation by Ang, Cole and Wuh 
Lin (2000) regarding the asymmetry with respect to the cost of informa-
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tion based on the principal – agent theory supports the hypothesis that the 
management’s share of ownership is comparatively important in compa-
nies with many different owners. On the other hand, this also explains the 
relatively large share of bank loans in bio-pharmaceutical companies 
owned mainly by other companies. Banks are able to lower the costs 
stemming from the asymmetry of information costs between the owners 
and the management by monitoring the company with its own resources. 
The willingness to provide a loan gives the owners a signal about the 
sound shape of the company and thus reduces the cost of gathering in-
formation.  
The ”Big and Beautiful” principal component is marked by the follow-
ing phenomenon: the more a company has intellectual property rights 
and R&D activity, the greater are its financial resources. This observation 
corresponds with the findings of Lerner and Merges (1998) obtained 
using international data. The more financial resources a company has, 
the more influence a company engaged in R&D collaboration has over 
decisions (e.g. about intellectual property rights). 
Lerner, Shane and Tsai (2002) studied the equity financing cycles pre-
vailing in the US biotechnology industry. According to them, companies 
seeking to finance their R&D activities are obliged to settle for partner-
ship agreements on unfavorable terms when the stock market is in a 
slump. These kinds of partnership agreements appear to be difficult to 
change when the situation in the stock market improves. In future stud-
ies it would be worthwhile to analyze at what stage do the non-financial 
companies obtain stakes in biotechnology companies that are already 
generating revenues.  
In the current situation prevailing in the financial markets, obtaining a 
listing on the stock exchange does not seem a realistic option. The li-
censing and royalty payments as well as mergers and acquisitions are the 
most common way of securing second round financing for commerciali-
zation projects. Thus technological expertise does not appear to suffice 
alone to achieve commercial success, but rather the start-up needs to 
engage in close-knit collaboration with another company and to invest in 
marketing competencies. 
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Appendix.  Results of Principal Component Analysis 
Communalities    
 Variable Initial Extraction 
Sources of financing  
Capital structure Solidity (equity per  
total debt & equity) 
1 0.6863903 
Equity financing   
Equity financing from individuals active  
in business (log euros) LNACTIV€ 1 0.8010382 
Equity financing from other non-financial 
firms (log euros) LNFIRM€ 1 0.838017 
Equity financing from government institution 
(log euros) LNPUBVC€ 1 0.9035721 
Equity financing from private venture  
capital organization (log euros) LNPRVC€ 1 0.8556579 
Capital loan financing from government 
institution (log euros) LNPUVCL€ 1 0.8724937 
Capital loan financing from private venture 
capital organization (log euros) LNPRVCL€ 1 0.7909272 
    
Intangible assets    
Human capital    
Number of personnel LNPERSON 1 0.9271824 
Number of doctors on staff LNDOCS 1 0.8224857 
CEO's experience (in years) LNCEOEXP 1 0.8187757 
CEO is a doctor (=1) post-graduated CEO 1 0.7225567 
Structural capital    
Research and development (R&D) costs 
(log euros) LNRDCOST 1 0.9164357 
Number of patents and patent applications 
(log) LNPATENT 1 0.8928357 
Age of firm (log years) LNAGET 1 0.7991473 
Patent per number of personnel Patents / total personnel 1 0.8508303 
R&D costs per total costs 
R&D costs per total 
costs 1 0.8566066 
Relational capital    
Public support to R&D activities (log euros) LNPBRD 1 0.9210542 
Problems in skilled labor supply (=1) 
Problems in skilled  
labor supply 1 0.7373992 
Sitra has financed a firm (=1) 
Sitra has financed  
a firm 1 0.7982579 
Tekes has financed a firm (=1) 
Tekes has financed  
a firm 1 0.8500641 
Public supports to R&D activities  
per R&D costs 
public r&d support per 
r&d costs 1 0.8427616 
Firm has top-5 auditor (=1) Top5 Auditor 1 0.7072709 
Collaboration with foreign academic  
institutions (=1) 
collaboration with foreign 
academic institutions 1 0.7907651 
Principal customer's share of total  
sales over 1/3  principal customer (>1/3) 1 0.660605 
Principal subcontractor's share of total  
purchases over 1/3  
principal subcontractor 
(>1/3 out of purchases) 1 0.7711855 
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Communalities, cont.    
 Variable Initial Extraction 
R&D collaboration with customers 
rd collaboration with 
customers 1 0.7862258 
R&D collaboration with subcontractors 
rd collaboration with 
subcontractors 1 0.6515332 
    
Tangible assets    
Tangible assets (log euros) LNTANG 1 0.8908755 
    
Background dummies   
Location in Turku region Turku 1 0.7502396 
Firm announces its core branch in  
pharmaceutical industry Pharma=1 1 0.8309156 
Firm has spun out from academic  
research research spin-off 1 0.8221582 
    
Business performance   
Present turnover    
Turnover (log euros) LNTO 1 0.8679751 
Exports per turnover exports per turnover 1 0.7579612 
Anticipated future turnover   
Anticipated future turnover in 2006 LNTO5 1 0.8479678 
Exports per turnover in 5 yrs 
exports per turnover in 
5 yrs 1 0.7962595 
    
 
Extraction Method: Principal 
Component Analysis.  
 
 
 
  
Appendix, cont. 
Total Variance Explained         
Component Initial Eigenvalues  Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings 
 Total % of Variance Cumulative % Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 7.5500655 21.571616 21.571616 7.5500655 21.571616 21.571616 5.155834 14.730954 14.730954 
2 5.3737336 15.353525 36.92514 5.3737336 15.353525 36.92514 4.6588054 13.310872 28.041827 
3 2.94936 8.4267429 45.351883 2.94936 8.4267429 45.351883 2.9549013 8.4425752 36.484402 
4 2.49134 7.1181144 52.469997 2.49134 7.1181144 52.469997 2.6240589 7.4973112 43.981713 
5 2.3085172 6.5957633 59.065761 2.3085172 6.5957633 59.065761 2.4885319 7.1100911 51.091804 
6 1.8265491 5.2187116 64.284472 1.8265491 5.2187116 64.284472 2.4314193 6.9469122 58.038717 
7 1.713833 4.8966657 69.181138 1.713833 4.8966657 69.181138 2.1736823 6.2105208 64.249237 
8 1.5897537 4.5421534 73.723292 1.5897537 4.5421534 73.723292 2.0816619 5.9476053 70.196843 
9 1.3767422 3.9335492 77.656841 1.3767422 3.9335492 77.656841 1.9519456 5.5769874 75.77383 
10 1.256533 3.5900944 81.246935 1.256533 3.5900944 81.246935 1.9155867 5.4731049 81.246935 
11 0.9546938 2.7276966 83.974632       
12 0.8947182 2.5563376 86.530969       
13 0.7623783 2.1782236 88.709193       
14 0.6166829 1.7619513 90.471144       
15 0.5806536 1.6590104 92.130155       
16 0.485015 1.3857572 93.515912       
17 0.4084618 1.1670338 94.682946       
18 0.3978799 1.1367997 95.819745       
19 0.3459201 0.9883432 96.808088       
20 0.2866466 0.8189902 97.627079       
21 0.2544 0.7268571 98.353936       
22 0.1755862 0.5016749 98.855611       
23 0.1269336 0.3626674 99.218278       
24 0.0909274 0.2597925 99.478071       
25 0.0701375 0.2003928 99.678463       
26 0.0523641 0.1496117 99.828075       
27 0.0361161 0.1031889 99.931264       
28 0.0240576 0.068736 100       
Extraction Method: Principal Component Analysis.       
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Component Matrix(a)          
  Component          
 1 2 3 4 5 6 7 8 9 10
LNPBRD 0.835376 0.0252071 -0.2069432 0.2053087 -0.070921 0.1636177 -0.0939433 0.2266713 -0.185606 -0.1055139
LNPERSON 0.7879374 0.2794558 0.1143391 -0.2723011 -0.2206523 0.0715007 -0.1096641 -0.1289529 -0.2416936 -0.0122283
LNRDCOST 0.7759517 0.1031488 0.1089786 0.3185527 -0.1969846 0.3173479 -0.1802982 0.0204263 -0.0809058 0.1065824
LNTANG 0.7202918 0.4721778 0.1247984 -0.0386221 -0.1927352 -0.1965564 0.0007183 0.2001652 -0.0306558 0.1234882
exports per turnover in 5 yrs 0.7163789 0.0215664 -0.1772552 0.1610748 0.4120551 0.1806152 0.1025551 -0.0709282 0.0662257 0.0537179
LNPRVC€ 0.6647698 -0.1850622 0.2686114 0.1372457 -0.329148 -0.0821671 0.2533517 -0.069659 -0.0561944 -0.3181437
Pharma=1 0.664488 0.1729131 0.0517115 -0.298995 0.1082562 0.3099998 0.0887926 -0.166412 0.3497015 0.041387
LNPATENT 0.6620579 0.027499 0.3243345 0.4140451 0.3715953 -0.1045055 -0.1411523 0.0551501 -0.0622035 0.0359632
LNPUBVC€ 0.6367867 -0.5238026 0.3248937 -0.2624533 -0.1976269 -0.074481 0.0182423 -0.0005234 -0.0647269 0.0118982
Tekes has financed a firm 0.6028728 0.2934693 -0.4023608 -0.2034334 -0.2321291 -0.2284507 -0.2918567 0.0468323 0.0164862 -0.059041
collaboration with foreign  
academic institutions 0.5982522 -0.2007331 0.270147 -0.227369 0.2343139 -0.0785412 0.251482 0.0940137 -0.3058899 -0.2028977
LNDOCS 0.5716328 -0.4507345 -0.0152973 -0.0254594 -0.1445188 0.2939711 0.2747969 -0.1340867 -0.0361689 0.2992867
principal customer (>1/3) -0.4821565 0.079205 -0.1479131 0.2873072 -0.1990086 0.0786958 0.3999769 0.1238526 0.223197 0.2156329
Top5 Auditor 0.4693151 0.1864997 0.0658002 -0.4660462 0.085417 0.0794999 0.0710998 0.3245882 0.2461685 0.2146519
R&D collaboration with customers -0.4453923 0.4349214 0.4031327 -0.1258584 -0.1247647 0.3322012 0.1989025 0.0112225 -0.1535042 -0.1765303
LNFIRM€ 0.1168886 0.8314251 -0.0617772 -0.2159564 -0.0797035 0.0527135 -0.2398101 0.1262628 0.0044691 0.005504
LNTO -0.1397957 0.8238015 0.3038595 0.0547549 -0.0879529 -0.170912 -0.0755769 0.1280682 -0.1037487 0.0680508
LNTO5 -0.0498077 0.8015217 0.171901 -0.0200594 -0.0012865 -0.030703 -0.0248733 0.2461485 -0.1270213 0.307914
  
Component Matrix(a), cont.          
  Component          
 1 2 3 4 5 6 7 8 9 10
Solidity (equity+caploans per  
equity+debt) -0.0932296 -0.6076626 0.1421402 0.0190996 0.3914056 0.0042876 -0.1350439 0.0566011 -0.1674337 0.2918642
exports per turnover 0.1979669 0.600224 -0.0250352 0.1656018 0.4533727 0.2450149 0.1930316 -0.0704757 -0.0121435 0.149987
LNAGET 0.4011932 0.5650278 -0.086716 0.3083616 0.1486892 -0.2353651 0.1784457 -0.2292884 0.010929 -0.2329972
Turku -0.0649344 -0.5416871 0.4156239 0.2654928 0.0234006 0.0037162 -0.2023419 0.39512 0.0571787 -0.0920635
Patents / total personnel 0.083628 -0.0702626 0.6226724 0.1606211 0.4523547 -0.2815908 0.0171916 -0.0720497 0.3380963 -0.1471932
public r&d support per r&d costs 0.277179 -0.118166 -0.5765545 -0.108299 0.4580709 -0.1073287 0.2360473 0.1670207 0.041851 -0.3179817
r&d collaboration with subcontrac-
tors 0.2943375 0.0855758 0.4879632 -0.080664 0.1636947 0.2297912 -0.3300587 0.0207895 0.2556993 -0.2420902
LNPUVCL€ 0.4031676 -0.16951 -0.4600136 -0.4152867 -0.0963217 -0.3454972 -0.1796908 -0.1311583 0.3032186 0.1645031
LNCEOEXP 0.3772668 0.1353715 -0.2036257 0.6224144 0.0757296 -0.409694 -0.1574782 -0.0104657 0.1740758 0.0214843
r&d costs per total costs 0.3788936 -0.2948607 -0.2396302 0.4707054 -0.0914218 0.3929414 -0.1629073 -0.0634095 0.3003204 0.2521991
LNACTIV€ 0.2982501 -0.494674 -0.0731743 0.2816268 -0.5705111 0.069478 0.0366376 0.0065268 -0.1662174 -0.1529424
Problems in skilled labor supply 0.1372081 -0.2096243 -0.4168142 -0.3987663 0.4441255 0.2608603 -0.0352393 0.0232762 -0.1998419 -0.1867252
Sitra has financed a firm 0.2893369 -0.3762562 0.1851437 -0.2175391 -0.0552852 -0.6349818 0.1367405 -0.0392827 -0.0119025 0.2544223
principal subcontractor (>1/3 out 
of purchases) -0.2665188 -0.2494189 -0.0557795 -0.1255829 -0.0624053 0.1173653 -0.5855763 0.4014793 0.2143348 -0.2266436
LNPRVCL€ 0.0906612 0.27056 -0.1896088 0.0773904 -0.3233272 0.014803 0.4332726 0.2885319 0.4294154 -0.3277673
research spin-off 0.0166507 -0.0577288 -0.4153908 0.2546267 0.1593404 -0.1004921 0.1028986 0.6477881 -0.3309965 0.0768097
post-graduated CEO 0.1791031 -0.2795362 0.3235305 -0.2171556 -0.0011761 0.043945 0.354817 0.5098706 0.222261 0.1526898
Extraction Method: Principal Component Analysis. 10 components extracted.       
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Rotated Component Matrix(a)         
  Component          
 1 2 3 4 5 6 7 8 9 10
LNPERSON 0.832105 0.2927441 0.1322656 0.180942 0.0462707 -0.1308048 0.0440874 0.0070351 0.1437658 -0.238616
LNPRVC€ 0.7291953 -0.3422608 0.0792421 0.0064245 -0.1433218 0.1884379 0.0927141 0.3199159 0.175508 -0.0517098
LNPBRD 0.7101219 0.0501616 0.5062112 0.1233892 0.225571 -0.002955 -0.0012586 0.1455102 -0.0218343 0.2650426
LNPUBVC€ 0.6670803 -0.4215487 0.020469 0.2328429 -0.0756838 0.067368 0.4044034 -0.1631527 -0.021218 -0.159249
collaboration with foreign  
academic institutions 0.6567743 -0.1521017 -0.1534355 -0.0386123 0.3175246 0.2453286 0.3108132 -0.1121465 0.1972234 0.0464505
LNTANG 0.6246222 0.5027768 0.1568919 0.2824646 -0.1366767 0.1098646 0.1902878 0.2139946 0.158399 0.0754496
principal customer (>1/3) -0.57591 -0.040821 0.0843069 -0.1881027 -0.2728226 -0.1732368 0.1070723 0.305578 0.1828322 0.2050922
LNTO5 -0.006055 0.864019 -0.0464692 -0.1264676 -0.2136363 -0.0258714 0.0799704 0.0188733 0.126698 0.1188911
LNFIRM€ 0.1428114 0.8464874 -0.0173129 0.0546188 0.0339195 -0.1441155 -0.1054838 0.2068893 -0.0905611 -0.1172471
LNTO 0.0291054 0.79202 -0.2188257 -0.171917 -0.3374104 0.1128627 -0.1133996 0.1310833 0.0677008 0.0343902
LNACTIV€ 0.4347158 -0.5968364 0.2226056 0.0136435 -0.276302 -0.2360336 -0.0760071 0.1685198 -0.0785015 0.1836142
exports per turnover -0.0411783 0.5636498 0.3084346 -0.2282227 0.2911241 0.1947704 -0.0299139 0.0272842 0.4077601 -0.0273975
r&d costs per total costs 0.0155806 -0.2737867 0.8721311 0.1137428 -0.0511727 -0.019355 -0.019818 0.0158407 -0.0649228 -0.0016541
LNRDCOST 0.6625738 0.1217836 0.667052 -0.0188419 -0.119805 0.0400348 0.0036206 0.0252775 0.0233005 -0.0116585
exports per turnover in 5 yrs 0.3262775 0.0422603 0.5481452 0.1334425 0.4599682 0.265756 0.072584 -0.0068137 0.2866655 0.007586
LNDOCS 0.3737643 -0.4185263 0.452299 0.0917618 0.0323151 -0.1930273 0.369102 -0.1238913 0.3084555 -0.0979447
LNPUVCL€ 0.0957648 -0.0782173 0.051416 0.871425 0.1926413 -0.1574209 0.0848235 0.0380141 -0.0222846 -0.1554057
r&d collaboration with customers -0.0988364 0.3205146 -0.3216521 -0.6730545 -0.157989 -0.1502506 0.0307584 0.1322626 0.017216 -0.2258172
  
Rotated Component Matrix(a)         
  Component          
 1 2 3 4 5 6 7 8 9 10
Tekes has financed a firm 0.4804135 0.3164 0.1268402 0.6067572 0.1458177 -0.1723796 -0.1465169 0.2320941 -0.0884225 0.0280044
Sitra has financed a firm 0.2277767 -0.2745604 -0.2896162 0.5429067 -0.2159746 0.2069765 0.3146271 -0.2103515 0.2323552 0.0752054
Problems in skilled labor supply 0.0682695 -0.1059925 -0.016068 0.03663 0.7935515 -0.203855 0.0225136 -0.2045395 -0.0791886 -0.0030356
public r&d support per r&d costs 0.0119703 -0.1388794 0.0049292 0.2532655 0.7797234 0.1012485 0.013735 0.2280527 0.0924603 0.283192
Patents / total personnel -0.022539 -0.0549271 -0.110751 -0.0663038 -0.0724985 0.8671487 0.1419462 -0.0759983 0.0130615 -0.2175898
LNPATENT 0.4857428 0.108746 0.3886552 0.020334 0.026577 0.651337 0.0035202 -0.190605 0.1079503 0.1437197
LNCEOEXP 0.090693 0.0722876 0.384487 0.3856561 -0.1303531 0.4596008 -0.3474778 0.1888537 0.1079087 0.335393
post-graduated CEO 0.0816593 -0.1379678 -0.0219097 -0.0478006 -0.0347189 0.1257641 0.8108388 0.0799661 -0.0640511 0.0954442
Top5 Auditor 0.2383208 0.3611944 0.1064743 0.2526889 0.2135282 -0.0054789 0.6101852 0.071895 -0.0328619 -0.1436143
LNPRVCL€ -0.0366105 0.0500265 0.0405761 -0.006474 0.0095817 -0.0297627 0.1843589 0.863081 0.0174781 0.07222
Solidity (equity+caploans per  
equity+debt) -0.1295055 -0.3693148 0.0521086 -0.0143842 0.0852078 0.1630511 0.1945555 -0.6540476 -0.0847032 0.1537927
principal subcontractor (>1/3  
out of purchases) -0.1552291 -0.0732395 -0.0232133 0.0431879 0.0461608 -0.0514284 0.0051391 -0.0359976 -0.8558859 0.0261279
Turku 0.0512032 -0.3970463 0.0541722 -0.2059953 -0.2337155 0.3542439 0.2311848 -0.1812437 -0.4786035 0.2216635
LNAGET 0.2536022 0.3464313 0.0975618 0.0790874 0.1188756 0.3572686 -0.3592118 0.3764894 0.4309932 0.027215
research spin-off -0.0219012 0.0591175 0.0876454 -0.001883 0.2292833 -0.0873727 0.0910199 0.0066571 -0.0656426 0.8588688
Pharma=1 0.3442345 0.1808318 0.3743293 0.1663415 0.3054103 0.0694434 0.3180964 0.1564287 0.1566771 -0.5134446
rd collaboration with subcontrac-
tors 0.2986942 0.1568297 0.1381328 -0.1610257 0.0497592 0.4044891 0.1120648 -0.0251105 -0.3591931 -0.4294338
Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser Normalization. Rotation converged in 13 iterations. 
  
 
Appendix, cont. 
Component Transformation Matrix         
Component 1 2 3 4 5 6 7 8 9 10
1 0.765137 0.0320552 0.4182002 0.3246962 0.185007 0.1786928 0.1698277 0.0863262 0.170267 -0.0421375
2 0.0041987 0.8961063 -0.0413413 -0.1074283 -0.036804 -0.0028326 -0.2072486 0.310354 0.1910855 -0.0811058
3 0.2510253 0.0512936 -0.2182918 -0.4258171 -0.474671 0.4777384 0.3123501 -0.2221041 -0.0531567 -0.3195603
4 -0.1009028 -0.1457236 0.5150882 -0.2530077 -0.3350404 0.3769598 -0.4109835 0.1339238 0.1150647 0.429908
5 -0.253488 0.1436023 0.0241452 -0.0893324 0.6552395 0.5479868 0.0291465 -0.3973281 0.1224651 0.0566903
6 -0.0052714 0.0039702 0.5298768 -0.6185944 0.2438627 -0.3808337 0.1289322 -0.0278712 -0.1533289 -0.301852
7 -0.0966353 -0.2193818 -0.161648 -0.2498701 0.0969588 -0.0375094 0.4021617 0.4030768 0.709077 0.1271416
8 0.0313192 0.2129071 -0.0161276 -0.097486 0.0476708 0.0217245 0.5248059 0.1678152 -0.480637 0.6376413
9 -0.4404811 -0.0381713 0.283704 0.319553 -0.0556658 0.3249916 0.2730393 0.4633235 -0.2121321 -0.4230602
10 -0.2696773 0.237797 0.3495738 0.270197 -0.3511029 -0.2119103 0.3640848 -0.5147954 0.3179943 0.0929881
Extraction Method: Principal Component Analysis.   
 Rotation Method: Varimax with Kaiser Normalization.    
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ESSAY 4.  
Intellectual Capital and Anticipated  
Future Sales in Small and Medium-Sized 
Biotechnology Companies:  
Empirical Evidence from Finland39 
Abstract 
The objective of the study was  to empirically verify impacts of intellectual 
capital to the anticipated future sales of small and medium-sized compa-
nies within the biotechnology industry. The Finnish biotechnology indus-
try is used as an example of an industry with high growth prospects but 
long and insecure product development phases. Theoretically, intellectual 
capital is divided into the following three categories: human capital, struc-
tural capital, and relational capital. In the empirical setting, survey data of 
small and medium-sized Finnish biotechnology companies are used. In the 
econometric analyses the interactions, or empirically co-variation, between 
the three categories of intellectual capital explain two thirds of the variance 
in the anticipated future sales of the sample companies. Thus, it seems that 
a well-balanced combination of human capital, structural capital, and rela-
tional capital implies value creation potential and high anticipated future 
sales.  
Key words: Biotechnology, intellectual capital, knowledge management, 
sales anticipations. 
 
                                                 
39  Thanks to professor Ilkka Kauranen for his supervision of writing this essay. I also 
thank Tomi Hussi for his important insights in definitions and settings of the re-
search framework. I appreciate the comments concerning the earlier versions of this 
paper given by the participants of the workshops “The Economics and Business of 
Bio- Sciences & Bio-Technologies: What can be learnt from the Nordic Countries 
and the UK?” in Gothenburg, September 2002 and ‘Innovations and Entrepreneur-
ship in Biotech/ Pharmaceuticals and IT/ Telecom’ in Chalmers University of 
Technology, Gothenburg, May 2003. The financial support from TEKES (the Na-
tional Technology Agency of Finland) and Helsinki University of Technology Lahti 
Center is gratefully acknowledged. 
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4.1  Introduction 
4.1.1  Background 
In valuation of the company or a single business project, prevailing 
methods in accounting and finance are based on assessing the worth of 
today’s investment in relationship to the positive cash flows in the fu-
ture. The net present value of the project or the company is derived 
from these future cash flows. Strictly speaking, the net present value of 
the investment is the difference between the discounted, or present, 
value of the future income and the amount of the initial investment (see 
e.g. Brealey and Myers, 2003). Both theoretically and in practice, the 
valuation of on-going companies or business projects, in contrast to their 
liquidation value, is linked to their ability to generate positive cash flows 
in the future.  
In management literature, the value of companies is often explained 
by the impact of intellectual capital, e.g. Edvinsson and Malone, 1997; 
Sveiby, 1997; Hall, 2001 and Mayo, 2001. Adequate intellectual capital 
enables the company to create new innovations and to exploit them 
commercially. This is a prime source for future sales especially in high 
technology industries.  
The anticipated future sales are determining the market valuations of 
companies. High present value estimates are characteristic of industries 
that have high prospects for future sales. The biotechnology industry is 
an archetype of industries with prospects for extraordinary high future 
sales. Because of its high future prospects, the biotechnology industry 
has attracted large infusions of private venture capital. Government 
agencies enhancing promising industries have also heavily supported the 
development of biotechnology.   
Despite the high impact of intellectual capital on the anticipated sales 
and, accordingly, on the valuation of companies, there have been only a 
few empirical contributions in these matters in the knowledge manage-
ment literature. Attempts to empirically measure the impact of intellec-
tual capital on value creation have been rare (Gu and Lev, 2001). Even 
though the biotechnology industry offers tempting future prospects and 
sets demanding challenges for venture capital industry and for public 
industry development agencies, there is a lack of research studies explor-
ing the special characteristics of companies in the biotechnology industry 
(Cumby and Conrod, 2001). 
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4.1.2  Objective and Scope of the Study 
The fact that the market valuation of companies is mainly based on antici-
pated growth prospects, challenges the reliability of the anticipated future 
cash flows disclosed by the companies. This study attempts to offer a tool 
on how these kinds of speculative future prospects can be assessed in a 
way that controls for individual and subjective biases of future anticipa-
tions. The intellectual capital framework offers insights into how the pre-
sent resources of companies can be used in empirical evaluations of future 
anticipations disclosed by companies themselves. This is especially rele-
vant in growth-oriented industries such as the biotechnology industry.  
The objective of the present study is to empirically verify impacts of 
intellectual capital to the anticipated future sales of small and medium- 
sized enterprises (SMEs) within the biotechnology industry. It is impor-
tant that the drivers behind the business logic and the valuation of 
 
 
Figure 1.  The positioning of the present study in relationship to 
different research methods and research traditions (IC = 
Intellectual Capital).  
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companies within the biotechnology industry can be well understood. 
The present study combines econometric discipline of research methods 
and knowledge management research traditions to reach the present 
research objective, Figure 1. 
The present study employs a well-representative survey sample of 
small and medium-sized Finnish biotechnology companies. The inter-
views were carried out at the beginning of 2002.40 Many of the Finnish 
biotechnology companies are research-based spin-offs, having at the 
time of the interviews low or no sales. The sample of companies consti-
tutes a good case for studying how anticipated future sales and corre-
sponding valuations are built on the intellectual capital of the companies. 
Accordingly, in the present study we empirically test the intellectual capi-
tal approach presented in the knowledge management literature (e.g. 
Sveiby, 1997; Edvinsson and Malone, 1997; Stewart, 1997; Ahonen, 
2000; Hussi and Ahonen, 2002) by applying statistical tools. 
4.2  Theoretical Background  
The knowledge management literature has flourished since the mid 
1990s. Nonaka and Takeuchi (1995) laid a foundation in the discussion 
on knowledge creation in companies. In the literature the intellectual 
capital of the companies was used as an explanation for the fact that the 
book values of companies are often lower than the market valuations of 
the companies. (Edvinsson and Malone, 1997; Stewart, 1997). 
In the knowledge management literature, intellectual capital is usually 
grouped into three partly overlapping categories. For example, Sveiby 
(1997) defines the following three categories: individual competencies, 
internal structures, and external structures. Edvinsson and Malone (1997) 
list the following three categories: human capital, organizational capital, 
and customer capital, respectively. Hussi (2001) and Hussi (2004) com-
bine these definitions and puts forward the idea that intellectual capital 
contains the following three categories: human capital, internal struc-
tures, and external structures. Hussi argues that the category of individ-
ual competencies is too narrow a definition for human capital. According 
to Hussi, human capital contains other aspects besides individual compe-
tencies. Such additions can include, for example, the health of individu-
                                                 
40  The paper draws on the ETLA and Etlatieto Ltd survey of Finnish biotechnology 
companies, conducted in March-May 2002. Descriptive survey findings have been 
reported in Hermans and Luukkonen (2002) and Hermans and Tahvanainen (2002). 
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als. On the other hand, external structures can include a wider scope 
than only customer relations. For example, many companies are closely 
linked to their suppliers or academic research networks. 
 
Figure 2.  Intellectual capital and knowledge management (Edvis-
son and Malone, 1997).  
In the present study, we apply a recent consensual definition of intel-
lectual capital (e.g. MERITUM project, 2002; Bontis, 2002a), which also 
groups intellectual capital into three categories, Figure 2. The first cate-
gory is human capital, which is composed of the skills and competencies 
of the company’s personnel. The second category is structural capital, 
which signifies the company’s ability to organize its activities in a way 
that tacit knowledge can be converted into intellectual property rights 
owned by the company.41 The third category is relational capital, which 
stresses the importance of external networks, for example, with custom-
ers and other partners. According to the knowledge management ap-
proach, when there is a close interaction between these three categories 
of intellectual capital, the firm is able to create value from its business 
activities and growth can be anticipated. A well-balanced combination of 
human capital, structural capital, and relational capital is needed and this 
requires proper knowledge management. For example, even if a com-
                                                 
41  Nonaka and Takeuchi (1995) define their seminal model in which they interpret 
how the tacit knowledge is converted to explicit knowledge and back to the tacit 
knowledge of other individuals and groups. In the present study we do not focus on 
the so-called SECI model but instead we focus on measuring the interactions be-
tween different categories of intellectual capital and its impact to anticipated sales.  
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pany has ample human capital represented by labor with a high level of 
expertise, the value creation is not guaranteed if production or marketing 
processes are not well organized or customers are not reached. 
 
Figure 3.  Intangible assets and long-run productivity of capital 
(Hussi, 2001). 
Ahonen (2000) and Hussi (2001) deepen the description behind the 
value creation mechanism, Figure 3. They divide intangible assets into 
generative assets and commercially exploitable intangible assets. The 
scheme in Figure 3 emphasizes the generative intangible assets as an en-
abler for the development of commercially exploitable intangible assets. 
The commercially exploitable intangible assets, in turn, enable the present 
value creation. The value creation is depicted as the interaction between 
human capital, structural capital (internal structure), and relational capital 
(external structure) in Figure 2. Generative intangible assets prepare the 
way for the commercially exploitable intangible assets in the future and af-
fect the long-run productivity of capital in Figure 3. 
4.3  Data and Research Methods 
4.3.1  The Survey Companies 
At the end of 2001 there were approximately 120 biotechnology compa-
nies actively operating in Finland (Kuusi, 2001; Hermans and Luukkonen, 
2002). The companies were interviewed by telephone in the spring of 2002 
and sufficient data was obtained from 84 companies. Of the companies 
interviewed, 12 companies were classified as large companies. A company 
was classified as a large company if two out of the following three condi-
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tions were fulfilled: the company has more than 250 employees, its sales 
are more than 40 million euros, or its total balance sheet exceeds 27 mil-
lion euros. Thus, 72 of the interviewed biotechnology companies were 
small or medium-sized and formed the research sample of companies. 
Using only small and medium-sized companies in the study increases 
the reliability of the study. Many of the large companies are multi-
functional with only a (small) part of their sales coming from biotechnol-
ogy products. Also some of the large sample companies are a part of a 
consolidated company and their financial reports are not given in a uni-
form manner. 
The survey data includes information about ownership, financial ac-
counting, input-output networks, as well as research and development 
activities. The survey also includes the company managers’ expectations 
about the future development of the companies. The survey contained 
120 questions of which about one third are used in the present study.  
Specific measures were taken in order to get undistorted answers from 
the company managers. For example, at the beginning of each interview, a 
confidentiality assurance was given to the respondents, assuring, for ex-
ample, no data that could identify a single company would be published. 
The psychological implications behind the sales anticipations would be an 
interesting research topic in itself, but in the present study these anticipa-
tions are taken as given.  
4.3.2  Variable Construction 
In the present study, we follow the definition of intangible assets (IA) pre-
sented in Figure 3, in which intangible assets are divided into two catego-
ries: generative intangible assets and commercially exploitable intangible 
assets. The amount and quality of generative intangible assets are meas-
ured in the present empirical study by several variables describing intellec-
tual capital. Commercially exploitable intangible assets are measured by the 
present sales of the companies. Accordingly, by studying separately gen-
erative intangible assets and commercially exploitable intangible assets, we 
can identify the impact that these two categories of assets have on the 
anticipated sales. In the present study, intangible assets are studied as 
stocks but intellectual capital through interaction (see e.g. Hussi, 2004).  
Many of the values of the variables in the present study have a very 
wide distribution and the distributions can be skewed. This can distort 
such analyses, which are based on linear correlations. Thus, as a common 
research procedure, variables are logarithmized before performing the 
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analyses. This transformation is not needed for variables that are ratios 
or that are dichotomous dummy variables.  
4.3.2.1  Generative Intangible Assets 
Variables to measure generative assets are constructed mainly based on 
Sveiby's (1997) notion that intellectual capital can be measured by using 
three categories of variables, namely 
a) growth and renewal 
b) efficiency 
c) stability.  
In biotechnology industry, large investments have been made in inten-
sive research and development activities to commercialize innovations or 
sell intellectual property rights. Only few of the anticipated potential inno-
vations have been successfully developed, and even less of them commer-
cialized. Thus, the importance of efficiency and stability is not as remark-
able as it is when there is something to sell. Accordingly, in the present 
study the focus is on the first category of variables, growth and renewal.  
Intellectual capital is grouped into three categories: human capital, inter-
nal capital, and relational capital. These categories are used when conceptu-
alizing the variables in the theoretical knowledge management framework. 
Theoretically, the interactions between human capital, internal capital, and 
relational capital are important in the value creation in companies. These 
categories of intellectual capital can be applied at the firm level (Mouritsen et 
al., 2000) and at the economy level representing groups of companies 
(Bontis, 2002b). The econometric procedures can be based on the view-
point of the business management literature, and the variables of knowledge 
management models can be linked to data on the biotechnology industry.  
Human capital (HC) 
Human capital is more central to the core of intellectual capital than the 
other two categories of intellectual capital (Edvinsson and Malone, 1997). 
We modify Sveiby’s (1997) classification in the construction of the three 
variables, which we will use to measure human capital in the companies: 
a) the total personnel 
b) the education level of the personnel (the number of persons 
holding doctoral  licentiate degrees) 
c) the business experience of the CEO (in years). 
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The total personnel measure the quantity and the critical mass of hu-
man capital in the companies. Biotechnology is a knowledge intensive 
industry and, thus, the total personnel is a relevant variable measuring 
the critical mass of human capital. The number of personnel in the com-
panies is connected to the age of the companies within the data. On the 
one hand, over half of the youngest companies in the sample employed 
less than 10 persons. On the other, almost half of the oldest companies 
had more than 250 employees. 
The two other variables attempt to capture features describing the 
quality and the skills of the personnel. The education level of the per-
sonnel measures the general quality of the human capital and the specific 
quality of the human capital in the form of the research training of the 
personnel. This variable measures the formal knowledge stock and the 
ability to process the knowledge stock.  
Table 1.  Description of the human capital variables. 
Statistics N      
HC Valid Missing Mean Median
Std.  
Deviation Sum 
Personnel 72 0 29.4 8 104.4 2 119 
Doctors and licentiates 72 0 3.0 2 3.8 215 
CEO's business  
experience in years 71 1 10.6 10 7.6 756 
 
The business experience of the company’s CEO attempts to measure 
the skills related to the business performance. It is interesting to note 
that the youngest biotechnology companies have hired many employees 
with doctoral degrees but CEO’s with doctoral degrees do not have long 
careers in business. 
Structural capital (SC) 
Structural capital includes the way of organizing the company’s activities 
and also the intellectual property rights of the company. The present 
study operates with three variables describing structural capital:  
a)  research and development input (research and development 
costs in euros) 
b)  patent intensity (the number of patent applications and patents) 
c)  the age of the firm (in years) 
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In the present study, we deviate from the mainstream measures (Sveiby, 
1997), which focus on the information technology inputs. However, 
Deeds (2001) brings out research and development expenditure as a focal 
source of innovation potential. Within the data at hand, research and de-
velopment intensity is strongly connected to the age of the companies.  
Over half of the young companies spend over 50 percent out of their total 
expenditure on research and development activities. This expresses clearly 
the nature of the biotechnology industry. Companies, which had a low 
research and development expenditure percent, were on average older than 
other companies in the sample. Such older companies were often owned by 
other non-financial companies.  
Lev and Sougiannis (1998) discuss the impacts of different reporting 
methods on the relation of research and development expenditure and 
realized earnings. In the present study, we do not use figures taken from 
the financial statements of the companies, but rather figures given directly 
by the companies in the interviews. In Ahonen’s (2000) terms, research 
and development expenditure can be regarded as a generative intangible 
asset whereas the patent portfolio is a commercially exploitable intangible 
asset. A key question related to a company’s structural capital and value 
creation is how its research and development expenditure can generate 
patent applications and patents that are commercially exploitable. Stewart 
(1997) also highlights the intellectual property rights as a way to create 
value with (internal) structural capital. The number of patents and patent 
applications is used to measure the future potential of the company.  
However, the interaction between the internal capability to produce patent 
applications and the external regulatory environment is essential. Because 
the variable measuring patenting intensity is the quantity of patent applica-
tions and the patents a company holds, it also reflects the future sales po-
tential arising from the innovation portfolio of the company.  
Table 2.  Description of the internal structure variables. 
Statistics N      
SC Valid Missing Mean Median
Std.  
Deviation Sum 
Research and development 
costs in million euros 72 0 1.39 0.17 3.40 100.34 
Patents and patent  
applications 72 0 11.8 4 26.6 849 
Age of company 72 0 7.2 6 4.9 521 
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The age of the company is employed as a variable measuring structural 
capital. Some factors, for example, the stability of the organizational 
structures are often difficult to measure, and they can be quantified by 
using age as an estimator (Sveiby, 1990 and Sveiby, 1997). The age of the 
company can affect how the internal affairs have been organized in a 
company in many ways. Organizational cultures differ from each other in 
old companies, on the one hand, and in young companies, on the other.  
Age can also contain some other specific features with high relevance 
for market valuation and sales potential. For instance, the drug develop-
ment process carries out a tightly regulated drug approval process with 
pre-clinical and clinical phases (1-3). Furthermore, even if a drug is ap-
proved, it will not self-evidently become a bestseller in the marketplace. 
It can be expected that when the company passes a single phase of the 
approval process, this affects positively the anticipations of the future 
sales and, thus, the valuation of the company.   
However, only 35% of the companies in the sample have disclosed 
that their core business is drug development. Thus, in order to control 
for the impact of special features within the drug development business, 
we added a dummy (0-1) controlling variables in the analysis. These vari-
ables indicate whether a single company belongs to some specific branch 
(=1) or not (=0). Accordingly, we were able to control for the impact of 
differences of business logics within separate branches (pharmaceuticals, 
diagnostics, biomaterials, industrial enzymes, food and feed, agro, ser-
vices, other). 
Relational capital (RC) 
Edvinsson and Malone (1997) and Stewart (1997) define the company’s 
relational capital as customer capital. Sveiby (1997) also takes into ac-
count supplier networks in relational structures. Market potential and 
catering to customer needs are fundamental requirements for success in 
any business. Most of the future of the market potential in small open 
economies results from the anticipated sales in international markets. 
Foreign exports are, thus, essential to companies acting in a small open 
economy that does not have a large home market, and the anticipated 
future sales of companies can be related to their plans to internationalize 
their operations. The present level of foreign exports varies among dif-
ferent age groups of the sample companies. The younger sample compa-
nies, in particular, anticipate a relatively rapid increase in their exports in 
the future. Accordingly, the demand-pull of the global markets can be 
considered a key external driver for anticipated future sales of the Fin-
nish biotechnology companies. However, the variable “anticipated change 
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in exports” is not utilized in the present study due to a simultaneity and 
feasibility problem. Anticipated exports growth is deemed to occur si-
multaneously with anticipated sales growth. Both are based on the com-
panies’ own articulations and this could raise a danger of explaining an-
ticipations by anticipations from the same source. 
Many of the early-stage biotechnology companies have no customers. 
Thus, their success rests on future anticipations. Potentials in research 
and development increase a company’s anticipated sales that, in turn, 
draw financial investments necessary to continue research and develop-
ment activities aiming at commercialization. When speaking of the early-
stage biotechnology companies, a most important aspect of relational 
capital is research and development collaboration and investor networks.  
A strong science base is necessary in order to attract large investments. 
(Darby and Zucker, 2002.)  
In order to obtain financing the company should be credible and 
trustworthy in the investors’ eyes. Guiso, Sapienza and Zingales (2001) 
state, “Whether such an exchange [financing] will take place depends 
upon not only the enforceability of contracts, but also the extent the 
financier trusts the financee. Thus, higher level of trust improves the 
efficiency of financial contracts and increases their use.” In this sense the 
definition of relational capital above is closely related to the concepts of 
social capital and trust. 
Relational capital is measured in the present study by seven variables, 
which are divided into the following three groups 
a) university collaboration intensity (university research and de-
velopment paid from governmental research and development 
support in euros) 
b) sources of equity financing (in euros, equity financing received 
from individuals active in business, private venture capitalists, 
governmental venture capitalists and other firms), 
c) sources of capital loan financing (in euros, capital loan financ-
ing received from private venture capitalists and governmental 
venture capitalists).  
The equity financing from persons who are actively involved in busi-
ness, private and governmental venture capital institutions and other 
firms measure ownership structures. Hermans and Tahvanainen (2002) 
showed that the ownership-related variables are loaded with expecta-
tions for value creation. Some investors are willingly involved in busi-
ness activities as board members. At best, the investors can contribute 
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to the businesses of the investee company significantly with their rela-
tions and experience. Capital loan financing is measured as money 
flows from private and governmental venture capital institutions to the 
biotechnology companies.  
Table 3.  Description of the external structure variables (in millions 
of euros). 
Statistics N      
Million euros Valid Missing Mean Median
Std.  
Deviation Sum 
University research and  
development in collaborating 
projects 
68 4 0.11 0.001 0.36 7.66 
Equity financing from indi-
viduals active in business  71 1 0.42 0.03 1.37 29.96 
Equity financing from other 
non-financial companies  72 0 0.56 0.00 2.28 40.04 
Equity financing from private 
venture capital companies  72 0 0.41 0.00 2.12 29.23 
Equity financing from  
governmental venture capital 
institutions  
72 0 0.35 0.00 1.44 25.46 
Capital loan financing from 
private venture capital  
companies 
71 1 0.28 0.00 1.00 19.69 
Capital loan financing from 
governmental venture capital 
institutions 
70 2 0.56 0.02 1.70 39.54 
 
In the science-based industry, research collaboration with academic 
institutions seems to be an essential form of relational capital. It also 
reflects the external governmental research and development support 
intensity. This is because Finnish authorities have typically set a con-
dition of university collaboration for granting their own research and 
development support to companies. In Stage 2 of the regression analysis, 
we choose academic collaboration and governmental equity financing 
and capital loan financing separately as variables measuring relational 
capital.  
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4.3.2.2  Commercially Exploitable Intangible Assets 
In order to avoid circular argumentation, we exploit the present sales as a 
measure of the company’s present ability to exploit its structural and 
relational capital. This decision is made following the argumentation of 
Ahonen (2000) and Hussi and Ahonen (2002). The above thinking pre-
dicts that value creation occurs in the interaction between all of the three 
categories of intellectual capital and, therefore, present sales cannot be 
taken as a predictor for relational capital only.  
The present sales are taken as a present measure of how effectively 
commercially exploitable assets have previously been utilized. To a great 
extent, the anticipated sales seem to rely on the market potential of the 
future, and not on the present sales and present market share. Almost 
one third of the sample companies had annual sales of less than 100 
thousand euros (see Table 4). The oldest companies had relatively high 
sales volumes.  
Table 4.  Description of the present and anticipated sales (in mil-
lions of euros). 
Statistics N      
Millions of euros Valid Missing Mean Median
Std.  
Deviation Sum 
Sales in 2001 72 0 1.80 .20 4.96 129.85 
Anticipated sales  
in 2006 70 2 11.73 1.40 31.78 821.12 
 
Present sales are an estimator to measure the part of the intangible 
assets that are already exploited commercially. Among the sample 
companies, the anticipated sales in the years 2001 - 2006 were on av-
erage expected to grow at about a 45 percent annual rate. The antici-
pated sales are a prime determinant in the valuation of the company. 
In the next section, anticipated sales will be the dependent variable in 
the regression analysis and will be explained by the indicators of intel-
lectual capital.  
4.3.3  Statistical Procedure 
A methodological contribution of the present study is the combining 
of econometric analyses with the knowledge management approach. 
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Econometric modeling is used as our main tool. Factor analyses are 
applied as an important analysis method. The factor scores resulting 
from the factor analyses are fed into regression analyses. The antici-
pated sales of the companies are explained by these regression mod-
els. 
Thus, there are two stages in the statistical procedure:  
Stage 1: Factor analysis is used to identify the three intellectual capital 
factors and produce factor scores for each company.  
Stage 2: Regression analysis is used to explain the companies’ antici-
pated sales in 2006. The intellectual capital factors are formed by factor 
scores produced in Stage 1. The factor scores are used as variables in the 
regression model. In other words, the output of the factor analysis is 
used as predictors that explain the anticipated sales of the sample of bio-
technology companies. 
First, we try to find the forms of interactions between the three cate-
gories of intellectual capital (IC). According to the knowledge manage-
ment theory, this is important for two reasons. First, the value creation 
in business activities is connected to the interactions between the three 
categories of intellectual capital. Second, there can be interactions that 
are not strictly connected to the value creation. It is important to sepa-
rate the latter kind of interactions from those that create value. In statis-
tical terms, the interaction between the three categories of intellectual 
capital is measured as the co-variation of the intellectual capital based 
variables.  
The idea in the first stage is to find the common variation between the 
variables and form the intellectual capital factors discussed above. Be-
cause an orthogonal factor analysis method is applied, the factors are 
uncorrelated with each other, which is an advantage in regression analy-
sis. This lowers the risk of multicollinearity between the independent 
variables. Factor scores are constructed from the factors and they are 
used as new variables in Stage 2. 
Our attempt is to explain the anticipated sales of the companies 
based on the knowledge management approach. Regression analysis is 
used to produce three alternative models. Firstly, we use original vari-
ables without the results of the factor analysis. Secondly, we construct 
a regression model with all the factors received from Stage 1. Thirdly, 
we regress only statistically significant factors and add some signifi-
cant dummy variables found in the data.  
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Despite the fact that we employ cross-sectional data, the analysis is 
dynamic in a similar sense as Bounfour (2002). We are interested in 
the valuation of assets and the input-output relations of intellectual 
capital. 
4.4  Results 
4.4.1  Stage 1: Factor Analysis 
Factor analysis produced four factors in Stage 1. Applying the gener-
alized least squares (GLS) method the factors interconnected the vari-
ables within three intellectual capital components mentioned above 
(see e.g. Sharma, 1996). We took natural logarithms from other than 
ratio variables or dummy variables. Appendix 1 presents the commu-
nalities for each variable. It shows that the factor model explains 28 - 
78 % of the variance of a single variable. The model can explain 73 % 
of the total variance of all the initial variables (see eigenvalues in Ap-
pendix 2).  
Then, using the rotated factor solutions presented in Table 5, we pro-
duced factor scores  for each case company and factor by multiplying the 
factor loadings by the values of the initial variables. Factor rotation was 
chosen instead of the initial factor solution due to the clarity of the in-
terpretation of the factors. The factor rotation was done using the vari-
max method, which is a rotation method that minimizes the number of 
variables that have high loadings on each factor. Thus in order to sim-
plify the interpretation of the factors, we utilize the results of the rotated 
solution. 
One factor indicates how different categories of intellectual capital in-
teract, or co-vary with each other. For example, the loadings of Factor 1 
in Table 5 presents co-variation between the three categories: critical 
mass of personnel (human capital), large patent portfolio and R&D ex-
penditures (structural capital), and university collaboration and equity 
financing from private venture capital companies (relational capital). 
Table 5 implies also that Factor 1 is related to the pharmaceutical indus-
try and negatively with the service sector. 
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Table 5.  Factor matrix. 
  Factor         
 1 2 3 4 5 6 7 8 9 
Patents and patent  
applications (log) 0.813 0.137 -0.014 -0.094 -0.087 0.161 0.002 0.007 0.117 
R&D expenditures (log) 0.810 0.125 0.159 0.298 0.064 0.059 0.082 0.092 0.011 
Expenditures on university 
collaboration (log) 0.764 0.148 -0.162 0.153 0.083 0.217 0.050 0.115 -0.109 
Personnel (log) 0.704 0.159 0.441 0.244 0.050 0.028 -0.051 -0.088 -0.020 
Services (=1) -0.357 0.020 0.132 0.237 0.275 -0.018 0.165 0.166 -0.047 
Pharma (=1) 0.327 0.162 -0.107 0.299 0.067 -0.112 -0.028 -0.121 -0.038 
Equity financing from 
government VC (log) 0.200 0.779 -0.050 0.155 0.055 -0.171 0.139 0.270 -0.086 
Equity financing from 
private VC (log) 0.307 0.754 -0.045 0.099 -0.134 0.054 -0.011 -0.054 -0.130 
Equity financing from 
persons active in  
business (log) 
-0.015 0.609 -0.117 0.091 0.032 0.185 -0.106 0.010 0.065 
Industrial enzymes (=1) -0.104 -0.164 0.058 -0.022 0.045 -0.121 -0.092 0.039 0.094 
Present sales (log) 0.102 -0.092 0.975 0.000 0.007 0.160 0.030 -0.050 -0.007 
Anticipated change in 
exports per turnover 0.249 0.245 -0.499 0.061 0.223 -0.198 0.116 0.203 0.028 
Equity financing from 
other companies (log) 0.395 -0.174 0.422 -0.161 0.133 0.021 0.018 -0.158 -0.152 
Doctors and licentiates 
(log) 0.357 0.273 -0.033 0.888 0.023 -0.016 -0.027 0.040 -0.063 
Agriculture (=1) 0.173 -0.137 0.167 -0.206 0.151 0.019 -0.081 -0.120 -0.063 
Diagnostics -0.034 0.031 0.029 -0.023 -0.993 0.008 -0.023 0.078 -0.052 
CEO experience (log years) 0.313 -0.002 0.156 0.061 0.043 0.779 0.070 0.026 0.150 
Age of company (log years) 0.055 0.101 0.376 -0.237 -0.190 0.526 -0.152 -0.175 -0.004 
Biomaterials (=1) 0.167 -0.084 0.065 -0.145 0.150 0.287 0.188 0.049 -0.118 
Capital loan financing 
from private VC (log) 0.011 -0.003 0.008 -0.011 0.007 0.000 0.999 0.034 -0.002 
Capital loan financing 
from government VC  
(log) 
0.122 0.155 -0.182 0.002 0.211 0.184 0.350 0.064 -0.011 
Turku (=1) 0.069 0.121 -0.142 0.017 -0.081 -0.014 0.045 0.939 -0.261 
Helsinki (=1) 0.000 -0.088 -0.048 -0.059 0.043 0.121 -0.003 -0.238 0.955 
Problems in skilled  
labor supply (=1) 0.145 -0.114 0.043 0.259 0.067 -0.215 -0.027 -0.063 0.282 
Factor loadings ¥ 0.30 bolded. 
Extraction Method: Generalized Least Squares.      
A 9 factors extracted. 18 iterations required. 
B Only cases for which SME biotechnology firm = 1 are used in the analysis phase. 
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4.4.2  Stage 2: Regression Analysis 
The outcome generated by the intangible assets is the anticipated future 
sales in Figure 4 instead of the long-run productivity of capital in Fig-
ure 3. The anticipated sales approximate the productivity of capital and 
the present value of the company due to the following reasoning. The 
biotechnology industry resembles the pharmaceutical industry in the 
sense that both have extremely long product development processes. 
Consequently, as many as one third of the companies in the sample are 
involved in the development of pharmaceutical products. Furthermore, 
when Scherer and Ross (1990) and Linnosmaa, Hermans, and Hallinen 
(2004) analyzed price-cost margins in the pharmaceutical industries in 
the USA and Finland, they found relatively high price-cost margins in 
both countries. This implies that physical capital does not play a pivotal 
role in the value creation process of the pharmaceutical industry. If this 
is also typical for the biotechnology industry, it seems reasonable to 
assume that the anticipated future sales imply growth in productivity of 
capital and the present value of the company. Hence, the original theo-
retical framework by Hussi and Ahonen (2002) holds for the frame-
work in Figure 4.  
 
Figure 4.  Intellectual assets and anticipated future sales of the 
company. Modified from Hussi (2001). 
The regression analysis exploits the theoretical models presented 
above. First, we utilize the initial variables without factor scores in the 
regression analysis. The results of the initial variable models are 
shown in Table 6. Generally speaking, the initial R2 ratios show that 
model 3 explains most of the variance of the variables in the model. 
However, when the adjusted R2 is observed, model 2 holds the best 
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fit.42 In this setting, the anticipated sales are almost entirely explained 
by the present sales. This describes a size effect (or scale economies) 
of the companies. Simplifying, if you are big now, you will be ex-
pected to be big in the future.  
When we regress the anticipated sales, explaining the sales in 2006 by 
the initial variables, only a few of the variables are statistically significant. 
The model does not contain the interaction effects of intellectual capital 
trying to relate intellectual capital measures directly and separately to the 
value creation (anticipated sales).  
Next we conduct the second phase by employing the factor scores 
formed above in the factor analysis. These factors describe how the three 
forms of intellectual capital are interlinked to each other. The results of 
the factor-based models 4, 5, and 6 are presented in Table 7.  
In model 4, we employ all the factors received from the generalized 
least square (GLS) method factor analysis in Stage 1. It implies that fac-
tors 2, 4, 5, 6, 8, and 9 do not significantly explain the anticipated sales. 
Therefore, we drop these factors from model 5. Then we add intangible 
assets to the analysis in model 6.  
Models 4, 5 and 6 are able to explain about 70 percent of the regres-
sors’ variance. For example, according to the adjusted R2, the independ-
ent variables in model 6 are able to predict systematically 70 percent of 
the variation of anticipated sales.  
The successful predictors are the chosen intellectual capital factors. As 
a result, the company anticipates high sales if the company’s intellectual 
capital is well balanced according to factors 1 and 3 in models 4, and 5. 
Factor 1 deviates also significantly from zero in models 4 and 5, but re-
mains insignificant in model 6. Model 6 contains a severe problem of 
multicollinearity: the independent variables Factor 1 and Tangible assets 
correlate significantly (r = 0.439, p = 0.001). This indicates that research-
intensive activities require also significant investments in equipment and 
loan financing (relational capital) with the anticipated future sales in 
Models 4, 5 and 6. The next section discusses on results of the empirical 
analysis.  
 
                                                 
42  Conventional R2 increases with the variables included in the model and decreases 
with the number of cases included in the analysis. The adjusted R2 takes those mat-
ters into account . 
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Table 6.  Regression model: Explaining anticipated future sales of 
small and medium-sized biotechnology companies by ini-
tial variables. 
Dependent variable: Anticipated sales in 2006.  
Variable  
Logarithmized variable (log) 
Dummy variable (d) 
Model 1: 
without dum-
mies  
Model 2: 
extended 
model 
Model 3:  
extended 
model with 
tangible assets 
R2 .744 .817 .837 
Adjusted R2 .672 .705 .691 
F-test 10.384*** 7.267*** 5.732*** 
    
Constant 1.880** (.909) 1.666 (1.070) 1.112 (1.644) 
Present commercially exploitable assets    
Present sales (log) .914*** (.126) .956*** (.144) .912*** (.183) 
Human capital    
Personnel (log)  -.131 (.291) -.477 (.313) -.684* (.385) 
Doctors and licentiates (log) -.174 (.343) -.529 (.391) -.367 (.546) 
CEO experience (log)  -.019 (.330) .070 (.401) -.697 (.566) 
Structural capital    
R&D expenditures (log)  .156 (.154) .230 (.160) .284 (.193) 
Patents and patent applications (log) -.037 (.215) -.121 (.256) .160 (.331) 
Age of company (log) -.368 (.371) -.397 (.396) .152 (.672) 
Relational capital    
Equity financing from other companies 
(log) 
.066 (.081) -.089 (.088) .122 (.104) 
Equity financing from persons active in 
business (log) 
.123 (.087) -132 (.091) .222* (.114) 
Equity financing from private VC (log) -.130 (.105) -.200* (.118) -.202 (.135) 
Equity financing from government VC 
(log) 
.092 (.098) .282** (.118) .185 (.168) 
Capital loan financing from private VC 
(log) 
.151 (.108) .029 (.090) .058 (.162) 
Capital loan financing from government 
VC (log) 
.004 (.087) .055 (.114) .123 (.119) 
Expenditures on university collaboration 
(log)  
.047 (.132) .136 (.143) -.039 (.184) 
Anticipated change in exports intensity (% 
units) 
 .002 (.812) -.419 (1.063) 
Problems in employing skilled labor (d)  1.136** (.519) .797 (.613) 
Pharmaceuticals (d)  .217 (.471) -.153 (.550) 
Diagnostics (d)  .566 (.544) .287 (.721) 
Biomaterials (d)  .667 (.553) .884 (.646) 
Industrial enzymes (d)  -.592 (.843) .203 (1.260) 
Agriculture (d)  .152 (.959) -.171 (1.122) 
Services (d)  .569 (.595) -.129 (.755) 
Helsinki (d)  -.064 (.570) .058 (.657) 
Turku (d)  -1.211* (.632) -.746 (.872) 
Tangible assets (log)   .108 (.177) 
Standard errors are in parentheses. The asterisk labels (*) stand for the level of the statistical 
risk of rejecting the null hypothesis incorrectly: the regression coefficient is zero. 
* 10 percent risk level,  ** 5 percent risk level,  *** 1 percent risk level. 
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Table 7.  Regression model: Explaining anticipated future sales of 
small and medium-sized biotechnology companies by in-
teracting factor scores. 
Dependent variable: Anticipated sales in 2006.  
Variable Model 4: 
all the  
factors 
Model 5:  
focal factors 
Model 6:  
focal factors and 
tangible assets  
R2 .724 .703 .722 
Adjusted R2 .678 .688 .700 
F-test 15.736*** 47.273*** 31.869*** 
Constant 7.001*** 
(.180) 
7.009*** 
(.177) 
5.800***  
(1.313) 
Factor 1: RC + HC .461**  
(.192) 
.468**  
(.188) 
.297  
(.270) 
Factor 2: HC + RC + SC + 
non commercial exploitability 
-.100  
(.195) 
  
Factor 3: RC + HC + SC + 
commercial exploitability 
2.137*** 
(.193) 
2.125*** 
(.188) 
2.029***  
(.260) 
Factor 4: HC + SC +  
commercial exploitability 
.010  
(.185) 
  
Factor 5: RC + HC .194  
(.183) 
  
Factor 6: RC + HC .135  
(.214) 
  
Factor 7: HC + SC + RC .461**  
(.178) 
.458**  
(.175) 
.371*  
(.198) 
Factor 8: RC + HC -.217  
(.181) 
  
Factor 9: HC + SC .155  
(182) 
  
Tangible assets   .100  
(.118) 
Standard errors are in parentheses. The asterisk labels (*) stand for the level of the statistical 
risk of rejecting the null hypothesis incorrectly: the regression coefficient is zero. 
* 10 percent risk level,  ** 5 percent risk level,  *** 1 percent risk level. 
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4.4.3  Discussion on Empirical Results 
Factor analysis measured interaction through statistical correlation (load-
ings) between initial variables and new factors obtained in the analysis. 
The loadings of these factors implied how different categories of intel-
lectual capital correlate with a single factor. Then factor scores were used 
in creation of new variables for each factor in the final solution. This 
formed the basis for measurement of interaction between the three cate-
gories of intellectual capital. In other words, high scores within some 
factor implied that the company has a high (low) amount of all these 
forms of intellectual capital that have high (low) loadings to this specific 
factor, respectively.  
The intellectual capital (IC) driven value creation of Factor 1 is de-
picted in Figure 5. There is the following co-variation within the three 
intellectual capital categories explaining high anticipated sales. A critical 
mass of personnel and doctors are directed to research and development 
activities, which are supported by a large patent portfolio. These compa-
nies are financed by private venture capital companies and other compa- 
nies. The most promising companies, within Factor 1, are partially re-
lated to the pharmaceutical sector.  
 
 
Figure 5.  Intellectual capital (IC) driven value creation within the small 
and medium-sized biotechnology companies (factor 1). 
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In other words, Factor 1 implies that if the bio-pharmaceutical com-
pany holds a critical mass of personnel and an experienced CEO (human 
capital); high R&D costs and a large patent portfolio (structural capital); 
and it has intensive collaboration with universities and it is equity fi-
nanced by other firms and private capital companies (relational capital), 
the company achieves high factor scores for Factor 1. The regression 
analysis models how these IC factor scores are linked with the antici-
pated future sales of the companies. The model results indicate that a 
high (low) Factor 1 score predicts high (low) anticipated sales in 2006, 
respectively.  
The same logic applies to Factor 3. The critical mass of personnel 
(human capital); high age of the company (structural capital); and signifi-
cant equity financing from other firms together with a low change of 
anticipated export intensity (relational capital) predict a high volume of 
anticipated future sales in 2006 (Figure 6).  
 
Figure 6.  Intellectual capital (IC) driven value creation within the small 
and medium-sized biotechnology companies (factor 3). 
Factor 1 emphasizes the significance of holding a patent portfolio in 
the drug development business. Patents and patent applications form a 
necessary base of intellectual property rights for commercial exploitation. 
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It is critical to hold patents related to those technologies which are the 
basis of the company’s own drug development. Without patent protec-
tion any other company can develop a generic drug based on the same 
chemical compound as a treatment for some specific disease. Without 
patent protection another company can take a free ride and get the same 
drug into the market by completing the generic drug approval process. 
In such a case the free-rider company can accomplish this with a very 
limited amount of R&D expenditures compared to the companies which 
invent new potential drugs.  
Factors 1 and 3 present how Saint-Onge’s et al. value platform is con-
cretized within the Finnish biotechnology industry (Figure 6). These 
companies have an above normal present sales level as was not the case 
in factor 3. Factor analysis seemed to be able to divide the size effect 
more effectively than the first regression model with the initial variables. 
For example, Factor 3 is closely related to the present sales and the criti-
cal mass of personnel in models 4, 5 and 6 as initial separate variables are 
in Models 1, 2 and 3, too. In contrast, Factor 1 is not loaded with the 
present sales level at all, but rather with research and development activi-
ties, number of patents, or university collaboration. 
In this empirical setting Factor 7 implies that capital loan financing 
from both private and governmental sources is strictly connected to the 
anticipated sales volumes of the biotechnology companies. However, the 
sensitivity of the solution of Factor 7 should be investigated, because the 
results of the factors, which explain a minor part of the variance of the 
initial variables, can be sensitive to the method used. However, the link 
between capital loan financing and anticipated sales remains interesting. 
Factor 7 may refer to dynamic impacts of financing. For instance, it 
would be important to investigate to what extent a company, when ap-
proaching potential financiers, raises its own estimates of anticipated 
future sales in order to get capital loan financing, and to what extent the 
company’s capabilities to exploit the market potential is strengthened as 
a result of being successful in raising new financing.   
4.4.4  Sensitivity Analyses 
In order to test how sensitive the results presented above are in relation 
to the compressing method we employ the principal component analysis 
(PCA) instead of the generalized least square (GLS) method factors. 
Then we apply the principal component scores in regressing the intellec-
tual capital interactions towards the anticipated sales of the biotechnol-
ogy companies. The results remain mainly parallel in the principal com-
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ponent analysis. The R2 of the regression model applying the principal 
component analysis is 61.4 %, which is somewhat lower than in the 
analysis applying the factor analysis. Four significant principal compo-
nents were found instead of the three (or two) factors explaining the 
anticipated sales.  
The principal component analysis comprises qualitatively similar basic 
features as the factor analysis. For example, in the principal component 
analysis, components related to factors 1 and 3 could be identified. The 
variables related to the region of the companies do not seem to be ro-
bust in this benchmark model. The Helsinki region with business experi-
enced leaders and capital loans from government institutions explain part 
of the anticipated sales in the benchmark model. Part of the anticipated 
future sales is explained by service companies that are already generating 
some sales and are owned by individuals active in the business.  
Another sensitivity analysis was made by performing the same re-
search analyses using relative measures instead of the absolute measures. 
The relative measures were attained from the absolute measures by di-
viding each of the values of the original variables by an appropriate vari-
able representing the size of the corresponding company. Obviously, this 
transformation was not needed for dummy variables or variables which 
already are ratios. Appropriate variables for dividing the values of origi-
nal variables were, for example, total costs or the number of personnel 
of the company.  
In the generalized least square (GLS) factor analysis done with the 
relative measures, three factors significantly explained the anticipated 
sales. The R2 of the regression model utilizing relative measures is 29.8 
%. The first factor had positive loadings with the variable describing 
other companies’ relative equity share and with the company’s innova-
tion intensity, which was measured by the ratio of patents and patent 
applications to labor involved in research and development activities. 
The first factor had a negative loading with the relative equity share of 
individuals active in business. The second factor had a positive loading 
with the ratio of present sales to labor, with the logarithmized age of the 
company and with government venture capitalists’ relative equity share. 
The third factor had a high loading with the ratio of present sales to la-
bor. The factors 1, 2, and 3 were related to the branches of agriculture, 
service, and diagnostics, respectively.  
The factor analysis applying the relative measures was not able to re-
veal the detailed structures behind the anticipated sales. This analysis 
stressed the importance of the present sales per labor and of branch spe-
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cific features. These results, together with the results of the principal 
component analysis above, raise a need for a closer look at branch spe-
cific phenomena within the biotechnology industry.  
4.5  Conclusions  
The present study relates the knowledge management theory and the meas-
urement of intellectual capital (IC) to the anticipated sales that small and 
medium-sized  biotechnology companies have articulated. According to the 
literature, value is created by the interaction of the three categories of intel-
lectual capital, namely human capital, structural capital and relational capital. 
We tested the theoretical framework among small and medium-sized 
Finnish biotechnology companies. In the first stage of empirical analyses, 
we identified factors that present interaction between the variables 
measuring the different categories of intellectual capital.  
In Stage 2 of the empirical analysis, we constructed two kinds of re-
gression models that explained the anticipated sales of the companies. 
Firstly, we utilized the initial variables. Secondly, we exploited factor 
scores from Stage 1. The regression models implied that the strict effects 
of single initial variables without interaction explained the anticipated 
sales at a general level as much as the factor-based variables that take 
into consideration the interaction between the categories of intellectual 
capital. The initial variable model stressed the present ability of commer-
cialization as an explanation for anticipated future sales.  
The factor-based model seemed to be able to separate some size-effect 
features. Particularly, two intellectual capital related factors were found 
that systematically explain the anticipated future sales. Both of these fac-
tors link to some degree human capital, structural capital, and relational 
capital. According to the first factor, the companies owing the highest 
anticipated sales levels have the critical mass of highly educated person-
nel and doctors directed to research and development activities. These 
companies hold large patent portfolios and they are partially owned by 
private venture capital companies and by other companies. According to 
the second factor, the critical mass of labor of an aged company has al-
ready generated sales. The company was mainly owned by other compa-
nies. Third significant factor was related to capital loans offered by pri-
vate and governmental venture capital companies.  
Three paths for further research are evoked by the present study. 
Firstly, in the present study some preliminary results concerning explana-
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tions for the anticipated future sales of Finnish biotechnology companies 
were obtained. Deeper analyses could help to build various economic 
forecast models. These could be, for example, macroeconomic, industry 
specific or region-based. Secondly, a follow-up study of the same sample 
of companies would be very attractive.  In it the real sales of 2006 could 
be compared to the anticipated sales, which were projected by the com-
pany managers in 2002. What kind of companies were the most success-
ful in realizing their anticipated sales? Thirdly, it would be interesting to 
investigate to what degree various kinds of investors have been able to 
select the companies that have turned out to be the most successful in 
terms of economic profitability and in terms of continuous intellectual 
capital development. 
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Appendix 1.  Communalities and total variance explained 
by factor analysis. 
Table A1.1  Communalities of the factor analysis 
Communalities(a,b)  
  Initial Extraction 
Sales  0.751 0.999 
RDcost 0.779 0.841 
Person  0.778 0.833 
Ceoexp 0.570 0.788 
Patent 0.692 0.811 
Age 0.568 0.669 
Docs 0.691 0.999 
Firminv 0.552 0.661 
Activinv 0.456 0.611 
PrVCinv 0.652 0.789 
GovVCinv 0.683 0.855 
GovVCL 0.420 0.526 
PrVCL 0.415 0.999 
UnivRD 0.717 0.802 
Dexport 0.622 0.730 
ProbPers 0.335 0.447 
Pharma 0.378 0.480 
Diagnost 0.498 0.999 
Biomater 0.305 0.410 
IndEnz 0.287 0.457 
Agricult 0.276 0.356 
Service 0.449 0.552 
Helsinki 0.546 0.999 
Turku 0.631 0.999 
Extraction Method: Generalized Least Squares. Only cases for which SME biotech firm 
= 1 are used in the analysis phase. 
One or more communality estimates greater than 1 were encountered during iterations. 
The resulting solution should be interpreted with caution. Appendix 1, continues. 
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Table A1.2  Total variance explained by generalized least square (GLS) 
method factors. 
Total Variance Explained(a)  
Factor 
Initial Eigen- 
values  
Extraction Sums  
of Squared Loadings 
Rotation Sums  
of Squared Loadings 
 Total 
% of 
Variance 
Cumula-
tive % Total
% of 
Variance
Cumula-
tive % Total
% of 
Variance
Cumula- 
tiv e % 
1 4.546 18.943 18.943 2.246 9.360 9.360 3.332 13.885 13.885 
2 3.238 13.493 32.435 1.872 7.802 17.162 1.951 8.128 22.013 
3 1.889 7.869 40.305 1.988 8.284 25.446 1.932 8.049 30.062 
4 1.745 7.270 47.575 1.932 8.049 33.495 1.382 5.760 35.822 
5 1.523 6.345 53.920 1.393 5.804 39.299 1.319 5.496 41.319 
6 1.400 5.834 59.754 0.733 3.053 42.352 1.298 5.407 46.726 
7 1.242 5.175 64.929 2.618 10.907 53.259 1.288 5.367 52.092 
8 1.083 4.514 69.443 1.191 4.963 58.221 1.222 5.091 57.184 
9 1.023 4.261 73.704 0.949 3.956 62.177 1.198 4.994 62.177 
10 0.849 3.537 77.241       
11 0.829 3.455 80.697       
12 0.754 3.144 83.840       
13 0.673 2.803 86.643       
14 0.518 2.158 88.802       
15 0.475 1.980 90.781       
16 0.450 1.875 92.656       
17 0.345 1.436 94.092       
18 0.318 1.326 95.418       
19 0.278 1.158 96.576       
20 0.228 0.950 97.526       
21 0.194 0.809 98.335       
22 0.177 0.736 99.072       
23 0.113 0.471 99.543       
24 0.110 0.457 100       
Extraction Method: Generalized Least Squares.     
Only cases for which SME biotech firm = 1 are used in the analysis phase.   
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Appendix 2.  Financial structure  
(Equity and capital loan financing from different sources) 
Table A2.1.  Estimated distribution of aggregate equity, capital loans, 
and debt by firm size and age (Hermans and Tahvanainen, 
2002). 
 Equity Capital loans Debt Total 
A: All (N=72)     
% 43.6 % 31.5 % 24.9 % 100.0 % 
(amount, mill.€)    305.3 
B: Breakdown by size of SME    
Small -6.9% 70.9 % 36.0% 100.0 % 
(amount, mill.€)    32.7 
Large 49.3 % 27.1 % 23.6 % 100.0 % 
(amount, mill.€)    274.7 
C: Breakdown by age of SME    
Infant 39.5 % 46.2 % 14.3 % 100.0 % 
(amount, mill.€)    162.7 
Adolescent 41.0 % 27.0 % 32.0 % 100.0 % 
(amount, mill.€)    64.1 
Middle-aged 54.4 % 4.6 % 41.0 % 100.0 % 
(amount, mill.€)    78.4 
Old n.a. n.a. n.a. n.a. 
(amount, mill.€)    n.a. 
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Table A2.2.  Estimated distribution of equity by firm size and age 
(Hermans and Tahvanainen, 2002). 
 Individuals Institutions 
 Active in 
business 
Other 
individ. 
Public
VC 
Private
VC 
Financial
instit. 
Other 
companies
Other
equity
Total 
sources 
of equity 
A: All (N=72)        
% 22.8 % 5.2 % 19.4 % 24.3 % 2.2 % 22.0 % 4.2 % 100.0 % 
(amount, mill.€)        215.0 
B: Breakdown by size of SME 
Small 32.1 % 2.8 % 27.1 % 7.3 % 1.8 % 24.9 % 4.0 % 100.0 % 
(amount, mill.€)        14.4 
Large 22.1 % 5.3 % 18.8 % 25.5 % 2.2 % 21.8 % 4.2 % 100.0 % 
(amount, mill.€)        200.7 
C: Breakdown by age of SME 
Infant 28.9 % 6.1 % 24.0 % 37.8 % 0.5 % 2.4 % 0.3 % 100.0 % 
(amount, mill.€)        116.1 
Adolescent 22.7 % 7.7 % 25.8 % 14.2 % 7.6 % 18.1 % 3.7 % 100.0 % 
(amount, mill.€)        50.8 
Middle-aged 8.2 % 0.2 % 1.3 % 2.3 % 0.5 % 73.3 % 14.2 % 100.0 % 
(amount, mill.€)        48.2 
Old n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
(amount, mill.€)        n.a. 
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Table A2.3.  Distribution of capital loans by firm size and age (Her-
mans and Tahvanainen, 2002). 
 Private    Public       
 
Dom. 
fin. 
instit. 
Foreign 
fin. 
instit. 
Foreign 
VC 
Private 
VC 
Public 
VC Sitra 
Finn-
vera Tekes
Other 
govt. 
& 
public Other Total 
A: All (N=72) 
% 0.6 % 0.0 % 4.0 % 18.1 % 0.4 % 13.7 % 0.3 % 53.4 % 0.0 % 9.6 % 100.0 %
(amount, mill.€)          96.2 
B: Breakdown by size of SME 
Small 2.5 % 0.0 % 16.9 % 18.4 % 0.0 % 37.7 % 1.4 % 19.2 % 0.0 % 4.0 % 100.0 %
(amount, mill.€)          21.7 
Large 0.0 % 0.0 % 0.3 % 18.0 % 0.6 % 6.7 % 0.0 % 63.3 % 0.0 % 11.2 % 100.0 %
(amount, mill.€)          74.5 
C: Breakdown by age of SME 
Infant 0.7 % 0.0 % 5.1 % 22.5 % 0.6 % 11.4 % 0.2 % 48.0 % 0.0 % 11.4 % 100.0 %
(amount, mill.€)          75.2 
Adoles-
cent 
0.0 % 0.0 % 0.0 % 1.4 % 0.0 % 20.1 % 0.7 % 76.1 % 0.0 % 1.7 % 100.0 %
(amount, mill.€)          17.3 
Middle-
aged 
0.0 % 0.0 % 0.0 % 5.4 % 0.0 % 29.9 % 0.0 % 55.4 % 0.0 % 9.3 % 100.0 %
(amount, mill.€)          3.6 
Old n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
(amount, mill.€)          n.a. 
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ESSAY 5.  
Projected Growth Effects of the 
Biotechnology Industry in Finland –  
The Fourth Pillar of the Economy?43  
Abstract 
This study aims to assess the impact of the Finnish biotechnology indus-
try on the economic growth in Finland. The study employs official data 
from Statistics Finland and new survey data covering 84 Finnish bio-
technology companies. The study offers methodological insights into 
how a new emerging industry can be treated as a statistical branch in an 
input-output forecast model and how probability distributions can be 
utilized in the model instead of point estimates. An econometric forecast 
for the economy-wide growth impact of the biotechnology industry in 
Finland is estimated. In the estimation procedure this study employs the 
survey data both in forming growth anticipations within a new emerging 
industry and assessing inter-industrial growth effects. Applied Monte 
Carlo simulations predict that the contribution of the biotechnology in-
dustry to annual GDP growth in 2002-2006 will be in the range of 0.05-
0.09 percentage points per annum with a probability of 90%. In com-
parison with the major sectors of the Finnish industry – forest industry, 
metal products and machinery industry, and electronics industry – this 
implies that it will rather take decades instead of years for the biotech-
nology industry to become a fourth pillar of the Finnish economy.  
Key words: biotechnology, economic forecast, growth contribution, 
input-output model, Monte Carlo simulation. 
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5.1  Introduction 
5.1.1  Background 
There have been growing expectations concerning the economic potential 
of biotechnology during the last two decades in Finland. Biotechnology is 
anticipated to become an important driving force in the economy after the 
era of information and communications technologies. Schienstock and 
Tulkki [1] have even raised a question whether the biotechnology industry 
will become a fourth pillar of the Finnish economy, next to the forest in-
dustry, the metal products and machinery industry, and the electronics 
industry.  
In Finland, the number of dedicated biotechnology firms has grown 
rapidly in the 1990s and is estimated to be one tenth of such firms in 
Europe (Kuusi [2]).The public sector has expended considerable re-
sources in training and R&D in this field. Private investments and ven-
ture funding have also grown decisively (Hermans and Tahvanainen 
[3]).The main application areas of biotechnology in Finland include 
pharmaceuticals, diagnostics, functional food, biomaterials, enzymes, and 
the food and chemistry businesses, as well as services related to these 
fields (see e.g. Hermans and Luukkonen [4]).  
Biotechnology is not easy to define as an industrial branch. The 
OECD Ad Hoc Meeting on Biotechnology Statistics defined biotech-
nology as “the application of science and technology to living organisms, as well as 
parts, products and models thereof, to alter living or non-living materials for the pro-
duction of knowledge, goods and services” [5].Public attention is usually paid to 
small dedicated biotechnology firms, but they are not the only ones to 
make and commercialize biotechnological discoveries. Some established 
larger firms are also involved in biotechnology R&D and commercializa-
tion. The entire field is closely related to scientific research, where many 
of the discoveries are made. The commercialization of the discoveries is, 
however, uncertain and the process is slow compared with, for example, 
the information and communications technologies (Luukkonen and 
Palmberg [6]).  
The high risk nature of the development processes of the biotechnol-
ogy industry must be taken into consideration when forecasting its eco-
nomic impacts. The delays in the development processes of biotechnol-
ogy companies as well as the risk of technological failure have to be in-
cluded as part of the forecasting model.  
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5.1.2  Objectives and Motivation of the Study 
Despite the high investments and expectations regarding the biotechnol-
ogy sector, there has not been much effort expended in estimating the 
economic growth impacts of the sector in the near future. It is well 
known that biotechnology firms report high growth potentials for sales, 
but the spill-over effects on other industrial branches and the growth 
contributions to the gross domestic product (GDP) have sparsely been 
analyzed. Ernst & Young [7] analyze the growth contributions of the 
biotechnology industry in the US in 1999.  
The objective of the study is to assess the impact of the Finnish bio-
technology industry on the economic growth in Finland. There were two 
obstacles to overcome in the construction of a forecast model. First, 
biotechnological applications span over several statistical subgroups in 
the official statistical classification, and thus the conventional statistical 
classes are not applicable for this new emerging industry – the official 
statistics and classification procedure within this area are still under con-
struction in OECD [5]. Second, the exceptional risks related to both the 
technological feasibility and delays in research and development proc-
esses are not reflected in the anticipated future sales disclosed by the 
biotechnology companies.  
In order to overcome the first obstacle, it was necessary to create a 
new industrial class of biotechnology in the conventional input-output 
table of Statistics Finland. The second obstacle was overcome by the 
application of Monte Carlo simulation, which simultaneously allows the 
implementation of the stochastic features of failure vs. success, and the 
probability distributions for anticipated future sales of the biotechnology 
companies.  
5.1.3  Research Procedure 
The forecasting procedure consists of 3 phases (Figure 1).  
1. Survey data that covers production and patterns of purchases 
and sales in the biotechnology industry are used in the forma-
tion of input-output tables estimating linkages to other indus-
tries.  
2. The biotechnology sector is added to the official input-output 
tables of Statistics Finland as a new branch. This enables the 
estimation of backward linkages to other industries. The 
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backward linkages depict how much the biotechnology sector 
increases purchases from other branches when its own sales 
grow, and vice versa. This enables estimation of the economy 
wide growth potential; the estimation is based on the Monte 
Carlo simulation using probability distributions of firms’ an-
ticipated future sales and bankruptcy risk during 10,000 itera-
tions.  
3. The results of forecast impacts are presented and discussed in 
the context of the Finnish economy.  
 
 
Figure 1.  Framework of the forecast model. 
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The biotechnology sector is classified under many statistical branches 
in official statistics (e.g. chemical production, food stuff production, bu-
siness services). However, the biotechnology companies differ a lot from 
other Finnish companies on average (Hermans and Tahvanainen [3]; 
Hermans [8]). For example, there are many biotechnology companies 
which do not have sales yet but which expect to have high sales in the 
future, based on relatively high expenditures on research and develop-
ment (R&D). The utilization of survey data is necessary in order to be 
able to estimate the input-output structures of these companies and their 
inter-industrial linkages and economic impacts. In the survey, small and 
medium-sized biotechnology companies announced their input-output 
structure (patterns of purchases and sales) at the end of 2001. They also 
disclosed their sales expectations.  
Most large biotechnology-related companies did not reveal their patterns 
of purchases and sales. Consequently, they could not be included in the new 
statistical branch of the biotechnology industry described above. The major-
ity of the large companies represent more mature entities compared to the 
biotechnology SMEs; thus, their input-output structures are closer to the 
average industrial classes than the biotechnology SMEs. Therefore, the large 
companies are treated as part of the existing statistical classes.  
Input-output modeling reveals supply and demand linkages between 
different branches. An industry uses the outputs of other industries as 
intermediate inputs in its own production processes. The industry sells 
its own output to another industrial branch, which uses that, in turn, as 
an intermediate input in its production. Input-output tables conclude 
these inter-industry linkages, and they have been used in many contexts, 
such as industrial forecast models (e.g. Burridge [9]), regional forecast 
models (Rickman [10]), and forecasting the dynamics of production wit-
hin a pharmaceutical company (Marangoni and Fezzi [11]).  
The word simulation refers to any analytical method which attempts 
to imitate a real-life system; usually other types of analyses are mathe-
matically too complex or too tedious to produce (Drakos [12]). One 
type of simulation is the Monte Carlo simulation, which randomly gen-
erates values for uncertain variables to simulate a forecast model using 
numerous iterations. The Monte Carlo simulation is used in a multitude 
of applications; examples thereof are nuclear reactor design, radiation 
cancer therapy, traffic flow, oil well exploration and econometric Dow-
Jones forecasting (ibid.). Monte Carlo simulation has also been used in 
the estimation of the input-output multipliers (see e.g. Bullard and Se-
bald [13]; Roland-Holst [14]).  
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This study constructs input-output multipliers from the cross-sectional 
data, and the simulation is utilized in the forecasting procedure. Without 
the use of simulation, an input-output model would result only in a sin-
gle outcome: a scenario in which all the positive expectations of the bio-
technology companies are realized. However, such a scenario does not 
reflect the most probable outcome.  
The presented forecast procedure uses both the input-output model 
and Monte Carlo simulation to numerically analyze the effect of varying 
uncertainty factors. The first factor is the threat of bankruptcy. It is de-
fined as a stochastic outcome: bankruptcy or continuing business at the 
end of 2006. Exogenous foreign demand constitutes the second uncer-
tainty factor. It is included as a probability distribution of anticipated ex-
ports by the Finnish biotechnology companies. These uncertainties are in-
cluded in the simulation. Instead of a single outcome, the model produces a 
distribution of all the potential outcomes given the assumptions behind the 
initial probability distributions. The assumptions are discussed in detail be-
low. 
This study is divided into four sections. The present section intro-
duces the background, objectives and rationale of the forecasting proce-
dures. Data employed in this study and assumptions behind the model 
are examined in Section 2. The input-output relations between the bio-
technology sector and other branches, those that use biotechnology in 
their processes and products and those that are suppliers to the biotech-
nology firms are also depicted. Section 3 employs a numeric Monte 
Carlo simulation-based input-output analysis to construct a growth con-
tribution scenario for the Finnish economy as a whole. Section 4 con-
cludes the results of the forecast and relates the projected growth of the 
biotechnology industry to the three main pillars of the Finnish economy.  
5.2  Biotechnology Industry in Finland  
5.2.1  Data 
This study employs a survey conducted by ETLA. The survey contains 
financial and business activity information on 84 Finnish biotechnology 
firms. A problem of the representativeness of the survey data arises be-
cause there were 131 biotechnology firms active at the end of 2001, and 
thus survey data represent only 64% of the sector. Furthermore, the 
sample seems to be slightly biased toward the older age groups: the sam-
ple contains three-fourths of the companies founded during 1991-1996 
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as well as companies founded earlier than 1991, but only 49% of the 
companies founded during 1997-2001 (Table 1). In order to form a plau-
sible estimation to depict the entire biotechnology sector in Finland, 
weights were constructed reflecting the age groups of the firms; the 
weights are inverses of the percentage shares of the sample in different 
age groups.  
Table 1.  Number of biotechnology firms in the sample of the ETLA 
survey respective to total population sorted by age 
groups. 
 before 1991 1991-1996 1997-2001 
ETLA sample 25 34 25 
Total number 34 46 51 
Percentage share of sample 74 % 74 % 49 % 
Weight 1.36 1.35 2.04 
 
The survey contains information on purchase and sales patterns of 72 
small and medium-sized enterprises (SMEs): from which main branches 
did they purchase their inputs, and to which main branches did they sell 
their outputs. This information was integrated as a new branch in the 
official input-output tables of Statistics Finland. The SMEs disclosed 
only the three most significant branches that they trade with, and thus 
there was not enough detailed information on all of the subclasses. This 
problem was eliminated by aggregation of branches, in which the entire 
input-output table was condensed to a 7x7 table.  
Detailed purchase and sales data were not disclosed by the large com-
panies, and therefore they were placed in the conventional industrial and 
service branches best fitting their activities. The existing structures of the 
branches of large companies were assumed to adequately illustrate their 
input-output patterns. The large companies are often multi-functional in 
the sense that they also have more conventional products. These esti-
mates contain only the share of biotechnology related sales disclosed by 
the companies, not their entire conventional production.  
A stochastic feature was included in the forecasting model. A discrete 
dichotomous setting for the probability of going bankrupt was added to 
the model. The bankruptcy risk was set at 5.7% for small and medium-
sized firms according to US experience in the biotechnology industry, 
and 1% for large-sized firms [15]. In Finland, the relative share of bank-
ruptcies has been slightly above 5% according to the ETLA biotechnol-
ogy database.  
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The growth forecast was based on the future sales figures according to 
the firms’ announcements. All biotechnology firms expect successful 
growth potential in the next 5 years, in 2002-2006. The estimation of 
exogenous foreign demand set into the input-output model was based on 
the anticipated future exports disclosed by the companies (Table 1). 
Instead of relying only on the estimates announced by the firms, prob-
ability distributions were utilized to create weighted anticipated future ex-
ports for every single firm. It was assumed that all the firms have the same 
risk of either delays in entering the marketplace with new products, or a 
market penetration that will not evolve as optimistically as expected. Thus, 
the probable anticipated future sales were formed by applying a uniform 
distribution. The lower limit of the distribution was set by current exports 
(in the end of 2001). The upper limit was set by the anticipated future ex-
ports in 2006 as announced by the company. Finally, a Monte Carlo simu-
lation with 10,000 iterations was run using the parameters above.  
5.2.2  Input-Output Structure 
The Finnish biotechnology industry is based on intensive international 
relations and foreign trade; two thirds of the sales are exported and al-
most one third of the purchases are imported (Figure 2). The biotech- 
 
Biotechnology SMEs 2001
Total output
in 2001
209 Mill. EUR
Biotechnology 2.8 %
Chemicals 3.2 %
Other industrial
production 6.1 %
Construction and
electricity 1.2 %
Services 14.3 %
Imported intermediate inputs 30.9 %
Value added 41.6 %
Food and feed 7.4 %
Chemicals 5.0 %
Other industrial
production 0.7 %
Health care 10.0 %
Other services 5.8 %
Exported output 68.3 %
 
Figure 2.  Input-output structure of the Finnish small and medium-
sized biotechnology companies.  
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nology industry purchases most of its domestic intermediate inputs from 
the service sector. Other domestic inputs contain the wages of labor and 
the profits or losses of the companies. The great losses, almost 100 mil-
lion euros in 2001, reduce the net domestic inputs. The inputs add up to 
209 million euros.  
In input-output models inputs always equal outputs, and thus total 
output is 209 million euros. The largest domestic customer branches to 
which the output is sold are health care services, the food and feed in-
dustry, and the chemical industry (incl. pharmaceuticals). Over 60% of 
the total output of services and products are exported. Thus, the foreign 
trade intensity is relatively high within the Finnish biotechnology SMEs.  
 
5.2.3  Growth Prospects  
Biotechnology firms are active in many industrial sub-branches. Most of 
the companies are related to pharmaceuticals or diagnostics, or both. 
There is also a significant number of firms involved in service activities, 
biomaterials, and the food industry. A few of the companies are focused 
on enzyme production or agriculture.  
The biotechnology companies seem to anticipate high growth in de-
mand for their products. The global market potential appears to be par-
ticularly attractive. Table 2 presents the anticipated growth rates of sales 
of the Finnish biotechnology industry by sub-branches.  
Table 2.  Anticipated annual growth rates of biotechnology sales of 
products and services for the 5 consecutive years, as an-
ticipated by the Finnish biotechnology companies in 
2002. 
Growth rate in % Domestic sales Exports Entire sales 
Pharmaceuticals 4 % 36 % 22 % 
Diagnostics 4 % 17 % 14 % 
Biomaterials 17 % 94 % 49 % 
Food and feed 3 % 11 % 7 % 
Industrial enzymes 7 % 5 % 5 % 
Agriculture 21 % 24 % 23 % 
Services 12 % 101 % 38 % 
Other 6 % 19 % 18 % 
Total 7 % 27 % 21 % 
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The table shows how the growth prospects vary among each sub-
branch of the biotechnology sector. The companies believe their sales 
will grow annually 21% on average over the next five years. The growth 
is expected to be realized mainly on the international markets. It seems 
that most of the firms expect that they can exploit a market potential 
throughout the world (Figure 3). 
A rather surprising finding is that the enzyme related industry expects 
only a moderate 5% growth. Finland is regarded as a giant in pulp and 
paper production, which is a heavy user of enzymes, and thus it would 
be expected to stimulate the demand for new enzyme applications (see 
Laestadius [16]). At the other extreme, biomaterials production is antici-
pated to grow almost 50% annually.  
 
Figure 3.  Export areas of the Finnish biotechnology firms in 2001 
and in 2006 (projections). 
The forecast procedure utilizes the companies’ expectations regarding 
their future exports growth. However, using the companies’ own expec-
tations introduces two possible types of bias to the model  
1. randomness at the company level: an arbitrary assessment of an-
ticipated future exports 
2. systematic error at the industry level: a tendency of the entire 
biotechnology sector to over-estimate systematically the level of 
anticipated future exports over the period of the survey.  
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Hermans and Kauranen [17] have analyzed the first type of bias. They 
related the measurable intellectual capital factors to the anticipated future 
sales of the biotechnology SMEs in Finland. The intellectual capital theory 
suggests that the interrelation of human, structural, and relational capital 
acts as a driver for value creation in a knowledge-intensive business (see 
e.g. Edvinsson and Malone [18]). In the study, they were able to construct 
an intellectual capital model, which explained 70% of the variance of an-
ticipated future sales. Consequently, measurable intellectual capital was 
tightly related to the anticipated future sales of the biotechnology SMEs: if 
a company holds a relatively high (low) level of intellectual capital, it also 
has high (low) growth prospects, respectively. Therefore, it seems well-
reasoned to rely on the companies’ expectations in the ordinal sense, that 
is, the companies with highest anticipated future sales are those that will 
probably sell more than those with lower expectations. 
 
Figure 4.  Probability distribution of an individual firm’s exports.  
Despite the ability to explain the variance of anticipated future sales 
of the biotechnology SMEs, the second bias remains. There are two 
main reservations. The first is related to the high risk in developing 
new biotechnology innovations, and particularly in converting them 
into commercially exploitable products. Second, there are doubts about 
the expected short time interval (here 2002-2006) for converting large 
losses into a flourishing business. The companies seemed to disclose 
their anticipated future sales within the most optimistic scenario, 
probably omitting the possibility of technical failures or severe time 
delays in product development. An example of this optimistic approach 
is visible in Figure 2, in which approximately 70% of the companies 
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plan to have access to the highly competitive North American market-
place within five years.  
In order to control for the second bias, probability distributions were 
applied while forecasting the economic impacts: a discrete probability dis-
tribution covering the bankruptcy risk, and a uniform distribution cover-
ing the sales expectations between the present and anticipated future ex-
ports (Figure 4). In other words, there is a 5.7% chance that a single firm 
will go bankrupt and 94.3% chance that its exports will be between the 
exports of 2001 and the anticipated future exports for 2006 [15].  
5.3  Economic Forecast 
5.3.1 Input-Output Analysis 
The econometric modeling procedure is initiated by input-output analysis. 
Input-output tables are utilized in order to estimate growth prospects cov-
ering inter-industrial linkages as well as contributions to the whole econ-
omy until the end of 2006. A conventional Leontief-type input-output 
matrix was constructed (see e.g. Forssell [19] and Giaschini [20]). The input-
output model describes the interlinkages between all branches of industry. 
Horizontal rows imply how the output of a single industry is used: as in-
termediate inputs in production processes of other industries and as end 
products to satisfy the domestic and foreign demand. Vertical columns 
depict how much an industry uses intermediate inputs from other indus-
tries and from imported inputs, and how much value added it produces. 
The method used in this study assumes that these structural multipliers, 
depicting the shares of input and output usage out of output, are fixed over 
the period that is analyzed. Equation 1 states the above relation formally: 
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The multiplier a is derived from a ratio: 
j
ij
ij x
x
a = , in which xj is the to-
tal (intermediary and final) output produced by the industry. The term xij 
measures how much the industry j uses the production of the industry i 
as an input. When i equals j, the multiplier a measures the intermediate 
inputs used within the companies of the same industry itself. The term y 
denotes a value of end products in an industry (1,…,n). Capital letters 
without subscripts are matrix notations referring to the terms above.  
Because YAIXXAIYYAXX 1)()( −−=⇔−=⇔+= . Therefore, 
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where ijb expresses how much industry i needs to produce so that indus-
try j could produce one unit of final product j.  
These matrix operations enable the use of the multipliers of the in-
verse matrix when estimating the effects of the growth in the biotech-
nology industry in Finland. The input and output structure of small and 
medium-sized biotechnology firms were added to the model as a new 
branch. Large-sized enterprises were treated as a part of their conven-
tional branch because they did not disclose any information on their 
purchase and sales patterns. 
Table 3.  Inverse matrix derived from input-output table. 
Inverse matrix 
Agriculture 
and other 
primary 
production
Bio-
techno-
logy 
Food 
industry
Chemical 
industry
Other 
industrial 
production
Construc-
tion and 
electricity
Health 
care 
services 
Other 
services 
Agriculture and  
other primary  
production 1.2410 0.0084 0.4465 0.0310 0.0637 0.0422 0.0064 0.0151 
Biotechnology 0.0002 1.0518 0.0020 0.0018 0.0001 0.0001 0.0013 0.0002 
Food industry 0.0641 0.0082 1.2768 0.0294 0.0193 0.0159 0.0085 0.0223 
Chemical  
industry 0.0247 0.0363 0.0178 1.0772 0.0263 0.0131 0.0092 0.0051 
Other industrial  
production 0.0966 0.1028 0.2030 0.1995 1.3697 0.3564 0.0617 0.1202 
Construction and 
electricity 0.0494 0.0263 0.0460 0.0484 0.0362 1.0779 0.0245 0.0652 
Health care  
services 0.0111 0.0034 0.0052 0.0014 0.0016 0.0017 1.0239 0.0054 
Other services 0.2439 0.2260 0.3688 0.2765 0.2640 0.3295 0.1898 1.3531 
 
Table 3 depicts the inverse matrix derived from the general form of 
Equation 3. The coefficients are interpreted as follows. The exogenous 
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increase of 1 unit in demand of biotechnology products and services will 
add 1.0518 units to the total output of the biotechnology industry due to 
the usage of intermediate products from the companies in its own indus-
try. A one unit increase in the output of the biotechnology industry is 
reflected by a 0.226 unit increase in the demand of other services (verti-
cal column “Biotechnology” in Table 3). However, only 0.0002 units of 
biotechnology outputs are produced for the other services (horizontal 
row “Biotechnology” in Table 3).  
Table 3 also shows that an exogenous change in demand for the out-
put of other sectors results only in a negligible increase of demand for 
the biotechnology products and services. This reflects the fact that the 
biotechnological applications are not yet tightly linked with other sectors’ 
production processes. For example, a one unit increase in production of 
health care services induces only a 0.0013 unit increase in purchases of 
inputs from the biotechnology industry.  
The input-output linkages can and probably will vary with time. For 
example, biotechnology products can replace some conventional chemi-
cal products in consumer and intermediate input markets, leading to an 
increase in the coefficients of the biotechnological inputs in the inverse 
matrix. However, this replacement, or crowding-out effect is not taken 
into account in the fixed coefficient input-output model based on cross-
sectional data.  
The multipliers are estimated from the cross-sectional data obtained 
through the ETLA biotechnology survey. The survey is the first of its 
kind in Finland. Thus, time series data are not available for the Finnish 
biotechnology sector, which at the moment excludes the construction of 
a time series model. 
5.3.2  The Monte Carlo Simulation 
This section presents the results of two simulation procedures. The first 
simulation contains only the predicted growth impacts of biotechnology 
SMEs on other industries. In addition to SMEs, the second simulation 
contains also the large biotechnology related multifunctional companies. 
The twofold approach was necessary in order to avoid blurring between 
the inter-industrial linkages and growth contribution to GDP.  
The input-output model estimates spill-over effects, and thus it reveals 
the impact of potential growth in the biotechnology industry on other 
sectors in the table. However, these spill-over effects could not be as-
sessed with a single simulation because the large companies are part of 
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the official branches, and SMEs are part of the newly formed branch of 
the biotechnology industry. The first simulation, containing only SMEs, 
indicates how large the spill-over effect is on other branches.  
The second simulation, which contains also the large biotechnology-
related companies, enables the estimation of the growth contribution of 
the entire biotechnology industry to GDP. However, it does not offer an 
insight into the spill-over effects on the specific branches since the out-
put growth effects of the large companies and spill-over effects cannot 
be distinguished from each other.  
Results of simulation 1 
The value added of small and medium-sized biotechnology companies 
was approximately 90 million euros in 2001. According to the results of 
our forecast model, the predicted nominal growth contribution of the 
biotechnology SMEs to the GDP in 2006 will be in the range of 181-446 
million euros with a 90% probability (Figure 5). This corresponds to the 
growth contribution of .03-.07 percentage points on annual average be-
tween 2002-2006. This prediction contains the multiplier effects from 
input-output tables to non-biotechnology branches. The value added of 
the biotechnology SMEs is predicted to be 125-309 million euros in 2006 
with a 90% probability.  
 
 
Figure 5.  Distribution of the forecast nominal contribution of the 
small biotechnology industry to the GDP in 2006.  
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Table 4 presents the main results of the forecast procedure. The overall 
contribution of the biotechnology business is slightly positive for the eco-
nomic growth in Finland. As mentioned above, the gross domestic prod-
uct (GDP) is expected to grow an additional 0.02-0.06 percentage units on 
annual average by the impact of the growth of biotechnology industry. 
The biotechnology industry is forecast to grow 18-34% on annual average 
between 2002-2006. The spill-over effects produced by the biotechnology 
industry are distributed unevenly among other branches. 
The spill-over effects are highest in the chemical industry, correspond-
ing to an increase in production of 0.04-0.09 percentage points in annual 
terms. The production of Other Industry (including production of in-
struments and food industry) is predicted to be stimulated by 0.01-0.02 
percentage points on an annual average.  
Table 4.  Monte Carlo simulation-based anticipated nominal growth 
contributions of small and medium-sized biotechnology 
companies in annual terms.  
Branch  
 
1. Annual growth 
contribution to  
a single branch 
(2002-2006), per-
cent, range of  
90 % probability 
2. Annual growth 
contribution to 
GDP (2002-2006), 
percentage units, 
range of 90 % 
probability 
3. Nominal  
contribution to 
the growth of  
the value added 
in 2006, million 
euros, range of  
90 % probability 
Agriculture, forestry, 
and other primary 
production 
 
0.01 – 0.02 % 0.00 – 0.00 % 
 
1 - 3 
Biotechnology SMEs 18.1 – 33.7 % 0.02 – 0.04 % 114 – 286 
Chemicals 0.04 – 0.09 % 0.00 – 0.00 % 3 - 7 
Other industry 0.01 – 0.02 % 0.00 – 0.00 % 10 – 25 
Construction 0.01 – 0.02 % 0.00 – 0.00 % 3 – 7 
Services 0.01 – 0.02 % 0.01 – 0.01 % 34 – 86 
GDP 0.02 – 0.06 % 0.02 – 0.06 % 165 – 414 
 
The service sector forms the largest sector in the Finnish economy; it 
produces 63% of the GDP. Despite a relatively low growth contribu-
tion of 0.01 percentage points, the contribution corresponds to 34-86 
million euros during 2002-2006; this is the largest contribution to any 
other branch in monetary terms. The impacts on construction, and 
agriculture and forestry remain low both as percentage points and in 
monetary terms.  
  
162 
As a whole, the high relative economic growth of value added of small 
and medium-sized biotechnology firms have only a low spill-over effect 
on the entire economy over the next five years according to the forecast 
model. There are two potential reasons for the low spill-over effects. 
First, there is a lack of the input-output data of large companies in the 
survey. This has been discussed above. Second, the volume of purchases 
and sales was still very low in 2001.  
It must be born in mind that even a single company showing significant 
success and consequently purchasing higher volumes would have a signifi-
cant impact on the entire input-output structure over time. In the second 
simulation, the classification of the large biotechnology related companies as 
a part of the conventional branches counteracts the effects of a single com-
pany affecting the input-output structure of the entire biotechnology industry.  
Results of simulation 2 
After predicting only the economic impacts of small and medium-sized 
biotechnology companies, a second forecast model was constructed 
combining SMEs and large multi-functional biotechnology companies. 
The multi-functional companies are those that also have essential pro-
duction activities in branches other than biotechnology. All the large 
 
 
Figure 6.  Distribution of forecast nominal contribution of the entire 
biotechnology industry to the GDP in 2006.  
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companies are placed in their conventional branches (not the biotech-
nology industry) in the input-output model. 
The value added of the entire biotechnology industry with production 
that utilizes biotechnology-based products or processes, was about 500 
million euros in 2001. The forecast model estimates that the growth of 
the entire biotechnology industry will contribute 315-623 million euros 
to the growth of the GDP in 2006 (Figure 6) with a 90% probability. 
This corresponds to a growth contribution of 0.05 – 0.09 percentage 
points to the GDP growth rates per annum.  
Table 5.  Monte Carlo simulation-based anticipated nominal growth 
contributions of entire biotechnology industry (incl. large 
companies) in annual terms. 
Branch  
 
1. Annual growth 
contribution to 
a single branch 
(2002-2006), per-
cent, range of  
90 % probability 
2. Annual growth 
contribution to 
GDP (2002-2006), 
percentage units, 
range of 90 % 
probability 
3. Nominal con-
tribution to the 
growth of the 
value added in 
2006, million  
euros, range of  
90 % probability 
Agriculture, forestry 
and other primary 
production 
 
0.03 – 0.06 % 0.00 – 0.00 % 
 
6 – 14 
Biotechnology  
SMEs 
 
18.3 – 33.7 % 0.02 – 0.04 % 
 
115 – 285 
Chemicals 0.18 – 0.99 % 0.00 – 0.01 % 15 – 81 
Other industry 0.03 – 0.10 % 0.01 – 0.02 % 51 – 134 
Construction 0.01 – 0.03 % 0.00 – 0.00 % 6 – 13 
Services 0.02 – 0.04 % 0.01 – 0.02 % 79 – 155 
GDP 0.05 – 0.09 % 0.05 – 0.09 % 315 – 623 
 
Table 5 presents the growth contributions of the entire biotech-
nology sector to other branches and the total GDP growth. The 
impact on the production of chemicals and chemical products is 
greatest: the annual growth contribution of biotechnology-related 
value added is forecast to reach the range of 0.18 – 0.99 percentage 
points. The entire biotechnology industry contributes to the growth 
of the production of Other Industry by 0.03 – 0.10 percentage 
points on annual average. Growth contributions to other sectors are 
not as significant. 
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The growth rates of production of a single branch can be very differ-
ent from the growth contribution rates presented in Table 5. For exam-
ple, the growth rate of value added in agriculture and other primary pro-
duction can even be negative covering the years of the forecast and thus 
its contribution to the GDP would also be negative. 
This study considers anticipated exports to be an exogenous variable. 
In other words, the increase in domestic demand resulted from an in-
crease in the use of inputs in domestic production. If part of the domes-
tic production had also been considered exogenous, the growth rates 
would have been slightly higher. 
5.4  Conclusions 
5.4.1  Summary 
This forecast study is intended to offer insights on the impacts of the 
Finnish biotechnology industry on the economic growth in Finland. The 
study focuses on converting expected growth potential into impacts on 
economy-wide growth. The use of Monte Carlo simulation enabled the 
use of probability distributions instead of point estimates in order to 
model risks related to the failure of a single company as well as time de-
lays in its product development and market launches.  
The present purchase-sales patterns of the small and medium-sized 
biotechnology companies were added as a new industrial sector to offi-
cial statistics. This procedure employed an input-output analysis, which 
enabled the estimation of economy-wide growth impacts. An inverse 
matrix with fixed multipliers was constructed, and the impact of exoge-
nous foreign demand between 2002-2006 was assessed using a Monte 
Carlo simulation with 10,000 iterations.  
The high percentage growth prospects of the Finnish biotechnology 
industry remained relatively moderate on an aggregate macroeconomic 
level. The growth contribution for the Finnish nominal GDP growth 
was 0.05-0.09 percentage points annually. This equals the growth impacts 
of 315-623 million euros in nominal terms during 2006.  
A noticeable impact on the chemical industry was seen. According to 
the simulations, the biotechnology companies add 0.2-1.0 percentage 
points to the annual nominal growth of chemical production in 
Finland. Many of the biotechnology firms act in chemical-related sub-
industries.  
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5.4.2  Further Studies 
This study opens views for further research:  
1. The sub-branches of the biotechnology industry differ from each 
other concerning their risk profiles. For example, the predicted 
time span from innovation to product launch is exceptionally 
long in drug development as compared to development of bio-
materials and industrial enzymes. The drug development is 
strictly regulated requiring extensive pre-clinical and clinical test-
ing before approval to initiate marketing. The Monte Carlo simu-
lation can be refined by using sub-branch-specific risk profiles 
which would add to the accuracy of the model.  
2. This study employed fixed input-output multipliers because only 
cross-sectional survey data was available. As time series become 
available, the changes of multipliers can be estimated over time 
using historical data. This would enable the incorporation of the 
evolvement of industrial structures into the model.  
3. Rantala [21] estimates a change of input coefficients over time 
with the help of R&D intensities of industrial branches. In the 
R&D-intensive biotechnology industry, the inclusion of these 
dynamic procedures to the input-output models could offer an-
other way of estimating the changes of input-output multipliers 
behind the forecast.   
4. This study does not analyze labor effects. However, the identifi-
cation of labor effects induced by the growth of the biotechnol-
ogy industry would be valuable in the macro-economic context 
(see e.g. Menrad et al. employing German data [22]).  
The forecast model presented in this study can be refined to support 
these four research set-ups. 
5.4.3  Biotechnology – the Fourth Pillar? 
Industrial history shows us that if a region or a country has no previous 
industrial tradition in a certain sector, successful businesses and new 
growth emerge slowly or only seldom. Finland has pinned high hopes on 
biotechnology as a source of new research-intensive growth. Almost all 
industrialized countries have the same goal, and many of them have al-
ready long traditions in this sector, whereas Finland has a short history in 
biotechnology. In Finland, the biotechnology sector’s volume of produc-
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tion measured by value added is about 500 million euros. In order to get 
a perspective on the growth possibilities, the biotechnology sector can be 
compared to the development of the currently strong sectors in Finland 
– the forest, machinery and electronics industries. 
In the early 1950s, the value of pulp and paper industry production 
was 500 million euros in 2000 prices (Figure 7). The electronics industry 
reached that level in the mid-1970s. If the biotechnology sector achieved 
the same growth as that of the electronics industry, it would reach the 
position of the “fourth pillar” of Finnish industry in about 30 years. If 
the life cycle of the biotechnology industry as an independent sector is 
comparable to the forest industry, the time span would be 50 years. Fi-
nally, if the growth rate of production of the biotechnology sector was 
sustained at the same level as in the forecast period 2001-2006, it would 
take 15-30 years to reach the same production level as the electronics, 
machinery and metal products, or pulp and paper industries have today.  
 
Figure 7.  Industrial production by sector 1948 – 2002, in year 2000 
prices (Hermans and Ylä-Anttila [23]).  
Even with a swift growth, it will take more than a decade for the bio-
technology industry to become one of the main pillars of the Finnish 
economy. It is likely that the Finnish economy’s new engine of growth 
will emerge from a combination of new and old sectors. In such a sce-
nario, biotechnology would play a significant role. 
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Appendix.   Simulation report of the model of small and  
medium-sized biotechnology enterprises. 
Summary Information 
Workbook Name SME_4.xls 
Number of Simulations 1 
Number of Iterations 10000 
Number of Inputs 144 
Number of Outputs 27 
Sampling Type Monte Carlo 
Simulation Start Time 9.3.2004 11:04 
Simulation Stop Time 9.3.2004 11:05 
Simulation Duration 00:00:28 
Random Seed 1692226105 
 
 
Output Statistics 
Name Cell 
Mini-
mum Mean 
Maxi-
mum x1 p1 x2 p2 
Agriculture and other primary  
production / Value added io D31 0.7 2.2 4.0 1.3 5 % 3.2 95 % 
Agriculture and other primary  
production / Contribution to  
own branch G31 0.003 % 0.010 % 0.018 % 0.006 % 5 % 0.015 % 95 % 
Agriculture and other primary  
production / Contribution  
to GDP I31 0.000 % 0.000 % 0.001 % 0.000 % 5 % 0.000 % 95 % 
Biotechnology /  
Value added io D32 58.5 198.7 353.2 113.6 5 % 285.8 95 % 
Biotechnology / Contribution  
to own branch G32 10.811 % 26.454 % 38.247 % 18.151 % 5 % 33.732 % 95 % 
Biotechnology / Contribution  
to GDP I32 0.009 % 0.029 % 0.052 % 0.017 % 5 % 0.042 % 95 % 
Food industry / Value added io D33 0.3 0.9 1.5 0.5 5 % 1.2 95 % 
Food industry / Contribution  
to own branch G33 0.003 % 0.009 % 0.016 % 0.005 % 5 % 0.013 % 95 % 
Food industry / Contribution  
to GDP I33 0.000 % 0.000 % 0.000 % 0.000 % 5 % 0.000 % 95 % 
Chemical industry / Value  
added io D34 1.5 5.1 9.1 2.9 5 % 7.4 95 % 
Chemical industry /  
Contribution to own branch G34 0.019 % 0.064 % 0.113 % 0.036 % 5 % 0.091 % 95 % 
Chemical industry /  
Contribution to GDP I34 0.000 % 0.001 % 0.001 % 0.000 % 5 % 0.001 % 95 % 
Other industrial production /  
Value added io D35 4.8 16.1 28.7 9.2 5 % 23.2 95 % 
Other industrial production /  
Contribution to own branch G35 0.004 % 0.012 % 0.021 % 0.007 % 5 % 0.017 % 95 % 
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Other industrial production / 
Contribution to GDP I35 0.001 % 0.002 % 0.004 % 0.001 % 5 % 0.003 % 95 % 
Construction and electricity / 
Value added io D36 1.4 4.8 8.6 2.8 5 % 6.9 95 % 
Construction and electricity / 
Contribution to own branch G36 0.003 % 0.011 % 0.019 % 0.006 % 5 % 0.015 % 95 % 
Construction and electricity / 
Contribution to GDP I36 0.000 % 0.001 % 0.001 % 0.000 % 5 % 0.001 % 95 % 
Health care services /  
Value added io D37 0.3 1.1 2.0 0.6 5 % 1.6 95 % 
Health care services /  
Contribution to own branch G37 0.001 % 0.002 % 0.004 % 0.001 % 5 % 0.003 % 95 % 
Health care services /  
Contribution to GDP I37 0.000 % 0.000 % 0.000 % 0.000 % 5 % 0.000 % 95 % 
Other services / Value  
added io D38 17.3 58.9 104.7 33.7 5 % 84.7 95 % 
Other services / Contribution 
to own branch G38 0.004 % 0.014 % 0.026 % 0.008 % 5 % 0.021 % 95 % 
Other services / Contribution 
to GDP I38 0.003 % 0.009 % 0.015 % 0.005 % 5 % 0.013 % 95 % 
Total / Value added io D39 85 288 512 165 5 % 414 95 % 
Total / Contribution to  
own branch G39 0.013 % 0.043 % 0.076 % 0.024 % 5 % 0.061 % 95 % 
Total / Contribution to GDP I39 0.013 % 0.043 % 0.076 % 0.024 % 5 % 0.061 % 95 % 
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Appendix.  Simulation report of the model of small, medium, 
and large-sized biotechnology enterprises. 
Summary Information 
Workbook Name SME_LE_03_2004.xls 
Number of Simulations 1 
Number of Iterations 10000 
Number of Inputs 180 
Number of Outputs 27 
Sampling Type Monte Carlo 
Simulation Start Time 8.3.2004 15:13 
Simulation Stop Time 8.3.2004 15:14 
Simulation Duration 00:00:41 
Random Seed 1069949287 
 
 
Output Statistics 
Name Cell 
Mini-
mum Mean 
Maxi-
mum x1 p1 x2 p2 
Agriculture and other primary 
production / Value added io D50 2.8 9.6 16.4 5.5 5 % 13.7 95 % 
Agriculture and other primary 
production / Contribution  
to own branch G50 0.013 % 0.045 % 0.076 % 0.026 % 5 % 0.063 % 95 % 
Agriculture and other primary 
production / Contribution to GDP I50 0.000 % 0.001 % 0.002 % 0.001 % 5 % 0.002 % 95 % 
Biotechnology /  
Value added io D51 58.1 199.7 351.3 114.9 5 % 284.9 95 % 
Biotechnology / Contribution  
to own branch G51 10.753 % 26.556 % 38.130 % 18.304 % 5 % 33.665 % 95 % 
Biotechnology / Contribution  
to GDP I51 0.009 % 0.030 % 0.052 % 0.017 % 5 % 0.042 % 95 % 
Food industry / Value added io D52 0.7 2.4 4.1 1.5 5 % 3.3 95 % 
Food industry / Contribution  
to own branch G52 0.007 % 0.025 % 0.042 % 0.015 % 5 % 0.034 % 95 % 
Food industry / Contribution  
to GDP I52 0.000 % 0.000 % 0.001 % 0.000 % 5 % 0.000 % 95 % 
Chemical industry /  
Value added io D53 5.2 48.5 90.9 14.9 5 % 81.4 95 % 
Chemical industry /  
Contribution to own branch G53 0.065 % 0.593 % 1.102 % 0.184 % 5 % 0.990 % 95 % 
Chemical industry /  
Contribution to GDP I53 0.001 % 0.007 % 0.013 % 0.002 % 5 % 0.012 % 95 % 
Other industrial production / 
Value added io D54 22.5 87.7 154.8 44.1 5 % 130.9 95 % 
Other industrial production / 
Contribution to own branch G54 0.017 % 0.065 % 0.115 % 0.033 % 5 % 0.097 % 95 % 
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Other industrial production / 
Contribution to GDP I54 0.003 % 0.013 % 0.023 % 0.007 % 5 % 0.019 % 95 % 
Construction and electricity / 
Value added io D55 2.9 9.7 16.1 6.4 5 % 13.0 95 % 
Construction and electricity / 
Contribution to own branch G55 0.006 % 0.021 % 0.035 % 0.014 % 5 % 0.028 % 95 % 
Construction and electricity / 
Contribution to GDP I55 0.000 % 0.001 % 0.002 % 0.001 % 5 % 0.002 % 95 % 
Health care services /  
Value added io D56 0.7 3.7 6.8 1.6 5 % 5.9 95 % 
Health care services /  
Contribution to own branch G56 0.001 % 0.008 % 0.014 % 0.003 % 5 % 0.013 % 95 % 
Health care services /  
Contribution to GDP I56 0.000 % 0.001 % 0.001 % 0.000 % 5 % 0.001 % 95 % 
Other services /  
Value added io D57 33.1 107.4 178.7 72.9 5 % 142.0 95 % 
Other services / Contribution  
to own branch G57 0.008 % 0.026 % 0.044 % 0.018 % 5 % 0.035 % 95 % 
Other services / Contribution  
to GDP I57 0.005 % 0.016 % 0.026 % 0.011 % 5 % 0.021 % 95 % 
Total / Value added io D58 150 469 776 315 5 % 623 95 % 
Total / Contribution to own 
branch G58 0.022 % 0.069 % 0.115 % 0.047 % 5 % 0.092 % 95 % 
Total / Contribution to GDP I58 0.022 % 0.069 % 0.115 % 0.047 % 5 % 0.092 % 95 % 
 
 
